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Table 1.4.1. Clinical Presentation.
Factor Level Bleeding
(u/ral)
0.01 Recurrent
spontaneous
0.01-0.05 Occasional
spontaneous 
mild trauma 
surgery
0.05-0.5 Trauma
surgery
The severity of the bleeding diathesis usually parallels the 
severity of the disorder. Occasional patients are found in 
whom the clinical grade of defect does not match assayed 
levels.
11.1 INTRODUCTION
1.1.1 The use of blood products in haemophilia - A double 
edged sword.
Haemophilia is an inherited disease predisposing the 
individual to prolonged and excessive bleeding. The only 
satisfactory treatment in severe haemophilia is 
replacement of the missing factor with blood products. 
Frequent use of blood products however is associated with 
a substantial risk of acquiring life threatening blood 
borne viral infections. For example, infection with the 
human immunodeficiency virus type 1 (HIV-1) carries a
30-75 percent chance of progression to AIDS in five years 
and non - A, non - B (NANB) infection results in chronic 
active hepatitis or cirrhosis in approximately 25 per 
cent of infected patients (1, 2).
On the other hand without treatment severe haemophiliacs 
would have a life expectancy that is half that of the 
general population and most would develop severe 
crippling musculoskeletal deformities (3).
To fully appreciate the risks and benefits of available 
blood products administered to haemophiliacs requires 
first, an understanding of why haemophiliacs bleed; 
second, a balanced evaluation of benefits as well as 
risks of blood products presently used and third, an 
appraisal of alternatives that may favourably influence 
outcome.
21.2 Why haemophiliacs bleed
Haemophilia is the commonest of the congenital 
haemorrhagic diseases.The term describes two disorders: 
factor VIIIC deficiency ( Haemophilia A # Classical 
Haemophilia) and factor IX deficiency (Haemophilia B or 
Christmas disease). The estimated incidence of factor 
VIIIC deficiency is approximately 1 in 10,000 live 
births, factor IX deficiency is ten times less common 
(3) .
Both are due to single gene defects on the X chromosome 
resulting in absence of the specified protein or a 
molecule with reduced activity. The mode of inheritance 
is sex linked.
To understand why haemophiliacs bleed requires a basic 
knowledge of how factor VIIIC and factor IX participate 
in coagulation and the nature of the deficiency. Both 
proteins are part of the intrinsic pathway of coagulation 
which consists of several inactive zymogens, and 
cofactors that are serially activated in response to 
exposure. to collagen or other negatively charged 
components of subendothelial connective tissue. 
Specifically factor VIIIC and factor IX are involved in 
the mid-phase of the coagulation cascade in the 
conversion of factor X to Xa (Figure 1.2.1).
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Figure 1.2.1
31.2.1 Factor VIIIC
Factor VIIIC is specified by a gene on the X 
chromosome.In vivo, factor VIIIC circulates non- 
covalently bound to von Willebrand factor, (factor VIII 
vWF) a large multimeric glycoprotein essential for 
platelet adhesion to subendothelium (4). The exact 
binding site of factor VIIIC to factor VIIIvWF is not 
known but has been localized to somewhere within the 
first 272 amino acids of factor VIIIvWF (5). Factor VIII 
vWF functions exclusively as a carrier molecule of factor 
VIIIC and plays no part in factor VIIIC cofactor 
activity.
1.2.2 Structure of factor VIIIC
The cloning of the complementary DNA (cDNA) and gene for 
human factor VIIIC indicates that factor VIIIC is 
synthesized as a single polypeptide chain of 2332 amino 
acids plus a leader sequence of 19 amino acids (6-9). 
There are 25 potential carbohydrate binding sites to 
asparagine: if all sites are occupied the molecular
weight for the glycoprotein would be approximately 
330, 000 (+. 20,000). This is similar to previous
biochemical estimates of the molecular weight of factor 
VIIIC (10, 11).
The cDNA sequence of factor VIIIC shows that the mature 
peptide has two different homologous domains (Fig 1.2.1), 
A and C. The A domains have approximately 30 percent 
homology and C domains are 40 percent homologous.
4Interestingly, the A domain also shows 30 percent 
homology with caeruloplasmin, whether this domain 
complexes with copper or other heavy metal ions is not 
known (6,7). Furthermore, the cDNA sequence of factor V 
shows homology to caeruloplasmin (12,13). This structural 
and functional similarity of factor Va and Villa as 
cofactors suggests that caeruloplasmin, factor V and 
factor VIIIC may have arisen from a common ancestral 
gene.
1.2.3. Biosynthesis of factor VIIIC
Organ transplant studies in canine haemophilia and the 
serendipitous observation of normalization of factor 
VIIIC after orthotopic liver transplantation in a severe 
haemophiliac with chronic hepatitis suggest that factor 
VIIIC is synthesized in the liver (14-21). This has been 
confirmed by detection of factor VIIIC messenger RNA in 
liver but not other tissues (22). In-situ hybridization 
studies and immuno - cytochemical studies show that 
hepatocytes and not Kuppfer or sinusoidal endothelial 
cells synthesize factor VIIIC (23-26).
1.2.4 Biological Function of Factor VIIIC 
Factor VIIIC is a component of the intrinsic pathway of 
coagulation (Figure 1.3.1) activation of factor VIIIC is 
a prerequisite in activation of factor X (27-29) . The 
reaction requires calcium ions and phospholipids, in-vivo 
phospholipid surface is provided by platelets and other
5cell membranes (30). No other physiological functions 
have been attributed to factor VIIIC (31).
1.2.5 Factor VIIIC Activation
Activated factor VIIIC has no intrinsic catalytic 
activity, therefore the mechanism by which factor VIIIC 
accelerates proteolysis by factor IXa of factor X is as 
a binding protein for factor IXa and X in a conformation 
favouring catalysis (31)). To participate in clotting 
reactions variable amounts of the B domain have to be 
cleaved (32). Thrombin is the most potent protease known 
to activate factor VIIIC (27-29,33-34).Thrombin activates 
factor VIIIC bound to factor VIIIvWF, upon activation or 
binding to a phospholipid surface factor VIIIC
dissociates from factor VIIIvWF.Activated factor VIIIC 
increases Vmax of catalysis of factor X almost 20,000
fold (29, 35).
Factor VIIIC is initially cleaved by thrombin after Arg- 
740 to yield heavy (M.Wt. 90,000) and light chain
fragments (M.Wt.80,000) (32). Heavy and light chain
fragments originate from amino and carboxy terminals of 
the precursor molecule respectively and are linked by 
calcium and/or other cations.Further thrombin digestion 
cleaves after Arg-372 of the heavy chain and, after light 
chain Arg 1689 (32).Which of these cleavages actually
results in factor VIIIC activation is still unclear (32- 
36) . Factor Xa acts at sites cleaved by thrombin and two 
additional sites have also been proposed (32).
6In vitro factor IXa activates factor VIIIC. The 
physiological relevance of this activation is unclear as 
the reaction requires high concentrations (37).
1.2.6 Inactivation of activated factor VIIIC
Factor VIIIC is probably inactivated in vivo by 
proteolytic degradation (28, 33). Several proteases
degrade activated factor VIIIC: the most important is
activated protein C (320). Protein C cleaves factor 
V U I C a  heavy chain at a single site but does not degrade 
the light chain (32). Protein C activation of (by 
thrombin) is regulated by thrombo-modulin at the 
endothelial cell surface (38) .
Non-proteolytic degradation of activated factor VIIIC has 
been described in vitro, but its physiological role is 
not known.
1.2.7 The molecular defect in haemophilia A
A single gene disorder such as haemophilia A may arise 
from gene deletions or a point mutation resulting in 
synthesis of a inactive molecule. Defective molecules 
(factor VIIIC antigen, cross reacting material [CRM]) can 
be detected by immunoassays using human anti-VIIIC 
antibodies (39-50). Attempts to identify inactive factor 
VIIIC or factor VIIIC antigen (cross reacting material or 
CRM,factor VIIICAg) in haemophiliacs have provided 
conflicting results. Initial studies found CRM in a
7small minority of moderate haemophiliacs (39-42), whereas 
subsequent studies have found CRM in all patients 
tested(43,44).
More recent studies using sensitive immunoradiometric and 
electroimmunoassays show that the majority of severe 
factor VIIIC deficient haemophiliacs are CRM negative, 
whereas almost all patients with moderate to mild 
haemophilia A have CRM present in amounts that are 
comparable to or exceeding circulating factor VIIIC of 
levels (45 - 50) .
The implications of these findings are that the 
functional defect in mild to moderately affected patients 
is due to presence of a defective molecule. Both mis- 
sense and non-sense point mutations are described in 
mild-moderately affected patients (51-52).In CRM negative 
patients and therefore the vast majority of severe 
patients, the molecule is absent.Antonarakis et al have 
screened 240 unrelated males for abnormalities in the 
factor VIII gene detectable by restriction 
analysis.Significant deletions were found in 14 patients 
and point mutations in 12 (53).More recently two
unrelated severe patients have been described who had 
insertions of Li elements in exon 14 of the factor VIII 
gene (54).
1.3.1 Factor IX
Factor IX is a glycoprotein with a molecular weight of 
55,000 of which 20 percent is carbohydrate (55). It is a
single polypeptide chain of 415 amino acids (56 - 61).
The complete amino acid sequence of factor IX has been 
deduced from a cDNA clone (59). It shows striking amino 
acid homology to both vitamin K dependent clotting 
factors and other serine proteases - suggesting that this 
larger family of proteins were probably derived from a
single ancestral gene (56).
Based on these homologies factor IX can be considered to 
have 4 distinct domains. Starting at the amino terminal 
these include:
1. The Gla Domain: In this domain 12 of the glutamine
acid residues are carboxylated to gamma carboxyglutamic 
acid (61).These residues are important for calcium
dependent phospholipid binding which is critical for 
complex formation with activated factor VIIIC and for 
subsequent conversion of factor X to factor Xa (62).This 
however, is not the only calcium binding site, high
affinity calcium binding sites are also found in the
first growth factor domain (63).
2. The Growth Factor Domain: This region consists of 
two homologous domains arranged in tandem (61).Both show 
limited homology to epidermal growth factor (61).Similar 
domains are found in other serine proteases.The function 
of these growth factor domains is not known.
9The first growth factor domain of factor IX contains 
another unusual residue B-hydroxyaspartic acid (Bha) at 
position 64 (63). About 25 percent of human factor IX
contains Bha, the remainder contains aspartic acid (63) . 
It has been suggested that Bha participates in calcium 
binding but direct evidence for this is lacking (63).
3. The Activation Peptide Domain: This domain contains
35 amino acids and shows considerable polymorphism 
particularly at the third amino acid (64). Factor XIa 
cleaves factor IX at two sites in this region (61).
4. The Catalytic Domain: This region is common to all
serine proteases and all share a common mechanism of 
proteolytic activation.Cleavage of the Arg-Val bond at 
Arg-35 allows the amino terminal Val residue to interact 
with Asp-104 (65). This interaction allows a
conformational change in the active site increasing its 
catalytic activity (65) .
1.3.4 Biosynthesis of Factor IX
Factor IX is synthesized by hepatocytes(57).The initial 
factor IX translational product contains an amino 
terminal extension or signal peptide which is cleaved in 
the rough endoplasmic reticulum (57) . Glycosylation of 
factor IX occurs co-transitionally and during transit of 
the protein via the Golgi apparatus (57) . Further post- 
translational modifications includes gamma carboxylation
10
of glutamic acid residues and hydroxylation of aspartic 
acid at residue 64 (66).
1.3.5 Biological function of factor IX
Factor IX can be activated by either factor XIa and 
calcium or by factor Vila tissue factor complex (67- 
75).Activation of factor IX is schematically shown in 
figure 1 .3.2.
Factor IXa can activate factor X in the absence of 
cofactors, however, in the presence of cofactors 
(calcium, phospholipid, and activated factor VIIIC) the 
rate of conversion is accelerated almost 200,000 fold 
(30) .
The interaction with calcium probably occurs at two 
sites, the Gla domain (contains 16 calcium binding sites) 
and a Gla independent site - this second site is thought 
to be Bha reactive at position 64 (76). The mechanism of 
interaction between activated factor VIIIC and factor IX 
is not known, but it has been shown that the activated 
factor IX beta form is more accessible for binding than 
activated factor IX alpha form (77).
In vitro studies have shown that factor IXa can activate 
factor VIIIC, the physiological significance of this is 
not clear (78). Other factor IX and activated factor IX 
interactions include:binding to antithrombin III and
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endothelial cells (79).The biological significance of 
these interactions are not known but may be elucidated by 
studying factor IX variants .
1.3.6 The molecular defect in haemophilia B
By using immunological rather than functional assays for 
factor IX, Farth et al in 1 986 and subsequently others 
showed that plasma from some factor IX deficient patients 
contained antigen or CRM reactive factor IX antibody (80 
-83) . Patients therefore can be further phenotyped into 
categories using a clinical, functional and immunological 
measures of the amount of factor IX present. Most of 
the recent advances in identifying defects in haemophilia 
B have been made in patients who have circulating CRM. 
Some examples of the known variants are given below.
Factor IX Chapel Hill
Factor IX Chapel Hill was first described in 1978 
(84).The molecular defect is substitution of histidine 
for arginine at position 145 (85). As shown in Figure
1.3.2. this is the first cleavage site in normal factor 
IX activation. Thus, factor IX Chapel Hill is not 
activated normally, only the Arg180 - Val181 bond is 
cleaved giving rise to a activated factor IX alpha 
molecule in which the activation peptide remains attached 
to the light chain (86.87). This variant has only 20 
percent of the clotting activity of normal activated 
factor IX beta (86,87).
Factor IX Alabama
As in factor IX Chapel Hill in this variant there is a 
point mutation, glycine is substituted for aspartate at 
position 47 (88) . It is not known how this affects
function but interaction with phospholipid is normal.
Haemophilia B Leyden
This variant is clinically functionally and 
immunologically distinct from others. Clinically, 
affected individuals are severely affected till puberty 
and have undetectable levels of factor IX antigen (90). 
However, after puberty both factor IX antigen and 
coagulant levels increase to greater than 50 per cent.The 
genetic defect is not known but presumably occurs in the 
regulatory portion of the gene.
Unlike the variants described above, which are CRM +ve, 
and are due to point mutations, some CRM -ve variants 
have been shown to be due to gene deletions and 
associated with inhibitors. However the association 
between gene deletions and inhibitors has only been found 
in 9 of the 23 patients characterized (92 97).
1.4 Treatment of bleeding episodes:
The impaired ability in haemophilia A and B to generate 
intrinsic factor X - activating complex predisposes the 
individual to bleeding. The frequency and severity of
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bleeding episodes parallels the deficiency in circulating 
factor levels, Table 1.4.1.
1.4.1 Principles of treatment
The aim in treating bleeding episodes is to raise the 
circulating level of factor VIIIC/IX into a haemostatic 
range. This can be achieved by using blood products or 
synthetic drugs. The type of treatment chosen will depend 
on 1. the degree of deficiency in the patient's plasma, 
2. the severity of injury or extent of surgery, 3. the 
bleeding site, 4. the presence of inhibitors, 5. the 
plasma volume of the patient, 6. the potency of the
material to be used, 7. the biological half life of the 
blood product.
1.4.2 Blood products
The recognition by Addis in 1911 that the defect in 
haemophilia resides in plasma and not platelets was a 
landmarkiV\the rational management of haemophilia (98) . 
Interestingly, blood transfusion had been suggested in 
the treatment of congenital bleeding disorders by 
Schonlein in 1832 and the first report of successful use 
of blood in the treatment of such a disorder was reported 
in 1840 (99, 100) .This form of therapy did not however 
become widely practiced and by the beginning of this
century serum was the only blood component in use.In
retrospect it seems likely that the success claimed for
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serum therapy was probably due to its use in haemophilia 
B patients (101).
Plasma was subsequently shown to be superior to whole 
blood (102, 103) .However, both blood and plasma had the 
obvious limitations of availability and because of short 
lived benefit, volume overload was a common problem.In 
addition their use had frustrating practical 
difficulties.
The further development of treatment paralleled 
improvements in blood banking and evolution of plasma 
fractionation on a scale ample to match clinical needs. 
Development was accelerated by the pressing needs of a 
plasma volume expander during World War II. A byproduct 
of albumin fractionation, Cohn Fraction 1 was found to be 
rich in fibrinogen and antihaemophilic factors, contains 
50iu factor V U I C / g  of protein(104) . Although this 
fraction was a significant improvement over plasma, its
use was limited by variability of the method and 
expense. The use of Cohn fraction 1 was therefore 
restricted to treatment of life threatening bleeding 
episodes and for surgery.
Cohn fraction 1 was rapidly superseded by Blombeck 
fraction 1-0, which contain 100iu factor V U I C / g  protein
(105). These and animal plasma products formed the
mainstay of haemophilia therapy for the next thirty 
years.
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The most important single achievement in the care of 
haemophiliacs was the observation by Pool and Robinson 
that the cold insoluble precipitate after controlled 
freeze-thawing of plasma was rich in fibrinogen and 
factor VIIIC (102). The importance of this observation 
was the potential of freeze-thawing providing a cheap, 
reproducible method for large scale production of factor 
VIII concentrates. Modifications of the method to improve 
purity, increase recovery, and prevent complications have 
been natural developments.
1.5 Factor VIII and IX containing blood products
A large number of different factor VIII containing blood 
products are now available. Despite initial apparent 
diversity,they can be classified into three main 
categories based on (i) factor VIIIC potency,(ii) 
protein content and (iii) specific activity (the ratio of 
potency/protein content). The three subtypes are
equivalent in their clinical effect, Table 1.5.1.
Cryoprecipitate
In the preparation of cryoprecipitate, human plasma is 
frozen at -4° to -70°C within six hours of blood 
collection and allowed to thaw at 2-4°C. The precipitate 
is collected by centrifugation and is either refrozen, 
alternatively it is redissolved in citrate buffer or a 
small amount of supernatant plasma and frozen. The
cryoprecipitate may be prepared from single donations or 
pooled (four to ten units). Pooled preparations can be 
either used directly or sterile filtered and freeze 
dried. The potency, protein content and specific activity 
of cryoprecipitate compared to other factor VIII 
concentrates are shown in Tables 1 5.1 and 1.5.2.
Some commercial manufacturers have scaled up the above 
method by pooling several hundred litres of plasma and 
freeze drying the precipitate. By using such methods the 
specific activity can be increased to 0.3iu factor 
V U I C / m g .
Advantages of small donor pool cryoprecipitate are:its 
simplicity in preparation, the relatively low cost and by 
selection of donors hepatitis risk can be reduced.lt is 
the treatment of choice in mild haemophiliacs who cannot 
receive desamino desarginine vasopressin (DDAVP). In both 
the UK and the USA cost of cryoprecipitate preparation 
is similar to that of intermediate purity factor 
concentrates (107,108). The main disadvantages of 
cryoprecipitate are the variability in potency between 
batches, the higher storage costs and the inability to 
heat sterilize.
Intermediate purity factor VIII concentrates
Cryoprecipitate is the starting material in preparation 
of all factor VIII concentrates. The cryoprecipitate
is washed with a glycine-ethanol-citrate buffer to 
extract protein contaminants and then subjected to cold 
precipitation associated with aluminum hydroxide 
adsorption to remove the prothrombin complex of proteins 
(110,11). Intermediate purity concentrates are rich in 
fibrinogen making reconstitution a problem and limiting 
concentrations achieved in solution to 15iu factor VIIIC 
/ml. The characteristics of such preparations are shown 
in Tables 1.5.1 and 1.5.2 (112).
Intermediate purity concentrates are the most commonly 
used blood products in the treatment of haemophilia A. 
Their main advantages are: ease of clinical use and a
high yield for economic use of plasma. Disadvantages 
include a high risk of transmitting viral infections in 
the unheated state and the additional potential risk of 
recurrent alloantigen exposure.
High purity factor VIIIC concentrates
High purity factor VIIIC concentrates have a specific 
activity greater than 1 iu factor V U I C / m g  .The first 
generation were prepared by further precipitation of 
intermediate concentrates with polyethylene glycol 
(113.114). Such high purity concentrates contain no 
albumin and reduced amounts of alpha and beta 
globulins.The main beta globulin that remains is 
fibronectin Table 1.5.2 .The main disadvantage of such 
clotting factor concentrates is the lower factor VIIIC
Table 1 .5.3l. Potency, purity and yield of factor VIII 
preparations.
VIII:C potency Specific activity Yield 
Preparation (u/ral) (u/ml) (%)
Fresh frozen plasma 1 0.017 100
Cryoprecipitate 3-6 0.1-0.3 35-50
Intermediate-purity 15-40 0.5-0.9 20-35
concentrate
High-purity 20-40 >1 8-23
concentrate
Table 1.5.2. Protein composition of factor VIII preparations.
(%of total proteins)
Preparation Fibrinogen Fibronectin IgG IgM
Cryoprecipitate 60-70
Intermediate-purity 42-50
concentrate
High-purity concentrate:
First generation 0-60
Second generation <1-80
20-25
15-35
17-46
2-30
5-8 1-2
10-12 2-5
6-30 1.5-4
<3-30 5-15
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yield because of the purification process which increases 
financial cost of production.
Affinity column purified factor VIII concentrates
Highly purified factor VIII concentrates have been 
recently manufactured using murine monoclonal antibodies 
and affinity chromatography. The manufacture of the 
product available in the UK takes advantage of the fact 
that, in normal plasma the procoagulant part of the 
factor VIII molecule is physically bound to von 
Willebrand factor. A monoclonal antibody specific to an 
epitope on the vWF protein is bound to insoluble 
Sepharose beads and poured into a gel column for 
chromatography. When cryoprecipitate is run through the 
column, the antibody binds to the vWF molecule. Factor 
VIIIC is separated from vWF by calcium and eluted from 
the column. The purified factor VIIIC is concentrated by 
ultrafiltration and further purified by additional 
affinity chromatography. The final product is stabilized 
with human albumin. The specific activity of the final 
product is 15.2 iu/mg protein and is due entirely to the 
albumin added (115).
Porcine factor VIII
The use of porcine and bovine factor VIII concentrates 
has been largely abandoned due to the high incidence of 
side effects (116). However a relatively new, highly
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purified polyelectrolyte porcine preparation has proven 
to be quite effective and has a much lower incidence of 
side effects (116,117). Its main use is in patients with 
factor VIIIC inhibitors.
1.5.4 Factor IX concentrates (Non activated prothrombin 
complex concentrates)
The early concentrates used in the treatment of 
haemophilia B were prepared from ethylenediamino tetra 
acetate (EDTA) anticoagulated plasma adsorbed with 
tricalcium phosphate, eluted with citrate and dried with 
ethanol(118). The starting material most commonly used 
now is cryopreciptate supernate, the vitamin K dependent 
proteins are adsorbed onto diethylaminoethyl (DEAE) 
cellulose and eluted with phosphate or citrate buffers. 
The final product is lyophilized. It contains relatively 
little factor VIIIC but has approximately equal amounts 
of factors II,IX and X (121).
In order to limit possible side-effects related to 
presence of thrombin and other activated factors some 
manufacturers add heparin.
Activated Prothrombin Complex Concentrates (APCC)
The manufacture of APCC was stimulated by anecdotal 
reports of the success of prothrombin complex 
concentrates in controlling bleeding episodes in a factor
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VIIIC deficient patients with an inhibitor (122). The 
concentrate used represented specific lots of prothrombin 
complex concentrate which had been withdrawn because of 
potential thrombogenic complications. Further use of 
these batches in patients with inhibitors provided
similar results and stimulated the production of
prothrombin complex concentrates which were deliberately 
activated in a controlled fashion to produce concentrates 
with so called factor VIIIC bypassing activity (123). 
Controlled studies have shown that prothrombin complex 
concentrates can control joint bleeds in up to 50
percent of episodes in patients with factor VIIIC 
inhibitors (124 -127)
Two activated prothrombin complex concentrates are 
available commercially - FEIBA (Immuno, Austria) and 
Autoplex (Hyland Laboratories). Both significantly reduce 
haemophilic and normal plasma clotting time (non-
activated PTT), while non-activated complexes produce 
only a modest decrease. Both products have been shown to 
be effective in clinical trials (126.127)
1.6 Synthetic drugs
1.6.1 Des deamino desarginine vasopressin
To date the only satisfactory alternative to blood 
products in the treatment of factor VIIIC deficiency is 
the pharmacologic analogue of vasopressin deamino 8 D
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desarginine vasopressin (DDAVP) (130-135). Theoretically
factor VIIIC deficient patients who have the capacity to 
produce factor VIIIC (ie CRM positive patients) should 
show increases in factor VIIIC, DDAVP is only 
satisfactory in securing haemostasis in patients with a 
mild deficiency (131-135). The response is dose dependent 
and reaches a maximum at 0.3 ug/kg increasing levels by 
four fold. The response lasts several hours and is more 
prolonged for factor V U I v W f  than factor VIIIC or factor 
VIIIAg (133). The mechanism of action is not known.It is 
often used in conjunction with tranexamic acid to inhibit 
induction of fibrinolysis (131,133).
1.6.2 Anabolic steroids
Initial studies with the attenuated anabolic steroid, 
danazol showed that administration of danazol for 2 weeks 
increased factor VIIIC and factor IX levels in patients 
with haemophilia A and Christmas disease respectively 
(136). All five treated patients showed rises in 
deficient factors ranging from two - six times basal 
levels. This has not been confirmed.A similar attenuated 
anabolic steroid, stanozolol showed only minor 
increases.Its use was further limited by an increased 
incidence of soft tissue haematomas presumably due to 
increased fibrinolytic activity (137).
1.6.3 Fibrinolytic inhibitors
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Decreasing fibrinolytic activity has the theoretical 
advantage of off setting the imbalance created by factor 
VIIIC and IX deficiency. Two such drugs have been used in 
haemophiliacs, epsilon amino caproic acid (EACA) and 
tranexamic acid. Both inhibit binding of plasmin to 
fibrin.
The results in preventing spontaneous bleeds with both 
drugs have provided contradictory results long term use 
at present cannot be justified (138 - 142). Studies of
chronically inflamed haemophilic synovium show increased 
plasminogen activator activity and it has been suggested 
that EACA may reduce bleeding during the chronic 
synovitic stage (143). The principal use of these agents 
however has been restricted to reducing dental socket 
bleeding after surgery (144 -149).
1.7 A balanced assessment of the risks and benefits of 
treatment:
1.7.1 Benefits
There is little doubt that appropriately used the blood 
products discussed in section 1.5 correct the haemostatic 
defect in haemophilia.
The immediate benefits in controlling haemophiliac 
bleeding are well established.However, benefit in the 
long term also requires to be measured.The influence of 
clotting factor concentrate use on life expectancy and 
joint disease are therefore reviewed.
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1.7.2 Life Expectancy
Studies that have reviewed life expectancy in haemophilia 
are shown in Table 1.7.1 (150 - 154). In two studies the
additional information necessary to compare results was 
not available (150,151). The data from the remaining 
three studies is comparable and therefore only the 
findings drawn by Rizza and Spooner on 5098 haemophiliacs 
UK are presented (154):
1 . The median life expectancy for a severe factor VIIIC 
deficient haemophiliac was 69.2 years and 79.2 years for 
a moderately affected patient. Median life expectancy of 
an English male was 72.8yrs. Therefore by 1 976 - 80
haemophiliacs in the UK were expected to have a near
normal life expectancy. Similar results were found in 
Sweden and Finland (152,153).
2. The overall annual death rate for severe haemophilia 
A (VIIIC < 2%) was 6.3 per thousand for 1976-80. No
cumulative UK data was available prior to 1969 but can be 
implied from data published by Ikkala on haemophilic 
deaths in Finland, where annual death rate decreased from
8.6 in 1930-39 to 4.8 per thousand in 1970-79 for
children under ten years of age. Similarly in Sweden it 
was found that death rates in severe haemophiliacs was no 
different from Swedish males.
Therefore, the use of blood products particularly 
cryoprecipitate and clotting factor concentrates was 
associated with a reduced mortality in haemophilia.
1.7.3 Joint Disease
Excessive bleeding may occur from any site in 
haemophiliacs, however, spontaneous haemorrhages into 
joints, muscles and the renal tract are the most frequent 
(3) . Clinical experience and several studies have shown 
that joint disease is the single most important cause of 
morbidity from bleeding in haemophilia. The incidence 
parallels the severity of the bleeding tendency and up to 
90 percent of patients with a severe deficiency have had 
this complication (153).
The benefits of early use of clotting factor concentrates 
in relieving symptoms of an acute haemarthrosis are well 
established. However, the impact of the early use and the 
amount of clotting factor concentrate used on the 
progression of the arthritis and frequency of 
haemarthrosis is not known but is being evaluated 
prospectively (156).
An interim analysis at two years of this prospective 
study shows that:
(i) The dose and type of replacement material does not 
affect frequency of bleeds.
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(ii) Multiple joints are involved and there is a 
progressive deterioration with age.
(iii) The clinical findings do not parallel the severity 
of radiological damage.
(iv) The degree of radiological damage is independent of 
dose used to treat the patient.
The only firm conclusion therefore that can be drawn at 
present is that clotting factor concentrates are 
effective in treating acute haemarthrosis but do not 
appear to significantly alter the natural history of 
joint disease but may delay its onset (156).
1.8. Complications of treatment with blood products
Complications that may result from the use of blood 
products include:
1 Infective: The major infective complications include 
hepatitis and human immunodeficiency virus 1 infections.
2 Non-Infective: These can be further subdivided into 
those with an immunological basis and those independent 
of an immune mechanism.
1.8.1 Infectious Complications of treatment with blood 
products:
After the widespread use of blood transfusion therapy in 
the 20th Century,data soon accumulated that implicated 
blood as a vehicle for the transmission of infectious
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organisms. In 1943 Beeson reported jaundice occurring in 
patients 1-4 months after transfusion with blood or 
plasma and suggested an infectious aetiology (157).The 
list of infectious organisms has gradually expanded, 
Table 1.8.1.
The biology of the infectious agent determines whether 
they are transmitted via cellular or cell free blood 
products. Haemophiliacs have a lifelong dependence on 
cell free blood products and are therefore particularly 
at risk of acquiring hepatitis,(due to hepatitis B and 
the non A, non B [NANB] viruses) and acquired 
immunodeficiency syndrome (AIDS) due to human 
immunodeficiency virus - 1 (HIV-1).
Hepatitis
Post-transfusion hepatitis is a well recognised and 
important complication of blood transfusion.lt is 
estimated that in the USA alone between 200,000 - 300,000 
cases occur each year. To fully appreciate the current 
understanding of hepatitis in haemophiliacs several major 
observations that have shaped and altered the course of 
post-transfusion hepatitis merit recounting.
First, and perhaps most important was recognition of the 
importance of donor source and greater hepatitis risk of 
commercial blood donations. The seminal observations in 
this area were by Allen and Kunin (158.159).
Table 1.8.1. Infectious agents transmitted by transfusion.
Viral
Hepatitis A 
Hepatitis B 
Hepatitis non-A, non-B 
Cytomegalovirus 
Epstein-Barr virus 
Serum parvovirus 
HTLV-I/HIV
Trepomnemal
Syphilis
Parasitic
Malaria
Filariasis
Trypanosomiasis
Toxoplasmosis
Babesiosis
Bacterial
Multiple organisms
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Second, the chain of events initiated by the discovery of 
hepatitis B surface antigen (HBs Ag, Australia antigen) 
by Blumberg and his associates in 1965; the association 
of this antigen with viral hepatitis (Blumberg 1967);the 
subsequent linking of this agent with type B hepatitis; 
the findings by Gocke 1970, and Okochi 1970 that 
transfusion of HBs Ag - positive blood was associated 
with hepatitis;the demonstration that exclusion of HBs Ag 
positive blood and commercial donors reduced post­
transfusion hepatitis by 85 percent and finally 
development of sensitive radio immunoassays for HBsAg 
detection in selecting blood donors (160 - 166).
The third major development was a test for the hepatitis 
A virus (HAV) in 1973 and subsequent recognition that 
non-B hepatitis cases were not due to HAV but due to a 
newly recognised,hepatotropic virus or groups of viruses 
that were designated non-A, non-B (NANB)(167 - 169).NANB 
now accounts for 85-98 percent of episodes of post- 
transfusion hepatitis.
Hepatitis B
The frequent exposure of haemophilic patients to 
hepatitis B virus (HBV) is evidenced by the high 
incidence of positive serological tests for HBV 
(170).The current situation regarding HBV infection can 
be summarized as follows:
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First, risk of HBV infection is strongly correlated with 
use of large pool concentrates and is greater with plasma 
obtained from paid donors (171).
Second, application of sensitive tests for detection of 
HBsAg to screen units of donated blood and plasma has 
resulted in a notable reduction in HBV infection, after 
first transfusion of concentrate. Prior to 1975 the 
attack rate was greater than 80 percent; more recent 
studies show a 75 percent reduction (172). Thus 
occurrence of HBV infection has not yet been entirely 
eliminated.
Third, most severe haemophiliacs are exposed to HBV 
before ten years of age.Acute infection is often 
asymptomatic or occasionally associated with mild non­
specific illness (172). On the other hand mild 
haemophiliacs who acquire infection usually do so later 
on in life and in such cases infection is more often 
symptomatic (172). The reason for this difference may not 
be a function of age but could be related to the 
acquisition of partial immunity conferred by passive 
transfusion of HBV antibody from previous transfusions of 
clotting factor concentrate.
Fourth, the finding that the proportion of HBsAg 
carriers in treated haemophiliacs is no higher than in 
non haemophiliacs with a similar exposure to HBV is 
reassuring (172). However, it must be noted that carriers
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are at a greater risk from chronic liver disease, not 
only from HBV but also in their greater susceptibility in 
acquiring delta virus infection (173). Such patients may 
benefit from treatment with recombinant alpha interferon 
- its efficacy however needs to be more fully established 
especially in the context of HIV-1 infection (172 - 174).
Finally, the efficacy and safety of HBV vaccine is well 
established in conferring immunity for at least five 
years. It is therefore potentially possible to eliminate 
further HBV infections.
NANB hepatitis
One widely accepted epidemiological definition of NANB 
hepatitis is a rise in serum alanine aminotransferase 
(ALT) above twice the upper limit of normal on at least 
two occasions at least two weeks apart in the absence of 
any known cause (176). Using such a definition the 
attack rate after transfusion of the first batch of 
unheated concentrate approaches 90 percent (177).
The risk of acquiring NANB hepatitis is significantly 
greater with clotting factor concentrates than 
cryoprecipitate and there is a greater risk with clotting 
factor concentrates fractionated from paid plasma 
donations rather than voluntary donations (178).
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Complications of NANB hepatitis:
The importance of NANB infection lies not in acute 
manifestations, but in its chronic sequalae. In non- 
haemophilic patients who acquire NANB, persistent or 
fluctuating elevations in ALT remain for at least three 
years in up to 70 percent of patients (179). 
Characteristically rises in ALT are fluctuating in nature 
with the periodicity in fluctuations decreasing with 
progression to chronicity. Percutaneous liver biopsy 
studies in such patients invariably show features of 
chronic hepatitis and in up to 20 percent of biopsied 
patients progression to cirrhosis occurs (180).The 
difficulty in distinguishing severe chronic persistent 
hepatitis from chronic active hepatitis limits the 
significance of firm conclusions being attached to a 
finding of chronic hepatitis.
Similar natural history observations are more difficult 
to obtain in haemophiliacs: first, the very nature of
the disease necessitates frequent transfusions and 
therefore the date of first infection often is not known; 
second at least two agents have been implicated in 
haemophilic NANB hepatitis and third clotting factor 
concentrates in the absence of infection may result in a 
chemical/allergic hepatitis (181,182).
Studies of serum ALT have been reported by several 
groups, Table 1.8.2 (183 - 192). The wide variations in 
percent prevalence of abnormal serum ALT level reported
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may be due to differences in patient selection or the 
natural history of the fluctuations in serum ALT. More 
meaningful information has been provided by longitudinal 
studies. There is agreement in statistically comparing 
longitudinal studies Table 1.8.2 that between 20-30 
percent of patients have persistent serum ALT
elevations. In the vast majority clinical signs of 
chronic liver disease were absent.
Studies of liver biopsy material show that the magnitude 
of rise in serum ALT does not reflect the nature of 
hepatic lesions,for example Carr et al found that the 
level of AST was the same in cirrhosis and chronic 
persistent hepatitis (192). However, additional 
information can be obtained by reviewing the pattern of 
rise; persistently raised levels of above 150 percent of 
normal levels for J>6 months indicate chronic hepatic 
disease - disappointingly, this does not distinguish 
between chronic persistent and chronic active. Clinical 
examination in such individuals for stigmata of chronic 
liver disease may help but these findings are 
infrequently present.
Fluctuating levels tend to indicate less severe liver 
disease; in a biopsy study of 15 patients with such a 
pattern, White et al found that despite presence of 
inflammatory portal tract lesions in all patients, only 
one patient had chronic active hepatitis, 11 chronic 
persistent hepatitis and the remainder no additional
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changes were present (193). The latter group after two 
years had normal ALT levels this did not help in
distinguishing lesions,although as a group mean ALT 
levels were lower.
The interpretation of serum ALT levels in haemophiliacs 
is further complicated by the ability of clotting factor 
concentrates to induce a non-infectious hepatitis (182).
Liver biopsies in haemophiliacs have provided worrying
but controversial data.The divided opinions on the
interpretation of findings are best illustrated in the
choice of titles of published series.
"Liver disease in haemophilia: An overstated
problem."(194)
"Progressive liver disease in haemophilia: An
understated problem."(195)
What then are the sources of controversy and are there 
any agreements.Liver biopsy or autopsy data have been 
reported in 278 patients, sequential biopsy data were 
available in 38 patients.The studies reviewed are shown 
in Table 1 .8.2.
Clinically important information can only be obtained 
from one study (2). In this collaborative, worldwide 
study biopsy (or autopsy) obtained material from both 
treated and untreated patients was independently
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interpreted by four histopathologists, using predefined 
and accepted criteria for histological grading. Despite 
these preconditions it was found that agreement in final 
diagnosis between all four pathologists was reached in 
only 55 percent of cases. The major area of 
disagreement was in classification of chronic persistent 
and chronic active hepatitis. These lesions accounted 
for between 7-72 percent of diagnosis in other studies. 
Furthermore in up to 10 percent of cases reported by 
Aledort et al the cause of liver disease was not directly 
attributable to NANB or hepatitis B infection - a finding 
in keeping with some other reports, Table 1.8.2.
Despite this there are areas of agreement and several 
conclusions can be drawn. First,cirrhosis occurs in about 
15 percent of patients, the nine percent figure from the 
cumulative Sheffield studies is not statistically 
different than that reported by Aledort (2) . Mannucci et 
al also report a similar incidence (203). The incidence 
of cirrhosis in haemophiliacs is therefore not
significantly different from that reported in the 
outcome of individuals who acquire NANB after elective 
cardiac surgery (204).
Second chronic hepatitis (without distinguishing between 
chronic active hepatitis and chronic persistent 
hepatitis) occurred in 71 - 91 percent of patients. The
prevalence of chronic hepatitis between the Aledort study 
and others showed considerable differences, in particular
Table 1.8.4. Serial liver biopsy studies.
Age at Interval
Author (Ref) 1st biopsy 2nd biopsy 1 St Bx mths
Aledort (2) CPH (5) CPH 6) }
CAH (6) CAH 2) } n /k N/K
CIRR (1) CIRR (2) }
Schimpf (201) CPH (3) CPH 4) 24 48
CAH (2) CAH 2) (18-25) (31-58
Hay (195) CPH (6) CPH 3) 32 47
CAH (4) CAH 2) (26-28) (31-58
CIRR (0) CIRR (5)
Mannucci (197) CPH (8) CPH 8) 12 36
CAH (2) CAH 2) (6-15) (36-36
CIRR (1) CIRR (1)
The median and interquartile ranges are shown for age and
N/K = not known
CPH = chronic persistent hepatitis
CAH = chronic active hepatitis
CIRR = cirrhosis
Chronic lobular and aggressive hepatitis was included under CAH.
22 1st biopsies = CPH - 2nd biopsy: CPH=17/ CAH=3/ CIRR=2.
12 1st biopsies = CAH - 2nd biopsy: CPH=5/ CAH=4, CIRR=5.
2 1st biopsies showed CIRR - 1 had died, he had concommitant delta 
in one the outcome is not known.
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there were major differences in lesions classified as 
chronic persistent hepatitis and chronic active 
hepatitis. On comparing the cumulative Sheffield results 
with those of Aledort et al, it was found that 
considerably greater numbers of cases had been classified 
by the Sheffield group as chronic active hepatitis than 
in the Aledort data.
An additional potential source of error in the cumulative 
Sheffield data was the inclusion two patients who had 
granulomatous lesions on biopsy (a feature that is not 
recognised in the spectrum of histological abnormalities 
reported in NANB hepatitis).
The best estimate of severe liver disease defined as the 
presence of cirrhosis and chronic active hepatitis in 
haemophilia therefore is 22 percent (cirrhosis = 15%;
chronic active hepatitis = 7%) . A more fundamental
question in planning for the health care of haemophiliacs 
is the prognosis of chronic hepatitis which accounts for 
up to two thirds of patients that are biopsied.
Four studies had reported on 38 serial biopsies, the 
cumulative results from these studies are shown in Table
1.8.3 (2,195,201,203). Accepting the difficulties in
histological differentiation of chronic active hepatitis 
and chronic persistent hepatitis if individuals with 
these lesions were considered as a group (n=34), six 
(18%) showed clinical or histological progression to
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cirrhosis, in 11 (32%) the histological diagnosis did not
change, three (9%) showed a histological deterioration.
Chronic hepatitis therefore progresses to cirrhosis in 32 
percent of cases
Human immunodeficiency virus - 1
The acquired immunodeficiency syndrome (AIDS) is a
clinical diagnosis, and is but one manifestation of a 
spectrum of clinical and subclinical disorders caused 
by the human immunodeficiency virus - 1 (HIV-1).
Haemophiliacs acquire HIV-1 infection from contaminated 
blood products. Aspects of HIV-1 infection in
haemophiliacs, in particular the immune response to HIV-
1, and the effects of HIV-1 on the immune system are 
discussed in subsequent chapters of this thesis. There 
are however, several aspects worthy of further review.
Human Immunodeficiency Virus - 1
HIV-1 is an RNA retrovirus and shares morphological, 
biological and molecular similarities to the visna virus 
of sheep, equine infectious anaemia virus and the 
recently described feline and bovine immunodeficiency 
viruses. It is also related to recently isolated 
primate retroviruses such as simian T lymphotrophic 
virus-III. It is distinct from HIV-2 in several respects, 
HIV - 2 has a more restricted distribution, it is most
prevalent in West and Central Africa. Other differences 
include significant variations in envelope proteins and 
to a lesser extent core proteins. HIV-2 has similar
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routes of transmission and risk groups, it also appears 
to be more adapted to the host and is less virulent.HIV - 
2 is more closely related to primate retroviruses than 
HIV-1. Cross-reactivity between the two viruses occurs 
in serological tests for HIV-1 but specific serological 
tests are now commercially available (reviewed 208,209).
Viral Tropism
The accepted sine qua non of HIV-1 infection is the 
progressive depletion of T-helper cells. The CD4 antigen 
expressed on human T-helper cells is a major cellular 
receptor for HIV-1 envelope protein gp120 (207). However, 
it is now apparent that HIV-1 can infect cells that lack 
CD4 and is found in endothelial and epithelial cells of 
seropositive individuals (208-211).
Alternative mechanisms may therefore govern infection. 
Fusion of the target cell membrane with the transmembrane 
envelope protein gp41 may be one such mechanism. The 
finding that HIV - 1 infection of cells is pH independent 
supports a fusion process (212). Furthermore, part of the 
sequence of gp41 is similar to the fusinogenic proteins 
of paramyxoviruses, and antibodies to gp41 protein 
neutralize HIV - 1 (213,214). The finding that HIV - 1
antibodies enhance HIV - 1 infection of cells in vitro
suggests virus-antibody complexes may permit infection 
of cells that express Fc or complement receptors (215). 
Cellular factors may also determine establishment of HIV 
1 infection, a single HIV - 1 isolate showed
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differential levels of productive infection in peripheral 
blood mononuclear cells from various individuals (216).
The immunopathology of HIV - 1 infection
A central dogma in HIV-1 infection has been that 
immunosuppression and immune function abnormalities in 
AIDS (Table 1.8.5) are due to progressive depletion of T- 
helper cells. Several observations have challenged this. 
First, the number of actively infected blood cells are 
small, although a larger number may be latently infected, 
“Ehis does not account for the profound T helper cell 
depletion in AIDS (217). Second, although syncitia 
formation accounts for the cytopathic effects of HIV-1 in 
vitro, syncitia have not been demonstrated in vivo (218). 
Third, many HIV-I isolates from immuno — compromised 
patients are not highly cytopathic in vitro (219). Last, 
T-helper cells from infected individuals but not actively 
infected show aberrations comparable to infected cells 
(220). Other mechanisms therefore require to be
postulated and these are summarized in Table 1.8.6.
Determinants of disease progression
Considering the biology of HIV - 1 it is not surprising
that up to 70 percent of infected individuals progress to 
develop symptomatic immunodeficiency within six years of 
infection (1). A more interesting aspect is why up to a 
third of infected individuals remain symptom free. 
Variables that may potentially affect the course of 
infection include virulence of the virus strain, the
Table 1.2.5. Immune function abnormalities in AIDS
T lymphocytes
(1) Decreased proliferative responses to mitogens, 
soluble antigens, and allogeneic cells.
(2) Decreased lymphokine production (IL-2,gammainterferon) 
in response to antigen.
(3) Decreased cytotoxic T lymphocyte activity against 
virus - infected cells.
B lymphocytes
(1) Polyclonal activation with hypergammaglobulinaemia and 
spontaneous plaque forming cells.
(2) Decreased humoral response to immunization.
(3) Production of autoantibodies.
Monocytes
(1) Decreased chemotaxis.
(2) Decreased IL-1 production
(or production of an inhibitor of IL-1).
(3) Decreased microbiocidal activity.
NK cells
(1) Decreased cytotoxic activity.
Table 1.8.6. Mechanisms of immune suppression by HIV infection.
Direct mechanisms
(1) HIV cytocidal effect on CD4+ lymphocytes.
(2) Functional defects in infected CD4+ cells:
(a) decreased expression of cell surface proteins (eg, 
IL-2 receptor, CD4);
(b) impaired production of lymphokines such as IL-2 or 
gamma interferon.
(3) Impaired antigen presentation and/or monokine 
production by infected macrophages; cell death.
Indirect mechanisms
(1) Generation of suppressor T cells and/or factors.
(2) Toxic or inhibitory effects of viral protein.
(3) Immune complex formation.
(4) Induction of autoimmune phenomena:
(a) autoantibodies resulting from polyclonal B cell 
activation or antigen mimicry;
(b) virus mediated, enhanced immunogeniticy of normal 
cellular proteins.
(5) Cytotoxic cell activity against viral or self proteins.
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antiviral immune response and the inherent sensitivity of 
the host cell to virus replication.
Several recent findings suggest that the immune response 
to HIV - 1 may be a determinant of outcome. First,
exposure to the virus is not invariably associated with 
infection. This has been shown in haemophiliacs and
homosexual men (221,222). Second, in a cohort of
homosexuals known to be HIV - 1 antibody positive six
individuals have become seronegative for antibody and
remain asymptomatic. Using the polymerase chain reaction 
it was shown that all previously had integrated provirus 
(223). Third, the frequency of virus isolation from 
peripheral blood is increased in asymptomatic individuals 
if the cell preparation is depleted of T suppressor 
/cytotoxic cells (224). Further studies showed that 
soluble cell secreted factors mediated the response. 
Taken together these findings suggest that the immune 
response to HIV - 1 may be an important determinant in
the outcome of HIV -1 infection.
1 . 8 . 2  Non in f e c t iv e  c o m p lic a tio n s  o f re p la c e m e n t th e ra p y  
in  h a e m o p h ilia .
The non infective complications of replacement therapy 
can be considered under two broad categories:
1 . Immune mediated.
2. Non immune complications.
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Immune mediated
Complications included in this group are listed in Table 
1.8.5. Immune reactions may mediate tissue injury by four 
types of reactions.
Anaphylactic (Intermediate Hypersensitivity) - Type I 
Reactions.
Anaphylactic reactions are caused by antigen - antibody 
reactions occurring on the surface of mast cells leading 
to release of histamine and other vasoactive amines.The 
incidence of such reactions has been reported to be as 
high as 19 percent (224). The majority are mild, manifest 
as fever and urticaria but in 0.7 percent systemic 
anaphylactoid reactions occur which may be life 
threatening (3). The mechanism is not clear but presumed 
to be to the contaminating immunoglobulins contained 
within clotting factor concentrates.
Non allergic reactions may also occur and consist of 
variable subjective complaints of dizziness, headache, 
and shortness of breath. Such reactions may be due to 
infusion of vasoactive substances contained within 
clotting factor concentrates.
Cytotoxic (Humoral Antibody) - Type II reactions.
Autoimmune haemolytic anaemia is the clearest example of 
a type II reaction. Haemolytic anaemia may occur in
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haeraophilic patients of blood group A,B or AB after a 
period of intensive therapy with concentrates (230-231). 
The haemolytic anaemia is due to the passive infusion of 
IgM and IgG anti-A and anti-B alloagglutinins present in 
factor VIII concentrates. Haemolysis usually starts after 
two or three days of intensive replacement therapy. A 
positive direct Coombs test is often found (3) . More 
recently, it has been suggested that the high frequency 
of low levels of haptoglobin in multitransfused 
haemophiliacs might be related to a certain degree of 
chronic, clinically unapparent haemolysis (232).
The presence of factor VIII/IX inhibitors (antibodies) 
can also be included under this category. Factor VIIIC 
inhibitors develop in approximately 10-15 percent of 
treated haemophilia A patients (233) . In the majority of 
cases inhibitors are IgG antibodies with kappa light 
chains (234-237). A few however have lambda light chains 
or were mixtures of IgG kappa and lambda chains (234, 
238, 239) . Heavy chain subtyping has shown that IgG4 
predominates (238). They are therefore non-precipitating 
antibodies and do not fix complement. This may explain 
why patients with an inhibitor do not develop renal 
damage when infused with factor VIII concentrates (238) .
Two types of factor VIIIC inhibitors can be recognized in 
vitro.
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Type I - appear to react with epitopes near the factor 
VIIC procoagulant site. The inactivation kinetics of 
factor VIIIC shows a steep slope and complete factor 
VIIIC inactivation occurs. Such inhibitors are saturated 
when sufficient factor VIIIC is added and there is a 
linear relationship between residual factor VIIIC 
activity and inhibitor concentration ( 2 3 4 ,  235, 238,
240) .
Type II inhibitors by contrast have complex inactivation 
patterns. These occur in a minority of haemophilic 
patients and the majority of non-haemophilic patients 
with inhibitors (234, 235, 238, 241, 242). It has been
suggested that type II inhibitors react with interaction 
sites of factor VIIIC and factor VIII von Willebrand 
factor (238, 243) .
The majority of factor VIIIC deficient patients have a 
severe factor deficiency, although inhibitors are 
reported in patients with moderate - mild haemophilia.The 
development of inhibitor invariably requires exposure to 
factor VIIIC, although the amount is quite variable. The 
majority of patients develop an inhibitor before the age 
of 10 years (244).
Most patients are "high responders" exhibiting a marked 
rise in inhibitor concentration following exposure to 
factor VIIIC.A few are "low responders" never having much 
of a amanestic response. Inhibitors in high responders
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usually persist whereas in low responders several 
clinical patterns are apparent.The inhibitor may 
spontaneously disappear or it may persist,the patient 
gradually becoming a high responder. In some it may 
remain unchanged and bleeding episodes can thus be 
continued to be treated with human factor VIII 
concentrates (3).
There is some evidence to suggest a genetic 
predisposition to inhibitor development. Inhibitors tend 
to occur more frequently in brother pairs and in black 
haemophiliacs. The occurrence of inhibitors before the
age of 20 years in up to two thirds of patients also 
suggests a genetic predisposition (244).
The sensitization to IgG subtypes and variants of 
complement C4 can also be considered as type II reactions 
(245, 246).
Immune Complex (Arthus) Type III Reactions
Type III reactions are induced by deposition of antigen - 
antibody complexes in tissues causing an inflammatory 
reaction via mediators such as complement. The
occurrence of serious side-effects with bovine and
porcine factor concentrates may have mediated by such
reactions. Immune complexes have not been found in human 
clotting factor concentrates, however, treated 
haemophiliacs have higher levels than normals of immune
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complexes detected by a variety of different methods 
(247-251). In a few hepatitis B antigen has been 
identified (247) .
The clinical significance of these findings is not clear, 
haemophiliacs with immune complexes have evidence of 
complement consumption but true immune complex mediated 
disease has been only reported infrequently. In one study 
a correlation between immune complexes and chronic 
synovitis, liver disease as well as episodes of 
haematuria was found (248).
Cell-mediated (Delayed Hypersensitivity) - Type IV 
Reactions
Type IV reactions are mediated by T lymphocytes and in 
which free antibody plays no part. Delayed
hypersensitivity can be tested in-vivo by challenging the 
immune system with dermal or intradermal antigens. 
Impaired cell mediated immunity using such tests has been 
reported in haemophiliacs independent of the HIV-1 
antibody status (see Chapter7).
1.8.3 Non Immune, non infectious complications of 
clotting factor concentrates
Thrombotic complications with factor IX complex.
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As a result of preparative procedures, some zymogens in 
factor IX concentrates became activated, with raised 
levels of factor IXa and Xa. Thrombosis both venous and 
arterial as well as disseminated intravascular 
coagulation are reported in patients treated with large 
doses of prothrombin complex concentrates. It has been 
suggested that patients with chronic liver disease may be 
predisposed to this complication because of impaired 
clearance of activated factors(3).
1.9 Safer clotting factor concentrates
The use of clotting factor concentrates in the treatment 
of haemophiliac bleeding has proven to be a double edged 
sword. The benefits of treatment are firmly established 
(section 1.7), on the other hand treatment carries a high 
risk of transmitting blood borne viral diseases (section 
1.8). Moreover,intermediate purity preparations contain 
substantial amounts of plasma proteins other than factor 
VIII (Tables 1.5.1 and 1.5.2). The clinical consequences 
of the repeated administration of this large alloantigen 
load is not clear. Recurrent alloantigen stimulation is 
implicated in changes in the immuno-regulatory ratio 
which may have predisposed some haemophiliacs to 
acquiring HIV-1 infection (221).
The development of safer clotting factor concentrates has 
therefore been arrived at by first reducing risk of
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acquired blood borne viral infections,and second by
reducing alloantigen load.
Measures employed to reduce risk of acquiring viral
infections include donor screening for viral markers such 
as hepatitis B surface antigen or anti-viral antibodies, 
for example anti-HIV-1 IgG antibody. Such strategies
minimize, but do not eliminate the risk of viral
infections.Various additional methods have therefore been 
sought.
Three main approaches have been used:
1. Heat
2. Chemical inactivation
3. Physical exclusion
1.9.1 Heat
Heat treatment is the most common additional virucidal 
method used. All methods based on heating use 
temperatures between 60°C and 80°C for 30-72 hours. Dry 
heat is the term applied when clotting factor 
concentrates are heated once lyophilized , this is the 
commoner method applied. Dry heat has also been applied 
to lyophilized concentrates resuspended in the organic 
solvent n heptane. The alternative is pasteurization (or 
wet heating) of concentrate in the aqueous phase with 
direct heat or a hot vapour. Wet heat has the advantage 
that less heat needs to be applied to achieve a given 
virucidal effect. The disadvantage is a lower yield.
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This has been partially overcome by addition of 
stabilizers such as glycine,sucrose or potassium citrate. 
Their use however reduces heating efficacy by a magnitude 
of 2 logs-jQ (252). The effect of temperature on factor 
VIII yield is dependent more on temperatures applied 
rather than duration (252). For instance increasing 
temperatures from 60°-70° or 80°C causes a 90 percent or 
greater loss in factor VIII activity. Heating for 72 
hours instead of 10 hours at 60°C does not result in 
additional loss (252).
Hepatitis
Despite donor screening for hepatitis B surface antigen, 
the use of clotting factor concentrates still carries a 
risk of contracting hepatitis B virus (HBV) infection. 
The impact of donor screening therefore has been to delay 
the onset of contracting HBV infection in patients 
receiving regular treatment with clotting factor 
concentrates by one to four years from first receipt of 
these products (253).
Although pasteurization of albumin (60° for 10 hours) is 
not associated with HBV infection, the same does not 
apply to clotting factor concentrates or plasma. 
Pasteurization of whole plasma at 60°C for 10 hours 
results in incomplete HBV inactivation (254).Dry heat 
applied to factor VIII concentrate at 60°C for 20 hours 
does inactivate HBV. Studies in chimpanzees inoculated 
with a dry heat inactivated factor VIII concentrate have
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confirmed that HBV is inactivated after such treatment 
(253).
The primary aim in heat treating concentrates is now 
prevention of NANB hepatitis,consequently a substantial 
number of patients recruited into virgin patient studies 
have received prior HBV immunisation. For instance 16 of 
26 patients entered into a study evaluating pasteurized 
factor VIII had been immunizjed; therefore no firm 
conclusions can be drawn on effects of newer wet heat 
treated preparations in preventing HBV infection (256). 
Dry heat at temperatures less than 60°C is ineffective in 
preventing infection (257).
The chronic sequalae of NANB hepatitis are a more serious 
problem in haemophiliacs (section 1.8). In the absence of 
a serological test the risk of infection can be reduced 
by screening plasma donations for raised serum ALT level 
and additional heat treatment. In the light of recent 
observations of a dry heat method which was shown to be 
effective in preventing infection in chimpanzees but 
resulted in hepatitis in animals and haemophiliacs, in 
vitro observations of efficacy can no longer be regarded 
to be critical enough and therefore are not reviewed 
(258) .
Haemophiliacs treated with a dry heat treated factor VIII 
concentrate at 60°C for 30 hours and 72 hours have a 
higher incidence of NANB hepatitis (257). Treatment with
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chloroform carries no additional benefit (257).Heat 
treatment in the presence of solvent (n heptane) using 
plasma screened for raised ALT activity appears to be 
safe but is not effective if plasma with raised ALT 
levels is used (259).
Preliminary studies with dry heated concentrate at 80°C 
for 72 hours appear to be safe but the numbers of 
patients treated meeting the International Committee on 
Thrombosis and Haemostasis criteria is small (n=13) 
(257). Heat treatment in the presence of steam appears to 
prevent NANB hepatitis but not hepatitis B (260) . Wet 
heat treatment for 10 hours at 60°C also appears to be 
effective in preventing acute NANB hepatitis (257).
HIV-1 inactivation
HIV-1 is a heat sensitive virus. It has been recommended 
that the duration and amount of treatment applied should 
aim at a reduction of viral infectious dose by 5 log^o 
infectious HIV-1 doses/ml (261). Heat inactivation 
studies show that when a one in ten dilution of cell 
culture medium of HIV-1 propagated in H-9 cells with a 
infectivity titre of > 105 is added to liquid factor
VIII concentrate and heated to 60°C one log^o is 
inactivated in about 30 seconds (262,263). The rate of 
thermal decay of wet heat is consistent with first order 
kinetics (263). In the liquid state ,thermal decay is not 
affected by the liquid matrix or the presence of
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stabilizers (263). Dry heat required 32 mins.Heating at 
60°C to reduce infectious doseso by ten fold (1 log)
(263) . Longer intervals however have been reported by 
others. Prince reported that heating lyophilized factor 
VIII concentrate at 60°C contaminated with a 1 in 10 
volume of HIV-1 propagated in a H-9 cell line resulted 
in 0-1 log^o inactivation at 10 hour and between 2-41og-|Q 
at 72 hours(262). Levy et al also showed a 2-5 log^o 
inactivation of HIV-1 after 24 hours heating at 68°C
(264). Lyophilisation alone had a minimal virucidal 
effect reducing infectious dose by 0.5-1 log^o (264).
These findings are in keeping with results of prospective 
surveillance studies of HIV-1 seroconversions with the 
use of heat treated factor concentrates (257). Dry heat 
treatment at 60°C for 30 hours (in the absence of donor 
screening) is inadequate in conferring protection against 
HIV-1 infection, whereas heat treatment at 68°C for 72 
hours (in the absence of donor screening) has not 
resulted in HIV-1 seroconversions (257). HIV-1 
seroconversions have not been reported with pasteurized 
concentrates (257).
1.9.2 Physical Exclusion
In vitro studies of a purified factor VIIIC concentrate 
(purity=5iu/mg) prepared by immunoaffinity chromatography 
using a mouse monoclonal antibody to von Willebrand 
factor have shown that this method in addition to
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removing other plasma proteins is effective in reducing 
HIV-1 log-jo titre of added infectious virus by at least 4 
log^o* A similar reduction occurs for the model viruses 
Sindbis/ Pseudorabies and Vesicular stomatitis virus. 
Additional dry heat treatment at 60°C for 30 hours 
inactivates a further 3 log^g of HIV-1 (115).
Although availability of such a pure concentrate would 
appear to be ideal treatment in haemophilia the clinical 
value of such a preparation is unclear. Preliminary 
uncontrolled observations suggest that in HIV-1 antibody 
positive patients the rate of CD4+ve T-cell depletion may 
be reduced. This, however, requires to be substantiated 
(269). Initial clinical studies also indicate that the 
risk of acquiring hepatitis after a first infusion is 
less than products heated in the lyophilized state at 
less than 80°C (257). None of the 25 previously untreated 
patients receiving this product have acquired hepatitis
(265) .
1.9.3 Chemical Inactivation
Lipid enveloped viruses can be inactivated by a 
combination of solvent and detergent (Tween 80/ether) 
without additional heat treatment (266) . Use of this 
combination is however limited as the detergent is 
difficult to remove after sterilization and ether is 
difficult to handle on a large scale. An alternative and 
more acceptable combination is tri(n-butyl) phosphate 
(TNBP) and sodium cholate, this mixture readily
51
inactivated HIV-1, hepatitis B and the Hutchison strain 
of NANB hepatitis virus, in vitro (267) . However, one 
putative strain of the NANB virus is resistant to 
chloroform treatment and is unlikely therefore to be 
susceptible to inactivation (268).
After sterilization both TNBP and sodium cholate can be 
easily removed from treated concentrate. The yield of 
factor VIII is high and the process is not associated 
with protein denaturation, however, electrophoretic 
mobility of some lipoproteins is altered (269).Initial 
primate studies confirm the in vitro observations and 
factor VIII concentrates treated with this mixture have 
been licensed by the USA Federal Drug and Food 
Administration (267). Preliminary human studies show that 
concentrate treated with TNBP/sodium cholate is not 
associated with acute NANB hepatitis (270).
Beta propionlactone with ultraviolet radiation 
inactivates HIV-1, hepatitis B and the NANB viruses (271- 
272) . This process of sterilization has been used for 
several years in Germany.lt is limited by the potential 
oncogenic effects of beta propionolactone which 
preferentially reacts with DNA or RNA by alkylation but 
does not affect the biological activity of coagulation 
proteins (272). No HIV-1 seroconversions have been 
reported with concentrate sterilized with this method 
(272) .
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1.10 Bio-free recombinant factor concentrates
Investigators working independently at two separate 
companies, Genentech and Genetics Institute, have 
succeeded in isolating and cloning the gene for factor 
VIII (6-9). The gene has been found to be 186 000
kilobases long and the coding information for circulating 
factor VIII is spread among 26 exons.The extreme length 
of the gene and necessity for extensive post 
translational modification discouraged the use of 
recombinant bacteria, such as E.coli for manufacture of 
this protein and thus initial attempts to produce the 
protein in culture systems have been with mammalian 
cells.Recombinant factor VIII has been successfully 
produced in Chinese hamster ovary cells traansfected with 
the coding sequence human factor VIIIC. Factor VIII is 
then purified to homogeneity by affinity chromatography 
with a mouse monoclonal antibody to human factor VIII and 
ion exchange chromatography. The recombinant protein has 
been shown to be fully functional in that it corrects the 
defect caused by the missing protein in haemophiliac 
plasma and, when injected into haemophiliac dogs, has 
been found to correct the clotting defect and to 
circulate with a half-life similar to that of native 
factor VIII. Thus, the evidence accumulating suggested 
that bio-engineering factor VIII is equivalent to the 
blood derived protein.
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Progress is also being made on bioengineered factor IX. 
The gene for factor IX has been cloned and several
biotechnology companies are trying to develop the 
bioengineered factor IX product (59). Bioengineered
factor IX has an additional complication in that it 
requires gamma carboxylation of a glutamyl side chain. 
Because factor VIII deficiency is nine times more 
prevalent in the population than factor IX deficiency, 
bioengineering factor VIII is more viable commercially
and is thus predicted to be available at an earlier date. 
There are no definite predictions as to when such 
products will be widely available; most investigators
indicate that a several years' delay is probable.
AIMS OF THESIS:
Background:
Clinical and laboratory ev idence of impaired cell 
mediated immunity has been frequently reported in 
haemophiliacs treated with clotting factor 
concentrates. Potential causes include:
1 The viruses transmitted via clotting factor 
concentrates.
2 A direct chemical "effect" of clotting factor 
concentrates on the immune system.
3 Alternatively, the frequent extraneous 
protein load of alloantigens infused may be 
responsible .
See Figure Aims of Thesis .
Impaired cell mediated immunity may arise due to:
1 Impaired T~helper/inducer cell activity, this 
may due to quantitative or qualitative changes.
2 Excessive T-suppressor/cytotoxic cell activity, 
either quantitaive or qualitative.
V\|
3 Impaired fubtion of monocyte/macrophages.
AIMS
The aims of this thesis were :
1 To study in vivo and in vitro cell 
mediated immunity in haemophiliacs
2 To determine influences of each of the 
potential causative factors.
3 To study the immune response and effects of 
the human immunodeficiency virus - 1
on cell mediated immunity in haemophiliacs.
These aims were achieved by studying prospectively a
well defined cohort of haemophiliacs treated with
clotting factor concentrates and :
1 Assessing the in vitro effects of clotting factor
concentrates on peripheral blood mononuclear cells 
from immunocompetent individuals (Chapter 3) .
2 Establishing the extent of exposure to HIV -1 and 
determining risk factors for infection in this cohort 
(Chapter 4).
3 Measuring the presence of HIV-1 antigen and 
correlating this to the antibody response.
In addition antibody dependent cell mediated 
cytotoxicity was measured to the enevlope protein, 
gp120 of HIV-1 (Chapter 5).
4 In chapter 6 the impact of HIV -1 infection in
haemophilia is discussed and evidence for clinical 
immunodeficency was sought in HIV-1 antibody negative 
patients.
5 In vivo cell mediated immunity was measured in 
Chapter 7.
6 Quantitaive changes in the immunoregulatory ratio 
were measured (Chapter 8)
7 Qualitative measurements of lymphocyte 
function were made and the effects of HIV - 1 
proteins on the immune system in vitro were 
established (Chapter 9).
8 The capacity to produce the lymphokine interleukin 2 
was also measured (Chapter 10)
HEPATITIS HUMAN IMMUNODEFICIENCY 
VIRUS
CLOTTING
FACTOR
DIRECT/CHEMICAL
ALLOANTIGEN
LOAD
9 B cell function is partly controlled by T cells and 
was therefore assessed (Chapter 11)
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CHAPTER 2 Patients and analysis
2.1  The West o f  S co tlan d  A d u lt  H aem op hilia  C en tre
The patient population studied in this thesis was 
recruited from the West of Scotland Adult Haemophilia 
Reference Centre. The Centre serves a population of 
three million and is responsible for confirming the 
diagnosis of haemophilia and management of registered 
patients.
2 .2  T rea tm ent P o l ic ie s  and C l i n i c  V i s i t s
2.2.1 The treatment policies of the Centre for acute 
bleeding episodes are summarized in Table 2.1.1
2.2.2 Clinic Visits:
Prior to 1981 registered patients were seen as bleeding 
episodes occurred or when haemophilia associated medical 
problems arose. Patients attended the clinic without 
prior notice and were seen by the doctor attached to the 
Unit.
In 1981 all registered patients were seen by me to assess 
the severity of joint disease. The results and indicated 
the need for a review clinic. A separate clinic was 
established, attendance at this clinic was in addition to 
visits for acute bleeding episodes. The aims of this 
clinic were:
1. To identify medical problems.
T ab le  2 . 2 . 1 .  T rea tm ent p o l ic y  o f  th e  U n i t .
D e f ic ie n c y
Factor VIII
Factor VIII
Factor VIII 
with inhibitor
Factor VIIIC 
with inhibitor
Factor IX 
Factor IX
S e v e r i ty
Severe/moderate
Mild
Low titre 
of inhibitor
High titre 
of inhibitor
Severe/moderate
Mild
Type o f  P rodu ct
Factor VIII concentrate
Cryoprecipitate or DDAVP
High dose factor VIII 
concentrate
FEIBA or factor IX 
concentrate or porcine 
factor VIII
Factor IX concentrate
Fresh frozen plasma
FEIBA - factor VIII bypassing activity (Immuno Austria) 
Porcine factor VIII - used was the highly purified
polyelectrolyte porcine preparation 
(Hyate-.C, Speywood Laboratories, UK) . 
DDAVP - des arginine aminovasopressin
(dose 0.3ug per kg body weight).
The dose of blood product used was determined by:
(i) patient weight
(ii) nature and Size of bleed
(iii) previous response.
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2. To treat chronic musculoskeletal problems
identified in the cross-sectional study. It had been 
previously found that such problems were difficult to 
manage during an acute bleeding episode.
3. To educate patients on preventive aspects of 
bleeding episodes.
4. To provide a genetic counselling service for 
patients and relatives.
5. To make available and advise on the availability of 
social services the patients were eligible for.
6. To encourage regular attendance at the dental clinic 
for preventive treatment.
7 In 1982 following reports of the Acquired 
Immunodeficiency Syndrome, to monitor the clinical and 
immunological outcome of selected patients (273)
All patients with chronic problems were asked to attend 
every six months and were seen by me and Dr G D 0 Lowe.
At each clinic visit bleeding problems that had arisen 
were discussed, in addition to other medical problems. 
All patients were examined, and blood withdrawn for the 
following:
1. Full blood count and differential (Coulter S ) .
2. Liver function tests which included serum bilirubin, 
alanine aminotransferase (ALT), aspartate
aminotransferase (AST), alkaline phosphatase, albumin and 
total globulins (Technicon Autoanalyser)
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3. Hepatitis B serology - hepatitis B surface antigen 
was measured at each clinic visit and the presence of 
hepatitis B surface antibody measured in 1982 and 1987/8 
(Abbott Diagnostics, Illinois, USA).
4. If indicated, factor VIIIC/IX levels were checked 
(one stage assay, based on the activated thromboplastin 
time) and plasma screened for an inhibitor (274, 275) .
2.3 Study Population
All patients reported in this thesis had therefore been 
seen regularly by me since 1981. From this population 
was drawn a cohort who were prospectively studied from 
1982 and retrospectively from 1977-1982. Criteria for 
recruitment into prospective studies included:
I Inclusion Criteria:
I . Patients with factor VIIIC or IX deficiency who had 
been treated with a blood product from this Centre during 
or after 1980. Untreated patients were also included for 
comparison.
II Exclusion Criteria:
1. Patients who were only temporarily registered.
2. Patients who were registered at our centre but who 
had transferred to another centre prior to 1982.
3. Patients permanently registered at this centre since 
1984.
4. Patients with factor VIIIvWF deficiency.
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To confirm that retrieval of clinic records was accurate, 
the names of registered patients were checked against 
the annual patient returns for 1980 to 1982 (inclusive) 
provided by the Oxford Haemophilia Centre.
Of 169 permanently registered patients (42 factor IX 
deficient; 127 factor VIIIC deficient) 133 were 
recruited (100 factor VIIIC deficient and 33 factor IX 
deficient). The reasons for not recruiting the remaining 
36 patients are summarized in Table 2.3.1
2.4 Demographic Characteristics of Recruited Cohort
The median age of the cohort was 30 years (range 16-76 
years), Table 2.4.1 shows the ages of factor VIIIC and IX 
deficient patients.
100 were factor VIIIC deficient and 33 were factor IX 
deficient. The median factor deficiency was 2 percent 
(Interquartile range [IQR] 0-40 percent), Table 2.4.2. 
Of these patients 49 were on home treatment.
2.5 Number of patients with inhibitors:
Eight patients had a factor VIIIC inhibitor, seven had a 
severe deficiency and one was moderately deficient in 
factor VIIIC. Five were high responders and had required 
regular treatment with activated prothrombin complex 
concentrates or porcine factor VIII. Two had required 
activated prothrombin complex concentrates
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intermittently. There were three low responders and in 
all three the inhibitor is now absent.
2 .6  Use o f  b lood products
For each patient recruited the total amount of clotting 
factor concentrate, cryoprecipitate or fresh frozen 
plasma used over seven years (1980-1986 inclusive) was 
recorded and a mean annual dose calculated and expressed 
as units of replacement therapy used per annum.
One unit of clotting factor activity was defined as the 
amount present in an international standard provided by 
the World Health Organization (WHO) and distributed by 
the National Institute of Biological Standards and
Controls (London UK) . The amount of clotting factor 
activity provided by the Scottish National Blood
Transfusion Service (SNBTS) had been calibrated against 
the WHO standard.
Commercial factor VIII clotting concentrates had been 
purchased from several different manufacturers. It was 
assumed that the labelled activity was correct, although 
prior to 1982 discrepancies between labelled and actual 
activity had been noted (276, 277).
The units to indicate activity in activated prothrombin 
complex concentrates were those defined by the 
manufacturer. At this centre FEIBA was used during the
study, the units had been assayed by measuring the
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shortening of the partial thromboplastin time of a 
substrate inhibitor plasma by the manufacturer.
For cryoprecipitate the regional blood transfusion 
service had assumed that each plasma donation contained 
100 iu of factor VIIIC activity.
The median mean annual dose of replacement therapy used 
per annum over the seven years was 9000 iu (IQR 1400 to 
41,000). The median mean annual dose of replacement 
therapy used by factor VIIIC deficient patients was
8778.5 iu (IQR 1627 to 46728) and by factor IX patients: 
median 9500iu (IQR 1000 to 38,000)(p = 0.7).
2.6.1 Cryoprecipitate and fresh frozen plasma
All cryoprecipitate and fresh frozen plasma used was 
obtained from local donations of whole blood by the 
SNBTS.
2.6.2 Factor VIII concentrates
Figure 2.1.1 shows the use of factor VIII concentrates by 
this centre during the study period. Prior to 1984 a 
proportion of the concentrate used was fractionated from 
plasma donations obtained in the USA. The remainder was 
fractionated by the SNBTS from local donations, mean 
donor pool size was 1,0000 donations.
2.6.3 Factor IX concentrate (Prothrombin complex 
concentrates)
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All factor IX deficient patients requiring treatment 
received a concentrate fractionated from plasma donations 
obtained by the SNBTS (mean donor pool size 10,000 
donations).
2.5.6 Activated Prothrombin Complex
Patients with high titre factor VIIIC inhibitor were 
usually treated with a commercially fractionated 
activated prothrombin complex concentrate (FEIBA Immuno, 
Austria).
2.5.5 Porcine factor VIII
After 1984 some patients were treated with a 
polyelectrolyte purified porcine factor VIII (Hyate C, 
Speywood Laboratories)
2.7 Liver Disease
Infection with hepatitis B and non-A, non B (NANB) 
viruses is common in haemophiliacs treated with clotting 
factor concentrates. Persistent infection with both 
types of virus results in chronic liver disease. Chronic 
liver disease due to hepatitis B is seen only in 
individuals who cannot clear antigen (72) . No such 
markers are available for NANB and the severity of the 
liver disease can only be accurately assessed 
histologically. One study showed that a rise in serum 
immunoglobulin IgG is associated with progression to 
cirrhosis, however there was a considerable overlap, 
limiting its clinical utility in individual patients
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(192). As liver biopsy is a potentially hazardous 
procedure (2) and does not currently influence 
management, it was not performed in this centre. A 
clinical grading of liver disease severity was devised, 
based on clinical and biochemical findings since 1977. 
For each patient all available results of serum ALT were 
graphed and patients classified using the algorithm 
shown, Figure 2.7.1. The minimum number of serum ALT 
measurements per year for all patients was two.
Six grades of liver disease were identified:
Grade 1: Clinical and laboratory evidence of chronic
liver disease in the absence of any other known cause. 
Clinical features sought included specifically 
hepatosplenomegaly indicative of portal hypertension, if 
clinically present this was confirmed by a radio 
nucleotide liver and spleen scan. In patients who had 
presented with clinical features of upper gastro­
intestinal bleeding, endoscopic evidence of oesophageal 
varices was sought. Splenomegaly in the absence of 
hepatomegaly was not included. Ten patients were included 
in this group, their clinical features are shown in 
Table 2.7.1.
Grade 2: No clinical evidence of chronic liver disease
but serum ALT persistently elevated above 150% of the 
upper limit of the laboratory normal (ALT>75IU/L) during 
the six years of prospective observation.
ALOGRITHM USED TO CLASSIFY LIVER DISEASE
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grade 6grade 5
grade 3
grade 4
grade 1grade 2
133 PTS.
> 2 ALT LEVELS 
PER ANNUM
FIGURE 2.7.1
1. PATIENTS WERE DIVIDED INTO THOSE WITH ABNORMAL AND 
NORMAL SERUM ALT DURING THE STUDY.
2. CASE NOTES OF PATIENTS WITH NORMAL ALT WERE REVIEWED 
AND FURTHER DIVIDED INTO THOSE WITH ABNORMAL (GRADE 
V) AND NORMAL (GRADE VI) ALT PRIOR TO THE STUDY.
3. PATIENTS WITH ABNORMAL ALT WERE DIVIDED INTO THOSE 
WHO DEVELOPED NANB HEPATITIS DURING THE STUDY - 
GRADE 4.
4. THE REMAINING 7 0 PATIENTS WERE SUBDIVIDED INTO THOSE 
WITH PERSISTENTLY ABNORMAL SERUM ALT (n=36) AND 
THOSE WITH INTERMITTENTLY ABNORMAL SERUM ALT, 
(n=34), GRADE 3.
5. PATIENTS WITH PERSISTENTLY ABNORMAL SERUM ALT WERE 
FURTHER SUBDIVIDED INTO THOSE WITH PORTAL
HYPERTENSION, (n=10) GRADE 1 AND THOSE WITHOUT,
(n=26) GRADE 2.
Table 2.7.1 Clinical features of patients with grade 1 
liver disease.
C l i n i c a l  F e a tu re s  Number o f  P a t ie n ts
Hepatosplenomegaly 10
Decompensated cirrhosis 3
Hepatic encephalopathy 2
Oesophageal varices 3
10 patients had grade 1 liver disease. All three 
patients with oesophageal varices have had variceal 
bleeding. The two patients with hepatic encephalopathy 
have died, in one, investigation (hepatic ultrasound) 
indicated the presence of tumour deposits.
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Grade 3: Patients who had no clinical evidence of
chronic liver disease but in whom the serum ALT 
fluctuated from above 75IU/L to normal.
Grade 4: Patients infected with NANB hepatitis during
the prospective period of study.
Grade 5: Patients with normal serum ALT during the
previous six years but with biochemical evidence 
suggestive of NANB hepatitis prior to 1980.
Grade 6: Patients with normal serum ALT during the
period of observation and no previous clinical or 
biochemical evidence of hepatitis.
Table 2.7.2 shows the characteristics of the patients 
with different grades of liver disease and Table 2.7.1 
the clinical features of liver disease noted in patients 
with grade 1 liver disease.
2.8 Hepatitis B Infection
Hepatitis B surface antibody (AusAb, Abbott Diagnostics 
Division) was checked in all patients in 1981/2 and in 
1987/8. Hepatitis B surface antigen was measured at
each clinic visit (Auszyme Abbott Diagnostics Division). 
During the study period one new hepatitis B infection 
occurred. At the end of the study 55 patients had 
evidence of previous hepatitis B infection, of these five 
were chronic virus carriers Table 2.8.1.
Table 2.7.2 Characteristics of patients in liver disease 
groups.
Grade Mean
of No annual
liver of Age dose
disease Pts (yrs) Severity of cfc Antigen
1 10 31 0 17423.5
(1) (28-43) (0-0) (600-65000)
2 26 33.5 0.5 19557.5 2
(7) (25-46) (0-5) (1400-45000)
3 33 30 0 16912 1
(5) (23-38) (0-5) (7724-46000)
4 13 29 8 4000 1
(5) (25-51) (5-10) (1160-6210)
5 21 35 0 36353 1
(3) (21-45) (0-1) (7387-78698)
6 23 28 5 1437
(7) (20-51) (4-20) (638-2986)
The medians and interquartile range^ ar^lKshown. There 
was no significant age difference^ Haemophiliacs with 
grades 4 and 5 liver disease had a milder severity of 
haemophilia (p=0.001/ Kruskal Wallis), these patients had 
also used significantly less factor concentrate per annum 
over the previous seven years (p=0.003/ Kruskal Wallis).
Table 2.8.1 The numbers of patients with serum markers 
of hepatitis B infections.
1981/2 1986/7
Hepatitis B Ab 65 66
Hepatitis B Ag 4 5
5 patients were persistent carriers of hepatitis B 
infection.
All had factor VIIIC deficiency.
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2.9 Materials and Methods
The details of materials and experimental methods used in 
clinical and laboratory investigations are reported in 
appropriate chapters.
2.10 Statistical Methods:
All data was analyzed using non parametric statistical 
methods (278).
2.10.1 Inter-Group Comparisons
The Mann-Whitney U test was used to analyse data between 
two independent groups. Only two tailed p values were 
considered significant. The Kruskal-Wallis one way 
analysis of variance test was used to examine for 
possible differences when there were more than two 
independent groups.
Fisher's exact test (two tailed) was used for comparisons 
between dichotomous data between groups.
2.10.2 Intra-group comparisons
The Wilcoxon rank sum test for paired data was used to 
analyse sequential continuous data obtained from single 
groups.
2.10.3 Correlations
The Spearman Rank correlation analysis was used to 
determine the association between continuous variables.
To quantify the relationship between two continuous 
variables regression analyses were used. Logistic 
stepwise regression was used to examine the relationship 
between several independent variables (either dichotomous 
or continuous) to a dichotomous dependent variable. 
Logistic regression rather than multiple regression was 
more suited to the analyses of the data for the following 
reasons:
1 A qualitative dependent variable could be used.
2 For a continuous dependent variable no prior assumption 
on its distribution was required.
The data was analyzed using a Statgraphics package 
version 2.1 (Statistical Graphics Corporation USA).
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CH A P T E R  3.1
DO CLOTTING FACTOR CONCENTRATES HAVE A DIRECT "CHEMICAL" 
EFFECT ON LYMPHOCYTE FUNCTION IN VITRO.
Summary:
Study objective: To compare the effects of intermediate
purity factor VIII, factor IX and a highly purified 
factor VIII concentrate on lymphocyte activation, 
proliferation, and interleukin 2 (IL2) production in
vitro.
Measurements: Peripheral blood mononuclear cells (PBMC)
from normal donors, were stimulated to proliferate with 
specific and non-specific activators in the presence of 
clotting factor concentrates. The capacity of normal 
PBMC to produce IL-2 in the presence of clotting factor 
concentrates was evaluated using a bioassay.
Results: Intermediate purity factor VIII concentrate
impaired PBMC activation and proliferation in a dose 
dependent manner. IL-2 production was also reduced. The 
highly purified factor VIII concentrate like factor IX 
had no such effects.
Conclusions: Intermediate purity factor VIII
concentrates have a direct chemical immunosuppressive 
effect. This may lead to in vivo impaired cell mediated 
immunity and predisposed some haemophiliacs to HIV-1 
infection.
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3.1.1. INTRODUCTION
Haemophiliacs depend on transfusions of blood products, 
such as cryoprecipitate and clotting factor concentrates 
to treat bleeding episodes. The use of such blood 
products is associated with a high incidence of viral 
infections such as non A, non B agents (NANB) , and the 
human immunodeficiency virus (HIV-1).
The frequent use of clotting factor concentrates may 
sensitize some haemophiliacs to allogenic proteins. For 
example, 10 to 15 percent of severe haemophiliacs develop 
IgG antibodies (inhibitors) to factor VIIIC (233), and up 
to 50 percent of haemophiliacs have antibodies to the Km 
and Gm determinants of IgG (245) . Sensitization to C4, 
complement allotypes also frequently occurs(246). 
Haemophiliac serum also contains immune complexes and 
depending on the size of the immune complex, immune 
stimulation as well as suppression can result (247-251).
Moreover the use of blood and blood products is also 
known to be immunosuppressive. For example, transfusion 
of blood and cellular blood products are standard 
practice in preparation of uremic patients for 
transplantation. Oplez et al showed that renal
allografts survived longer in patients with prior 
transfusions, this correlates with the degree of 
immunosuppression (279-281). Conversely, in bone marrow
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transplantation pre- transfusion is associated with a poor 
outcome (282). Furthermore,use of blood during surgical 
resection of tumours results in an increased mortality 
and risk of metastatic seeding. This is independent of 
histological type or clinical grade of the tumour but 
depends on the type of blood product used (283-290). In 
controlled animal experiments infusions of allogenic 
plasma but not cellular blood products promote chemically 
induced sarcoma growth (291-292). In autoimmune diseases 
the replaced plasma during plasmapheresis shows a 
beneficial effect greater than would be expected from 
the removal of immune complexes alone and in patients 
with idiopathic thrombocytopenia purpura the possibility 
that an immunosuppressive factor is present in 
preparations of human gammaglobulin has been raised (293- 
300) .
A single blood transfusion activates both cellular and 
humoral immune reactions. The beneficial effect in 
renal transplantation is mediated by both cellular 
suppressive and protective antibody responses (281). An 
unidentified component of plasma is implicated in the 
tumour promoting effects of transfusion (301 - 304).
A haemophiliac therefore can potentially develop impaired 
cell mediated immunity due to the viruses transmitted by 
blood products, but also by factor concentrates having a 
direct "chemical" effect on the immune system.
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To examine the latter possibility the effects of clotting 
factor concentrates on lymphocyte function in vitro were 
investigated.
3.1.2 METHODS
Heparinised peripheral venous blood (20 units 
preservative free heparin/mls, Leo Laboratories) was 
obtained from healthy heterosexual, male non-haemophilic 
volunteers aged between 19 to 35 years.
Cell separation
Peripheral blood mononuclear cells (PBMC) were separated 
by density centrifugation of heparinised venous blood 
using a modification of the method originally described 
by Boyum (305). Blood was diluted in a 1:1 ratio with 
Eagles' Minimum Essential Medium (MEM) and layered on to 
a sodium metrizoate gradient (Lymphoprep, Nyegarrad and 
Co, Oslo, Norway) in 15mm plastic conical tubes (diameter 
12mm) (Costar, Cambridge, Massachusetts, USA), in a 1:1 
ratio. Following centrifugation at 400xg for 30 
minutes, the mononuclear cell bands at the 
Lymphoprep/plasma interface were aspirated using 2mls 
plastic pipettes and pooled in plastic conical tubes. 
The cells were washed twice in MEM by centrifugation at 
600xg for 5 mins, and the cell pellet resuspended in
0.9 mis of cell culture medium. A 10ul aliquot was 
removed, stained with 90ul of white cell staining fluid 
(2% glacial acetic acid, and a few grains of crystal 
violet in distilled water) and the number of cells in
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10ul counted in a standard haeraocytometer (Improved 
Neubauer) . The cell suspension was placed on ice until 
used.
F a c to r  c o n c e n tra te s
Heat treated and non heat treated intermediate purity 
factor concentrates VIII and IX (IPFC VIII/IX) were 
obtained from the Scottish National Blood Transfusion 
Service. Pure human factor VIIIC isolated from the 
factor VIII complex by a mouse monoclonal antibody to 
human factor VIIIVwF and stabilized with 5% human albumin 
(Monoclate, Armour Pharmaceutical Co [MC]) was compared 
to the IPFC preparations.
All materials were reconstituted according to 
manufacturers' directions, cell culture medium was used 
for subsequent dilutions of the reconstituted 
preparation.
P re p a ra t io n  o f  agents used to  s t im u la te  lymphocytes
Both the non specific T-cell mitogens, 
phytohaemagglutinin (PHA) (Sigma, Poole, UK) and 
concanavalin A (Con A) (Sigma, Poole, UK) and the 
specific soluble antigen (PPD) were used. Final 
concentrations of these stimulants for optimal lymphocyte 
proliferation had been previously standardized. PHA and 
Con-A were used in a concentration of 50ug/ml per 
1x106cells/mls respectively. PPD was used in a final
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concentration of 0.5ug.ml and 5.0ug/ml per 
1x106cells/mls.
Functional Assays
Proliferative responses were measured by culturing PBMC
in 96 well, round bottomed, micro-titre plates (Gibco,
Paisley, UK) . Each well contained PBMC at the above 
concentrations, mitogen or antigen and one of the 
following:
1. Non heat treated IPFC (VIII).
2. Non heat treated IPFC (VIII) standardized for 
citrate concentration.
3. Heat treated IPFC (VIII).
4. Pure factor VIII in albumin which had been heat
treated (MC).
5. Non heat treated IPFC (IX).
6. No factor concentrate.
7 Factor concentrate in the absence of mitogen/antigen
The clotting factor concentrates were used at the 
following concentrations: 0.5iu/mls, 0.05iu/mls, and
0.005iu/mls. These concentrations are similar to those 
achieved in vivo after factor concentrate infusion.
The cell culture medium was Rowell Park Memorial 
Institute medium (RPMI-1640) containing 10 % pooled human 
serum supplemented with 50iu/ml penicillin, 100ug/mls 
streptomycin, and 2mmol/l L glutamine (Flow
Laboratories,Irvine, Scotland). All cultures were
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performed in triplicate at 37°C in a 5% CO2 enriched 
humidified environment for 3 days. For mitogens and PPD 
stimulated cultures were maintained for 4 days.
Proliferative responses were measured by the 
incorporation of [ H] thymidine after a four hour pulse 
with 1uG of [ H] thymidine (for PPD cultures cells were 
pulsed for 18 hr). Cultures were harvested on an 
automatic cell harvester (Skatron, Flow Laboratories, 
Irvine, UK) by suction through glass fibre paper.The 
paper was washed with 5% methanol and trisodium acetic 
acid, allowed to dry and transferred to scintillation 
vials. After addition of scintillation fluid, (toluene 
[Proanlyar analytical May & Baker] 2,5 diphenyloxazole 
[Scintillation grade Packard]), incorporated [ H] 
thymidine was measured on a Beta counter (LKB, Croydon, 
UK) .
In further experiments PBMC in culture medium were pre- 
incubated with IPFC (VIII) and washed prior to addition 
of PHA or with PHA prior to addition of IPFC (VIII) at 
37°C in a 5% CO2 enriched humidified atmosphere.
Effect of factor concentrates on an interleukin-2 (IL-2) 
dependent cell line
1x106 Jurkat cells (an IL-2 dependent lymphoblastoid cell 
line) were incubated in the presence and absence of heat 
treated IPFC (VIII), or MC at the above concentrations,
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proliferative response was measured after 2 days by 
measuring amount of [ H] thymidine incorporated.
C e l l  v i a b i l i t y
1x1 06 cells/ml in cell culture medium and IPFC (VIII) at 
a concentration of 5iu/ml were maintained for three days 
in a humidified atmosphere supplemented with 5% CO2 at 
37°C and cell viability assessed as for counting 
experiments except cells were stained with Trypan blue, 
100 cells were counted and the number of stained cells 
(dead) subtracted to give a percent viability.
IL-2 secretion and assay
f:
1x10 PBMC from normal were incubated in complete 
RPMI/2% fetal calf serum (FCS) with or without factor 
VIII concentrates as described for functional assays in 
the presence of PHA (2 ug/ml) . After 48 hours, the 
supernatant was separated from the cells by
centrifugation at 500xg, and stored at -20°C until
assayed.
Supernatant IL-2 activity was measured in a standard 
biological assay using the HT2A cells (Cetus Corp, 
California, USA).
I L - 2  assay
A bioassay was used to measure supernatant IL-2 
production, using an IL-2 dependent cell line and 
measuring the increase in cell proliferation (306).
Cloned, murine, T-helper cells (HT2 cell line) (Cetus
Corp., California, USA) maintained in RPMI 1640
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containing 5% heat inactivated FCS supplemented with 
exogenous IL-2 for continued growth. The cell line was 
subcultured at a cell density of 4x104 cells/mls and fed 
with 20 units/ml human recombinant IL-2 (rIl-2) (BCL) 
every 48hrs in RPMI 1640/10% FCS and 2x1 O'5
mercaptoethanol (complete medium).
48hrs after feeding with IL-2, the cells (HT2) were 
washed twice by centrifugation in RPMI 1640 and viability 
assessed by Trypan blue exclusion. 1.5x10 HT2 cells
were resuspended in complete medium. 100ul of the cell 
suspension was dispensed into flat bottomed 96 well 
plates (Nunc. Gibco Ltd, Paisley, UK) to which serial 
solutions (100ul) of the supernatant of varying
concentrations of standard (rIL-2)) were added in
triplicate. After approximately 24hrs incubation, the 
plates were pulsed with Ii^ Gu [^H] thymidine (20ul of 
50uG/ml per well) and incubated for a further 4 hours. 
The plates were harvested onto glass fibre filters using 
a cell harvester (Skatron, Flow Labs, Irvine, UK) and the 
radioactivity incorporated into DNA determined by liquid 
scintillation counting.
Serial two-fold dilutions of 100u/ml recombinant IL-2 
final concentration was used to obtain a standard curve.
Analysis of results
The results were expressed as units/mls IL-2 (u/ml) by 
first subjecting the data to probit analysis (to
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determine the relationship between the frequency of 
occurrence of specific events and the dose that is 
responsible for the induction of those events). The 
results were determined at the 50% maximal [3H] thymidine 
incorporation end point of our laboratory standard.
3.1.3 RESULTS
Lymphocyte proliferation in the presence of intermediate 
purity factor VIIICconcentrate.
PHA stimulates all T-cell subsets, whereas Con-A is a 
specific T-suppressor cell mitogen and PPD stimulates a 
distinct functional subset of T-helper lymphocytes that
can be identified with a Leu 8 antibody (307,308). Figure
3.1.1 shows that non heat treated IPFC (VIII) at
concentrations, (0.005-0.5units/ml) significantly
impaired lymphocyte proliferation. The effect was
independent of the stimulus used for proliferation. 
Therefore in subsequent experiments only PHA was used. 
Figure 3.1.1 also shows that the effect of IPFC (VIII) 
was dose dependent and Table 3.1.2 shows that IPFC 
(VIII) did not shift the maximum proliferative response.
The impaired proliferation could be due to (a) a direct 
effect of IPFC (VIII) on lymphocytes; (b) binding of IPFC 
(VIII) to PHA; (c) non specific binding of IPFC (VIII) to 
cells; or (d) a cytotoxic effect of IPFC (VIII) on 
lymphocytes.
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Figure 3.1.1 The Effect of IPFC (VIII) 
on Lymphocyte Transformation
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Figure 3.1.1. Median values for the three stimulants are 
shown. Significant impairment of lymphocyte
proliferation occurred at all concentrations.
Table 3.1.1 The effect of IPFC (VIII) on lymphocyte
transformation.
Stimulant Dose (units/ml)
0 0.005 0.05 0.5
PHA 48230
<24787-
79618)
280068
(19170-
33035)
18287
(11192-
26237)
5018 
(3049- 
16038)
90 . 5 
(51- 
143 )
CON-A 29152 30291 18396 3090 135
(23190- (23465- (12676- (3049- (104-
33366) 33035) 19664) 5212) 143)
PPD 22551 20858 11192 10357 52
(1202- (13768- (4140- (4824- (46-
74538) 29278) 17978) 25144) 66.6)
Tne median 
proliferation 
units/ml IPFC 
proliferation 
inhibition was
and interquartile ranges for lymphocyte 
in counts per minute are shown. At _>0.05 
(VIII) significantly impaired lymphocyte 
compared to baseline (p<0.05). No
observed at 0.005 units/mls.
Table 3.1.2 Kinetics of IPFC (VIII) inhibition of
lymphocyte proliferation.
Length of 
culture (hrs) PHA PHA + (IPFC VIII)
24
48
83.65
(68.3-121.65)
12783
(10815.9-14543.2)
28.65
(24.3-34.4)
1170.5
(984-1336)
72 36830
(34086-38369)
1232 
(970.5-1583)
120 17673
(14714.5-22908.5)
1100
(1080-1243)
168 4188.5
(2575-5788.5)
1963
1642-2573)
The median and interquartile ranges of cell proliferation 
in counts per minute are shown of 7 experiments f IPFC 
(VIII) and PHA were added at time 0 and cells harvested 
at the times shown, IPFC (VIII) significantly impaired 
lymphocyte proliferation at all times (p<0.05). IPFC 
(VIII) was used at a concentration of 0.5 units/mls.
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Cell viability after pre-incubation with IPFC (VIII) for 
36 hours or in its absence showed IPFC (VIII) did not 
have a direct cytotoxic effect as judged by Trypan blue 
exclusion, Table 3.1.3.
To exclude binding of IPFC (VIII) with lymphocytes, PBMC 
were incubated with IPFC (VIII) for 12 hours, washed and 
then stimulated with PHA. Figure 3.1.2 shows that 
significant suppression still occurred. Pre-stimulation 
with PHA and then adding IPFC (VIII) did not impair cell 
proliferation, Figure 3.1.3r . •
In further experiments the possibility that Tris/0.02M 
trisodium citrate, the buffer used in preparation of IPFC 
(VIII) was excluded as the cause of inhibition. Figure
3.1.4 and table 3.1.4 shows effects of IPFC (VIII) were 
independent of citrate content.
A comparison between IPFC, heat treated IPFC (VIII) and 
MC
Figure 3.1.5 and Table 3.1.5 shows the effect of a dry 
heat treated IPFC (VIII) was similar to a non heat- 
treated preparation at all concentrations. MC had no 
significant effect on lymphocyte proliferation in 
equivalent concentrations to heat treated IPFC (VIII), 
Figure 3.1.5. At 0.5 units/ml MC caused less inhibition 
than IPFC (VIII).
Effect of IPFC (IX)
FIGURE 3.1.2 PREINCUBATION OF
LYMPHOCYTES WITH IPFC (VIII)
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Figure 3.1.2. Median values are shown. PBMC were 
preincubated with IPFC (VIII) and stimulated with PHA at 
times shown. 0 values indicate proliferation in absence 
of IPFC (VIII). IPFC (VIII) used at 0.5 units/ml. 
Significant impairment occurred at all times (p<0.05).
Table 3.1.3 
viability.
The effect of IPFC (VIII) on cell
Cell viability (%) 
PBMC 85 (63-90)
PBMC + IPFC (VIII) 86 (56-98)
The medians and interquartile ranges of percent viable 
cells after 36 hours incubation in the absence and 
presence of IPFC (VIII) are shown. There was no 
significant difference. A total of six experiments were 
performed.
Co
un
ts
 
Pe
r 
M
in
ut
e
5 0 0 0 0 1
40000 ‘
30000 -
20000 +" 
-10
FIGURE 3.1.3 TIME COURSE OF
LYMPHOCYTE PROLIFERATION
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Figure 3.1.3. Median values are shown. PBMC
preincubated wit PHA and 0.05 units/ml IPFC (VIII) added 
at times shown. No inhibition occurred after time 0.
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FIGURE 3.1.4 CITRATE IONS DO 
NOT AFFECT LYMPHOCYTE 
PROLIFERATION
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Figure 3.1.4. Median values are shown. IPFC (VIII) 
reconstituted according to manufacturers instructions, 
all subsequent dilutions made with RPMI with added 
citrate ions. There was no significant difference.
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Figure 3.1.5 A COMPARISION OF 
IPFC(VIII) AND HIGHLY PURIFIED 
FACTOR CONCENTRATES
400001 IPFC(VIII)
IPFC(VIII)Heat
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Log Dose of Factor Concentrate
Figure 3.1.5. Median values are shown. Dry heated non­
heated IPFC (VIII) impaired PBMC proliferation with PHA. 
MC at equivalent concentrations did not impair PBMC 
proliferation except at >.0.5 units/ml. Values compared 
to basal proliferation in absence of concentrate, less 
inhibition occurred with MC at 0.5 units/ml compared to 
IPFC (VIII) (p=0.02).
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IPFC(IX) caused no inhibition of lymphocyte 
proliferation, Figure 3.1.6.
The Effect of clotting factor concentrates on IL-2
production.
One mechanism by which IPFC (VIII) may impair lymphocyte 
proliferation is by reducing IL-2 production or 
affecting the IL-2 response. This series of experiments 
shows effects of factor VIII concentrates on IL-2
production. Figure 3.1.7 shows that IPFC (VIII) but not 
MC had a dose dependent effect on proliferative capacity 
of Jurkat cells.
The ability of IPFC (VIII) to reduce IL-2 production was 
further investigated by examining the potential of IPFC
(VIII) and MC to reduce IL-2 secretion from PHA
stimulated lymphocytes, Figure 3.1.8.IPFC (VIII) 
significantly reduced IL-2 production whereas MC had no 
significant effect.
3.1.4 DISCUSSION
Cell mediated immunity, as measured in vivo by skin 
testing and in vitro by counting T-cell subsets has been 
frequently reported to be impaired in haemophiliacs 
treated with clotting factor concentrates (310-316). 
This could be due to human immunodeficiency virus-1 (HIV- 
1) infection, or to other viruses (eg NANB viruses). 
Alternatively IPFC (VIII) in the absence of these
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FIGURE 3.1.6 IPFC (IX) - EFFECT ON 
LYMPHOCYTE TRANSFORMATION
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Figure 3.1.6. Median values are shown. IPFC (IX) dry 
heated impaired PBMC proliferation at 5 units/ml only.
FIGURE 3.1.7 THE RESPONSE OF JURKAT 
CELLS CULTURED IN THE PRESENCE 
OF IPFC (VIII) OR MONOCLATE
Monodate
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Figure 3.1.7. Median values are shown. Jurkat cells 
cultured in presence of IPFC (VIII) or MC at
concentrations shown. IPFC (VIII) caused significant
impairment of proliferation at all concentrations.
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Figure 3.1.8 Effect of IPFC (VIII) 
and Monoclate on IL - 2 Production
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Figure 3.1.8. Median values for percent maximum IL-2 
activity are shown. IPFC (VIII) impaired IL-2 production 
from PBMC at all concentrations.
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infections may directly "chemically" impair immune 
responses. Despite availability of tests to identify 
individuals infected with HIV-1 it has remained uncertain 
if treatment with IPFC (VIII) in the absence of HIV-1 and 
NANB infection is immunosuppressive.
The present study showed that IPFC (VIII) had the 
potential to modulate T-lymphocyte function. The
experiments showed that intermediate purity factor VIII 
concentrates inhibited specific and non-specific T- 
lymphocyte proliferation in vitro, in a dose dependent 
manner. This inhibition was not due to an alteration of 
the time course of the proliferative response to PHA. 
Neither was it due to a non-specific cytotoxic effect as 
measured by trypan blue exclusion, Table 3.1.2.
Although in the present study only one batch of IPFC 
(VIII) was used, others have reported similar findings, 
suggesting that the impaired response was not peculiar to 
the batch investigated (316-319).
These observations raise two main questions: firstly,
what component of IPFC(VIII) mediated this effect, and 
secondly what is the mechanism? The active component of 
IPFC (VIII) did not appear to be the citrate buffer 
(Figure 3.1.4). The proteins contained within IPFC 
(VIII) include: immunoglobulins, fibrinogen/fibronectin
and the factor VIII complex. Using a very pure factor 
V H I C  concentrate and factor IX concentrate, no
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inhibition of proliferative response was seen at 
replacement concentrations (Figure 3.1.6/7). This
suggested that some "contaminant” of IPFC (VIII) is 
responsible.
Others have shown that purified fibrinogen and 
fibronectin at equivalent concentrations had no effect 
(317). It has been suggested that this effect may be 
mediated by a small molecular weight inhibitor which can 
be dialysed (31 7, 320); this has not been confirmed by
others (318,321). Interestingly it has been shown that 
immunoglobulin preparations have a similar inhibitory 
effect (322) . In more recent studies Sandilands et al 
have shown that intravenous immunoglobulin contains FcY 
receptor antibodies, which are known to be 
immunosuppressive (323). Such antibodies are also present 
in IPFC (VIII) (324) . Their presence in IPFC (IX) and MC 
has not yet been investigated.
On activation T cells secrete IL-2 which mediates 
continued proliferation of T cells by an autocrine 
mechanism (325). Figure 3.1.7 shows that IPFC (VIII) 
reduced proliferative capacity of Jurkat cells, an IL-2 
dependent cell line and impaired the secretion of IL-2 
from PHA stimulated lymphocytes,Figure 3.1.8. IPFC (VIII) 
did not affect lymphocyte proliferation once PBMC had 
been activated and stimulated to proliferate (Figure 
3*1.4). This suggested that IPFC (VIII) affected 
activation of lymphocytes. The possibility that IPFC 
(VIII) bound PHA was excluded (Figure 3.1.3). It is
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therefore possible that IPFC (VIII) blocks post-receptor- 
binding events.
An alternative explanation may be interaction of a 
component or component of IPFC (VIII) with non-T cells 
such as macrophages, generating inhibitory signals (or 
factors) . In this regard it has been shown that IPFC 
impairs monocyte function (326) . This effect was 
reproduced by using immunoglobulin complexes and was 
mediated by a high molecular weight fraction which 
contained immune complexes or IgG aggregates (326) .
The finding that IPFC (VIII) inhibited lymphocyte 
function in vitro may explain impaired cell mediated 
immunity in vivo in haemophiliacs in the absence of 
HIV-1 infection. The clinical significance is not clear. 
Whilst there are reports of a higher incidence of 
tuberculosis and anecdotal instances of lymphomas, the 
exact prevalence of these observations needs to be 
substantiated and the effects of viruses other than HIV- 
1 excluded in non HIV-1 infected haemophiliacs (327-329).
It is not known if such abnormalities may have 
predisposed haemophiliacs to HIV-1 infection. In this 
study factor IX concentrates did not impair lymphocyte 
proliferation Figure 3.1.7, this may explain differences 
in the prevalence of HIV-1 infection between factor 
VIIIC and factor IX deficient haemophiliacs. The relative 
risk for HIV-1 infection in factor IX deficient patients
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is four times less than patients with factor VIIIC 
deficiency (Chapter 4.2). However, HIV-1 preferentially 
partitions into cryoprecipitate during plasma 
fractionation (330).
In conclusion this study showed that IPFC (VIII) impaired 
lymphocyte function in a dose dependent manner. This 
finding raises the interesting possibility that use of 
factor concentrates in the absence of HIV-1 contamination 
is potentially immunosuppressive.
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CHAPTER 3.2
IMMUNOSUPPRESSION FOLLOWING REPLACEMENT THERAPY IN 
HAEMOPHILIA - A ROLE FOR LYMPHOCYTE FC GAMMA-RECEPTOR 
(FCY) BLOCKING ANTIBODIES.
Summary
Study objectives Do treated haemophiliacs have FcY-
receptor blocking antibodies.
Study design: Open, cross-sectional comparison.
Study population: Multitransfused uraemic patients.
Haemophiliacs treated with clotting factor concentrates. 
Homosexuals with and without AIDS.
Measurements: IgG antilymphocyte antibodies that block
the FcY receptor were measured. The ability of 
haemophilic IgG to inhibitor T-cell transformation was 
determined.
Results: 67 percent of haemophiliacs had IgG
antilymphocyte antibodies levels were higher than in 
normal controls but similar to multitransfused uraemic 
patients. Homosexuals with AIDS had the highest levels. 
Conclusion: Treated haemophiliacs had IgG FcY receptor
antibodies that inhibit T-cell transformation. 
Depression of cell mediated immunity by these antibodies 
may have predisposed haemophiliacs to HIV-1 infection.
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CHAPTER 3.2
3.2.1. INTRODUCTION
Haemophiliacs may develop immunodeficiency from the 
viruses transmitted by clotting factor concentrates or 
due to alloantigens contained within such preparations. 
In the previous section it was found that intermediate 
purity factor VIII concentrates impaired lymphocyte 
function in vitro. An alternative mechanism may be an 
immune response to alloantigens present as contaminants 
in clotting factor concentrates. Such immunosuppression 
may have predisposed some haemophiliacs to HIV - 1
infection (331) .
The beneficial effect of pre-transplant blood
transfusions on renal allograft survival is well
established (279, 280) . It has been proposed that the
transfusion effect is due to production of 
immunosuppressive, anti-lymphocyte antibodies (304). 
Macleod et al showed that following transfusion, 
antibodies which had the capacity to block FcY-receptors 
(FcYR) on B lymphocytes are induced. The presence of 
such antibodies correlates with subsequent renal
allograft survival (304).
Haemophiliacs depend on frequent transfusions of blood 
products and may develop such antibodies in response to 
alloantigens present as contaminants in such products 
(332). This study attempted to detect FcYR blocking
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antibodies in the sera of multitransfused uraemic 
patients, haemophiliacs, and homosexuals with and without 
the acquired immunodeficiency syndrome (AIDS).
In haemophiliacs presence of FcYR blocking antibody was 
correlated with the mean annual dose of clotting factor 
concentrate used, and HIV-1 status. Furthermore the 
capacity of IgG fractionated from haemophilic serum to 
inhibit T-cell proliferation was investigated.
3.2.2. PATIENTS AND METHODS 
Patients and Controls:
Serum was obtained from the following groups: (a) 17
heterosexual normal subjects with no previous history of 
blood transfusion or pregnancy, (b) 54 uraemic patients
on long term dialysis, all of whom had been previously 
transfused (c) 39 haemophiliacs, 30 had factor VIIIC
deficiency and 9 factor IX deficient patients, (d) 15
homosexuals, of whom none had received blood 
transfusions. Six of this group had AIDS manifest as an 
opportunistic infection in all, 3 also had Kaposi's 
sarcoma (serum from uraemic, homosexuals and AIDS 
patients were provided by: Dr M Forwell, Western
Infirmary, Glasgow, and Dr J A Harvey, Southern General 
Hospital, Glasgow, respectively).
The case notes of haemophiliacs were reviewed and the 
following additional information obtained:
(i) Mean annual dose of clotting factor concentrate
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used over the previous seven years.
(ii) HIV-1 status - HIV-1 antibody was detected
using a commercial enzyme linked immunosorbent
assay (Wellcozyme).
(iii) Age.
Serum IgG Preparations
IgG was obtained from serum by diethylaminoethyl- 
cellulose cellulose (DE52 - Whatman). Both serum and
DE52 were equilibriated with 10mM phosphate buffer at 
pH7.8 prior to chromatography. IgG preparations were
dialyzed against phosphate buffered saline (PBS), pH 7.2, 
for 18hrs at 4°C and ultracentrifuged (105,000xg for 1hr) 
prior to use. 500ul aliquots were stored at -20°C till 
used. The preparations were used at a concentration of 
1mg/ml in PBS. The purity of the preparations was 
assessed by immunoelectrophoresis and no other class of 
IgG was detected by radial immunodiffusion. The
monomeric nature of these IgG preparations was confirmed 
by polyacrylamide gel electrophoresis and by gel 
filtration (SephacrylS300 - Pharmacia).
Anti-Lymphocyte Antibodies - The EA-rosette Inhibition 
Assay
1x10^ monocyte - depleted normal peripheral blood 
lymphocytes were resuspended in 120ul IgG preparation, or 
in PBS alone as a control. Following incubation at 3 7°C 
for 30 minutes, cells were washed twice in 14, Hanks
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Essential Medium (HEM) and mixed with an equal volume of 
chicken erythrocytes (E) which had been pre-sensitized 
with an equal volume of rabbit IgG class antibody (A) . 
The tubes were then centrifuged at 200xg for 5 minutes, 
EA rosette pellets were resuspended and fixed in 3% 
glutaraldehyde. Cells were resuspended in 0.75% trypan 
blue and inspected under sealed cover slips. Results 
were expressed as the percentage inhibition of EA rosette 
formation produced by IgG compared with PBS control. 
Inhibition of T-cell transformation
Normal human peripheral blood mononuclear cells (PBMC) 
were separated (Chapter 3.1.2) and resuspended in RPMI 
1640 culture medians with 10% heat inactivated autologous 
serum and antibiotics (Chapter 3.1.2) at a concentration 
of 4x10^ cells, 50ul of PBMC (2x105 cells), 50ul of IgG 
(1mg/ml in PBS) and 10ul of phytohaemagglutinin (PHA- 
110ug/mls). They were then cultured in flat bottomed 9 6 
well microtitre plates. The cells were incubated at 3 7°C 
for 66hrs in a humidified atmosphere of 5% CO2 in air. 
The cells were pulsed with radiolabelled thymidine and 
harvested as previously described (Chapter 3.1.2).
3.2.3 RESULTS
Figure 3.2.1 shows that IgG from haemophiliacs had 
significantly higher percent inhibition of EA rosette 
formation compared to controls. The values were 
independent of HIV-1 antibody status, (Figure 3.2.2). 
There was no correlation with age (r=.15, p=0.21) or mean 
annual dose of clotting factor concentrate used.
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Figure 3.2.1 IgG CLASS ANTI LYMPHOCYTE 
ANTIBODIES BY EA ROSETTE INHIBITION
100 -
80-
60-
40-
20 -
CGNTROL TRANSFUSE HAEMOPHIUACS HOMOSEXUALS
Figure 3.2.1 Haemophiliac IgG caused significantly
greater inhibition of EA rosette formation compared to 
normals.
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FIGURE 3.2.2 IgG ANTI LYMPHOCYTE 
ANTIBODIES IN HAEMOPHILIACS 
WITH AND WITHOUT 
10Q HIV-1 ANTIBODY
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Figure 3.2.2. There was no significant difference in 
median EA rosette inhibition between HIV-1 antibody 
positive or negative haemophiliacs.
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Figure 3.2.3 shows effect of IgG from haemophiliacs on T-
lymphocyte transformation.
3.2.4. DISCUSSION
This study showed that upto 66 percent of haemophiliacs 
have antilymphocyte, FcYR-blocking antibodies. The level 
of the antibody was not related to HIV-1 status nor the 
mean annual dose of clotting factor concentrate used. It 
would therefore seem that antibody production in these 
patients may be determined by the immune response to the 
repertoire of alloantigen(s) to which the individual is 
exposed rather than the total antigen load. Forwell et 
al (1986) have also shown that the FcYR-blocking antibody 
cross-reacts with spermatozoa, and this may explain the 
high levels found in homosexuals who receive anal 
spermatozoa (333). Rectal insemination into rabbits 
produces IgG reactive with lymphocytes and a reduced 
responsiveness to T cell dependent antigens (334).
An immunosuppressive role for FcYR-blocking antibodies is 
suggested by the previously described correlation between 
the occurrence of these antibodies and renal allograft 
survival (304) . The present study showed that FcYR- 
blocking antibodies can suppress T-cell proliferation, as 
assessed by inhibition of PHA transformation, thus 
providing further evidence that these antibodies are 
immunosuppressive. Although the precise mode of action 
is not known it would seem likely that these antibodies 
react with lymphocyte membrane alloantigens associated
Pe
rc
en
t 
In
hi
bi
tio
n
FIGURE 3.2.3 INHIBITION OF PHA 
BLASTOGENESIS BY HAEMOPHILIC 
SERUM
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Figure 3.2.3. Haemophiliac IgG resulted in significant 
inhibition of proliferation of PHA induced blastogenesis 
of normal PBMC.
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with FcYR and indirectly trigger release of non-antigen- 
specific soluble suppressor factors; a mechanism 
generally thought to be initiated by direct binding of 
immune complexes to the FcY-receptor itself. Although 
aggregated IgG could produce such an effect in vitro it 
would seem unlikely that aggregates account for these 
findings, since IgG from normals and patients were 
prepared in parallel using an identical technique which 
involves an ultracentrifugation step designed to remove 
any aggregated or complexed IgG. Furthermore, the 
monomeric nature of the IgG used in this study was 
confirmed by gel filtration. FcYR-blocking and
inhibition of PHA blastogensis would therefore appear to 
be due to a genuine antibody effect and not to non­
specific binding of IgG to the FcYR. This does not 
however preclude the possibility that antigen:antibody 
complexes may also be present in the serum of alloantigen 
stimulated patients and which may also contribute to 
triggering of non-antigen-specific suppressor cell 
mechanisms.
In conclusion, lymphocyte (FcYR-blocking) antibodies were 
demonstrated in haemophiliacs, as previously shown in 
other groups of patients exposed to alloantigens (333) . 
These antibodies may have the capacity to stimulate 
release of soluble suppressor factors which in turn 
inhibit T-cell activation. If this occurs in vivo, then 
depressed cell mediated immunity (CMI) may result. 
Although depressed CMI is desirable where prolonged
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allograft survival is required, such antibodies may pre­
dispose to infection. The occurrence of these antibodies 
in patients known to be at risk for the development of 
AIDS suggests that the FcYR-blocking antibodies may play 
a role in the progression of HIV-1 infection to AIDS. 
The presence of these antibodies in all 6 homosexual 
patients with clinically diagnosed AIDS would support 
such a hypothesis.
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CHAPTER 4.1
The Epidemiology of H IV infection in West of Scotland 
Haemophiliacs.
Summary
Study Objective: To study the epidemiology of HIV
antibody in adult haemophiliacs. To compare available 
HIV-1 ELISA antibody tests.
Study design: Open cross-sectional with retrospective
review.
Study population: All haemophiliacs who had received a 
blood product from the West of Scotland Adult Haemophilia 
Centre since 1980.
Measurements: Serum HIV-1 antibody by Type I and Type
II ELISA antibody tests. Positive results were confirmed 
by western blotting and immunofluorescence.
Results: The prevalence of HIV-1 antibody was 17
percent. The peak annual incidence for HIV-1 antibody 
occurred in 1983 and antibody was first detected in 1981.
Conclusions: Both commercial Type I and Type II ELISA
for HIV-1 antibody were comparable in sensitivity and 
specificity. The prevalence of HIV-1 antibody in this 
cohort (17 percent) was lower than the U.K.. national 
average of 39 percent in haemophiliacs treated since 1980 
(369) .
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4.1.1. INTRODUCTION
The acquired immune deficiency syndrome (AIDS) is 
characterised by a progressive lymphopenia, predominantly 
of T helper/inducer lymphocytes, which renders the 
individual susceptible to a variety of opportunistic 
infections and malignancies. AIDS itself is a clinical 
diagnosis and is but one manifestation of a spectrum of 
clinical and subclinical immunological disorders caused 
by the human immunodeficiency virus-1 (HIV-1), also known
as human T cell lymphotropic virus III, lymphadenopathy 
virus or AIDS related virus (335-338).
Conclusive evidence that HIV-1 has a primary aerological 
role in AIDS includes: in vitro the virus specifically
infects and depletes lymphocytes that express the CD4 
antigen producing a T-helper/inducer (T-h, CD4+ve) 
lymphopenia (339, 340) - an invariable finding in AIDS
patients (341-345). HIV-1 can be frequently isolated 
from patients with AIDS and AIDS related syndromes (336). 
Virtually all such individuals have serological evidence 
(serum IgG antibody) of exposure to the virus (346, 
347). Finally inoculation of HIV-1 into humans results in 
AIDS as seen in transfusion - recipient pairs (348-350).
HIV-1 infected individuals can be identified indirectly 
by serological tests, or by identifying viral proteins in 
serum, alternatively HIV-1 can be isolated from 
stimulated peripheral blood mononuclear cells. HIV-1
93
isolation is time consuming procedure, requires 
considerable laboratory expertise and containment
facilities, it is therefore expensive and results show 
considerable inter-laboratory variation. Serological
tests are cheaper, less labour intensive and are both 
sensitive and specific for HIV-1. The principles of the 
available serological tests are shown in Figure 4.1.1.
The enzyme linked immunosorbent assay (ELISA) tests are 
the most frequently used tests to screen serum samples 
for HIV-1 antibody. False positive results have been 
reported in multiparous women, multiply transfused
individuals such as thalassaemia patients, and others 
whose medical history may have led them to react non-
specifically with HIV-1 antigens (351-353).
Confirmatory tests are therefore necessary in ELISA 
positive samples, examples include Western blotting (WB), 
immunofluorescent (IF) tests and radio-
immunoprecipitation assays (352,352). False negative 
results have been infrequently reported with WB (354, 
355). Occasional false positive results have been
reported with WB (356, 357).
AIDS was first reported in haemophiliacs in 1982 (273).
Subsequently immune aberrations similar to those found in 
AIDS patients were noted in clinically well
haemophiliacs treated with clotting factor concentrates 
(311, 312). In a previous study of haemophiliacs from the
F ig u re  4 . 1 . 1  S o lid  Phase methods f o r  th e  d e te c t io n
o f a n t i -H IV
Type
1 Ag + specimen + anti hu IgG/enzyme + substrate
{specimen
2 Ag + {
{anti HIV/enzyme + substrate
3 anti hu IgG + specimen + Ag + anti HIV/enzyme + 
substrate
4 Ag + specimen + Ag/enzyme + substrate
KEY solid phase surface
Ag = HIV antigen 
hu = human
Figure 4.1.1 The four types of HIV-1 antibody
assay.
* HIV-1 antibody.
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West of Scotland similar findings were reported (316). In 
the present study, presence of serum IgG antibody was 
sought as a marker of HIV-1 infection to determine the 
epidemiology of HIV-1 infection in a well-defined cohort 
of haemophiliacs, treated with clotting factor 
concentrates or plasma or cryoprecipitate. The
sensitivity and specificity of available ELISA tests was 
compared to WB and IF tests which were taken as the gold 
standards for presence of HIV-1 antibody.
4.1.2 METHODS 
Patients
All patients with haemophilia who had been treated with a 
blood product at the West of Scotland Adult Haemophilia 
Centre since 1980 were included in this study; additional 
selection criteria for entry into the study are given in 
Chapter 2. Of the 133 patients entered 100 were factor 
VIII deficient, and 33 had factor IX deficiency) . The 
median age was 30 years (Interquartile range [IQR] 23 to 
44) . At the time of this study no patient had AIDS or 
clinical features suggestive of HIV-1 infection.
Methods
Serum samples collected from this cohort between 1977 and 
1987 were assayed for HIV-1 antibody. All samples were 
tested for HIV-1 antibody using three different ELISA 
tests. The initial screening was done in 1984 using a 
Type I non commercial ELISA test. In this assay disrupted
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whole virus was the substrate (HTLV III - H9) (358) .
Samples were run in duplicate and a known negative 
control was run eight times on each microtitre plate, the 
results for each being averaged. Samples were compared 
with negative control results through the ratio of the 
two values (346) .
In 1985, the 1984 serum samples and the most recent 
specimen (1985) from all patients were tested on two 
different types of ELISA: a competitive inhibition assay 
(Type 2), Wellcozyme (Wellcome Diagnostics, Beckenham, 
Kent) and another Type 1, direct assay (Abbott 
Laboratories, Chicago, Illinois, USA). The principles of 
these tests are as follows:
Direct HIV-1 ELISA (Type I - Abbott Laboratories)
HIV-1 propagated in culture is the substrate for this 
assay. Viral antigens are obtained by treating
propagated virus with a detergent and sonication. 
Antigen is then coated onto a solid phase: in this test 
beads are used. The coated beads are incubated with a 
diluted specimen and control sera. If HIV-1 antibody is 
present it binds to antigen on the solid phase and can be 
detected by goat antibody to human IgG conjugated to 
horseradish peroxidase. Bound conjugate can be detected 
by a colour reaction using o-Phenylene-diamine. The 
colour reaction in a specimen containing antibody is 
directly proportional to amount of antibody.
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Competitive inhibition HIV-1 ELISA (Type II
Wellcozyme)
Chemically inactivated HIV-1 antigen is captured onto 
purified anti-HIV-1 previously immobilized onto a solid 
phase, in this case microwells. Test samples and control 
sera are incubated in separate wells with anti-HIV-1 
chemically conjugated to the enzyme horseradish 
peroxidase (the conjugate). Competition for binding to 
the immobilized antigen occurs between antibodies to HIV- 
1 in the sample or control sera and conjugate; HIV-1 will 
block binding of conjugate. After washing wells to 
remove the samples and excess conjugate the enzyme 
remaining bound to the wells is visualized using 
3,3',5,5' tetramethylbenzadine iodine and hydrogen 
peroxide to give a yellow reaction after termination of 
the reaction with sulphuric acid.
The amount of conjugate, and hence colour, remaining in 
the wells is inversely related to concentration of HIV-1 
antibody in the sample.
Western Blotting (Dupont)
HIV-1 is propagated in cell culture and inactive antigen 
obtained using detergent and sonication. The HIV-1 
antigen polypeptides are fractionated according to 
molecular weight by electrophoresis using polyacrylamide 
slab gel in the presence of sodium dodecyl sulphate. The 
separated polypeptides are then transferred from gel to 
nitrocellulose by electrophoretic blotting.
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Nitrocellulose strips containing HIV-1 specific protein 
are then reacted with test serum specimens. The 
antigen/antibody complex is visualized using a goat anti- 
human immunoglobulin biotin conjugate, an avidin- 
horseradish peroxidase conjugate, and 4 -chloro-1-napthol 
substrate.
4.1.3 RESULTS
Comparison of tests
Table 4.1.1 gives the results of each of the three ELISA 
tests for samples obtained during 1984 and 1985. One 
sample was weakly positive by the non-commercial Type I 
assay but was negative in the second Type 1 test and the 
Type II ELISA. The 1985 and all subsequent samples from 
this patient have remained negative.
All positive samples (n=42) in any test were confirmed by 
WB and IF. Only the weakly positive sample in the first 
type I direct ELISA was negative by WB; all positive 
samples had at least two envelope protein antibodies and 
one core protein antibody present. Figure 4.1.1 shows a 
typical positive WB result. Similar results were 
obtained by the IF test, (Table 4.1.2). Sera from 50 
persistently ELISA HIV-1 antibody negative samples were 
tested by WB; none were positive.
No false positive reactions were obtained using the two 
commercial ELISA tests, (Table 4.1.2). Both had a high
Table 4.1.1. The results of ELISA serological tests to 
detect anti IgG HIV-1 antibody.
Type 1 (NC)
1984 20/133 (15%)
1985 ND
Type 1 (C)
19/133 (14%) 
22/133 (16.5%)
Type I I
19/133 (14%) 
22/133 (16.5%)
The Type I and II commercial ELISA tests for HIV-1 
antibody gave similar results. One sample was positive
in the non-commercial ELISA and negative in both 
commercial assays.
ND = Not done
NC = Non commercial
C = Commercial
•L
STRIP ASSAY RESULT
REACTIVE PROFILE
(II
j_gpl60 
I— gpl20
W -p64
(|^p55/p53
B-gp4i
dp-p31 
■  -P24
M-p15
Figure 4.1.5. a  positive Western blot. To establish a 
diagnosis requires envelope, polymerase and group antigen 
encoded products. gp160 = envelope glycoprotein
precursor; gp120 = outer envelope glycoprotein; p64 =
reverse transcriptase component; p55/p53 = gag protein
precursor; gp41 = transmembrane envelope glycoprotein; 
p31 = endonuclease; p24/p15 = Core gag protein.
Table 4.1.2 Results of Western blots and
immunofluorescence test in samples positive in any ELISA.
T est Number te s te d  Number p o s i t iv e
Western blot 45 44
Immunofluorescence 45 44
The one sample that was positive in the non-commercial 
ELISA was negative by both Western blotting and 
immunofluorescence.
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sensitivity and specificity using WB and IF as the 
standard, (sensitivity = 100%, and specificity = 100%).
In c id e n c e  and p re v a le n c e  o f H IV -1 in fe c t io n  
Figure 4.1.3 shows the cumulative annual incidence of 
HIV-1 infection during this study (1983-1987) using the 
competitive ELISA test. Three seroconversions occurred 
in 1985 after the introduction of heat treated factor 
concentrate; in one patient seroconversion occurred after 
receipt of heat treated factor concentrate. The details 
of this patient are given at the end of this section. 
The prevalence of HIV-1 infection at the end of the study 
was 16.5 percent.
Stored, retrospective, sera from all HIV-1 antibody 
positive patients were obtained and tested by ELISA and 
WB, (Figure 4.1.4) 14 samples from 6 patients between
1974 and 1 980 were available, none were positive. The 
first positive sample was found in 1981. Patients (n=14) 
in whom a negative sample was available the mid-point 
between the last negative and the first positive was 
taken as the date of seroconversion. No negative sample 
was available in 8 patients; in these patients the date 
of the first positive sample was taken as the date of 
infection.
Seroconversions after the introduction of heat treated 
factor concentrates.
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Figure 4.1.3. A Kaplan Meier analysis of cumulative HIV- 
1 antibody positive results.
Table 4.1.4. Retrospective serum antibody results for HIV-
1 .
P a t ie n t 1977 1978 1979 1980 1981 1982 1983 1984 1985
1 - - - + + + + +
2 - + + + +
3 + + + +
4 - - - - + + +
5 - + + + +
6 - + + + +
7 - - - + + + +
8 + + + +
9 + + + +
10 - + + + +
11 - + + + +
12 - - - - + + + +
13 - + + + +
14 - - - + + +
15 - - - - + + +
16 - - - + + +
17 - - - - + + +
18 - - + + +
19 - + +
20 - - - +
21 - - -/ +
22 - - -/ +
Figure 4.1.4 . 
serum.
negative; + = positive; blank no
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At this Centre, all patients were commenced on heat 
treated factor VIII concentrate December 1984. One 
seroconversion occurred in 1985; his treatment history is 
given below:
Patient 1
Age = 42
Factor VIIIC deficient; level < 1iu/dl 
No inhibitor
Year Number of units used Source of
concentrate
1980 18,180 SNBTS
1981 13,720 SNBTS
1982 37,980 SNBTS
1983 83,630 SNBTS
1984 150,640 SNBTS
1985 173,830 SNBTS
HIV-1 serology (ELISA, Wellcozyme, Western Blot [Dupont])
Date Result
20.03.83 - ve
09.09.83 -ve
05.10.84 -ve
25.10.85 +ve
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The type of factor VIII concentrate used in 1984 and 1985 
was of intermediate purity. He had received twenty 
different batches, of which ten were heat treated.
Twenty-nine HIV-1 antibody negative patients had been 
treated with the same batches, none were HIV-1 antibody 
positive. In the absence of any other seroconversions no 
one batch could be implicated.
4.1.4 DISCUSSION
The primary objective of this study was to evaluate the 
ability of available ELISA tests to detect HIV-1 antibody 
in haemophiliacs. This was specifically done in 
haemophiliacs because effects of previous transfusions, 
high frequency of immune complexes and effects of chronic 
liver disease on the performance of ELISA tests had not 
been established. The two commercial ELISA tests were 
found to be similar in their sensitivity and specificity 
to detect HIV-1 antibody in haemophiliacs. The initial 
Type 1 ELISA used was sensitive but not specific. The 
results of the commercial tests in these haemophiliacs 
are comparable to those reported in other UK high risk 
groups (359) . Both tests were comparable in cost and 
required equivalent amounts of time for optimal usage. 
Therefore, for the purposes of screening haemophiliacs 
for HIV-1 antibody either test can be used.
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Initially two confirmatory tests were used, however WB is 
now the preferred method. This method has the additional 
advantage of providing a discriminatory picture of the 
antibody response. The major disadvantages of WB are: 
the procedure is complex, slow and expensive. 
Furthermore, the interpretation of samples that react to 
only core proteins can be difficult. In individuals not 
at risk for HIV-1 infection, this may indicate; either an 
infection with some as yet unidentified virus 
immunologically related to the known human retroviruses, 
or an early phase of HIV-1 infection,
The major advantage of the IF method is that the 
procedure requires less time than WB, however, the 
conventional IF requires the additional use of a 
fluorescent microscope and expertise in the 
interpretation of marginally positive results (352). An 
alternative to IF and WB is the radioimmuno-precipitation 
assay (RIPA) (352). Although RIPA is an accurate method 
of demonstrating HIV-1 antibodies, it has remained a 
specialist procedure.
Using the described methods, the prevalence of HIV-1 
infection in this cohort was 17 percent. The peak annual 
incidence of HIV-1 infection occurred in 1984, and 
antibody was first detected in 1981. The prevalence of 
infection is lower than that reported in haemophiliacs 
from the USA where the overall prevalence among 
haemophilia A patients has been approximately 70% and for
1 02
haemophilia B patients 35 percent (360) and other parts 
of Europe (361) but comparable to Eastern Scotland (221).
This may reflect regional differences in amount of
treatment given, contamination of the donated plasma pool 
with HIV-1 or variations in host susceptibility to HIV-1 
infection (see Section 4.2).
HIV-1 infection in this cohort occurred later than in USA 
haemophiliacs (362, 363) but at a time similar to other
UK haemophiliac patients (364). Although the peak 
incidence of HIV-1 infection occurred at the same time as 
in the East of Scotland (221), initial infections
occurred earlier. The explanation may be different 
sources of clotting factor concentrates used. In the 
West of Scotland prior to 1984 factor concentrate
fractionated from plasma donations in the USA and
Scotland was used, whereas in Eastern Scotland only 
locally donated plasma fractions were used.
HIV- 1 seroconversions in patients receiving heat-treated 
factor concentrates have been reported (257) . The 
patient reported in this section had received non-heated 
treated factor concentrate as well as that treated with 
dry heat at 72°C for 24 hours. He had no other risk 
factors for HIV-1 infection. However, it is difficult to 
be certain that infection occurred due to a failure of 
heat treatment - a negative serum sample was not 
available prior to receipt of heat treated concentrate. 
Furthermore, the appearance of antibody may take up to 14
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weeks in haemophiliacs and in homosexuals an even longer 
duration has been noted (2 2 1 , 365). Twenty-nine other 
HIV-1 antibody negative haemophiliacs received the same 
batches, none seroconverted. There are several
possibilities to explain infection (a) it occurred from 
non-heat treated concentrate; (b) occurred from heat- 
treated concentrate, due to either (1 ), (2 ), (3 ): 1 . the
size of the HIV-1 innoculum may have been larger in this 
patient; 2 . he had a constitutional predisposition to 
HIV-1 infection; 3. previous treatment with factor
concentrate had primed his immune system to allow HIV-1 
infection to establish itself.
In vitro studies suggest that adequate heat treatment 
should have eliminated the risk of further HIV-1
infections occurring in haemophiliacs (Chapter 1 ) . 
Nevertheless, 18 seroconversions have been well 
documented, 14 occurred prior to donor screening for HIV- 
1 antibody or with concentrates dry heated at
temperatures of 60-68°C for 30-72 hours. All
commercially manufactured dry heated intermediate purity 
concentrates have been withdrawn (257). Several
alternatives to dry heat have been suggested. HIV-1 
seroconversions have not been reported with pasteurized 
concentrate, however the numbers of patients treated is 
small (257) . Prince et al have reported that treatment 
with detergent and sodium cholate inactivates HIV-1 
(267). Clinical studies with such preparations are in 
progress (270).
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In the West of Scotland measures instituted to prevent 
further HIV-1 infection in haemophiliacs via transfusion 
include heat treatment of all clotting factor 
concentrates. Further, all blood donors are provided 
with information about risk factors associated with HIV-1 
infection and high risk individuals are requested to 
defer donations, and all donations are screened for HIV- 
1 antibody. HIV-1 infection has occurred after the use 
of screened blood donations. The estimated odds are 
1:40,000 (366). Assays for HIV-1 antigen or other tests
that detect antibodies to recombinant HIV-1 antigens are 
at present being considered for screening blood donations 
so that the "window period" from acquiring infection to 
manifesting detectable serum IgG antibody is covered 
(367, 368) . A more recent development has been the
ability to detect integrated HIV-1 provirus (369). The 
method is based on the polymerase chain reaction (PCR), 
in which selected DNA sequences are amplified several 
thousandfold using primer base pairs, in this case from 
multiple regions of the HIV-1 genome. The efficacy of 
this method is not yet known.
In conclusion, this study showed that the available ELISA 
screening tests were capable of detecting HIV-1 antibody 
in haemophiliacs. Using such tests it was shown that HIV- 
1 infection first occurred in 1981; the peak annual 
incidence of HIV-1 infection occurred in 1984; and the
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prevalence was 16.5 %. The steps taken to prevent
further HIV-1 infections occurring in haemophiliacs have 
been discussed.
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CHAPTER 4.2
Risk Factors for HIV-1 infection in haemophilia.
Summary
Study objective; To determine treatment- and host- 
related risk factors for HIV-1 infection in haemophilia.
Study population; 133 treated haemophiliacs in whom the
HIV-1 antibody status was known.
Measurements; Mean annual dose of clotting factor 
concentrate used, source of concentrate, type of 
concentrate used, age, hepatitis B serology, severity of 
liver disease.
Results: HIV-1 antibody positive patients had used:
(a) more concentrate per annum
(b) more commercial concentrate
(c) were significantly younger than seronegative patients 
Hepatitis B markers (surface antibody and antigen) 
occurred more frequently in seropositive patients. 
Severity of liver disease was similar.
Conclusions: The mean annual dose; source and type of
clotting factor concentrate used were independent risk 
factors for HIV-1 infection.
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4.2.1 INTRODUCTION
The prevalence of HIV-1 infection in severe haemophiliacs 
from the USA is as high as 90 percent and a similar high 
prevalence has also been found in Europe (360, 361). In 
the UK the overall HIV-1 antibody prevalence is 38.8 
percent (370) . One explanation for the geographical 
differences may be variations in sampling policies, 
however within the UK a uniform sampling method was 
applied. Despite this a varying regional prevalence was 
seen.
Ludlam et al have reported that exposure to an infected 
batch of factor concentrate did not invariably result in 
infection (221). Such resistance to infection has also 
been noted in homosexual men (222). Studies of animal 
retroviral infections show similar differences in 
susceptibility to infection (371). Failure of the
virus to establish infection may be due to: (a) the
relative virulence of the virus strain; (b) the inherent 
sensitivity of the host cell to virus replication; (c) 
genetic determinants or (d) levels of the antiviral 
immune response. The latter possibility has been raised 
by the occasional finding of asymptomatic individuals who 
have been HIV-1 seropositive becoming seronegative (223). 
The role of genetic factors in susceptibility to HIV-1 
infection remains controversial. Steel et al showed a 
trend for histocompability locus DR-3 and susceptibility 
to HIV-1 infection (372). Eales et al reported an
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association with group specific complement (vitamin D 
binding factor) but this initial claim has been retracted 
(373). Inherited partial C4 deficiency has also been 
suggested as a risk factor for infection (3 7 4 ).
An alternative explanation may be the frequency of 
exposure to HIV-1. In homosexuals a history of frequent 
sex with an individual in whom AIDS subsequently 
developed was independently associated with subsequent 
AIDS (375). In haemophiliacs exposure to HIV-1 depends 
on the degree of contamination of the donor plasma pool, 
as well as the amount of treatment given.
A proportion (8 percent) of the total factor VIII 
concentrate used at prior to 1984 was imported from the 
USA, (Figure 2.1.1). In this cohort HIV-1 antibody was 
first detected in 1981 and the peak annual incidence of 
infection occurred in 1983 (Chapter 4.1.1). The use of 
factor VIII concentrate imported from USA may therefore 
have been one predisposing factor to infection.
The influence of age and liver disease (due to hepatitis 
B and non-A, non-B) in predisposing to HIV-1 infection is 
not known. Chronic liver disease can be associated with 
laboratory abnormalities suggestive of immunodeficiency 
(376) .
The primary aim of the present study was to identify 
treatment related risk factors for HIV-1 infection. The
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mean annual total dose of clotting factor concentrate 
received, the type and source of clotting factor used by 
HIV-1 antibody positive and negative patients was 
compared. Age and severity of liver disease was also 
considered.
4.2.2 METHODS
Patients
Selection criteria and demographic characteristics of the 
study population have been previously described, (Chapter 
2.1). Briefly, 133 adult haemophiliacs who had received 
a blood product from the West of Scotland Adult 
Haemophilia Centre since 1980 were studied. Of these 100 
patients were factor VIII deficient and 33 factor IX 
deficient.
Since December 1 984 no patient at this centre had been 
treated with non-heat treated clotting factor concentrate 
imported from the USA. The prevalence for HIV-1 antibody 
in 1984 was 14 percent, only one patient with factor IX 
deficiency was known to have HIV-1 antibody.
Methods
The case notes of all treated patients were reviewed and 
the following information recorded:
1. Total amount of clotting factor concentrate used from 
1980-1984, inclusive.
2. The type and source of clotting factor concentrate
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used.
3. In those patients in whom a negative serum sample HIV- 
1 antibody was available, batch numbers of clotting 
factor concentrate used between last negative and first 
positive serum sample were recorded. The names of all 
seronegative patients who had received these batches and 
number of infusions were noted.
The criteria used to classify for severity of liver 
disease are given in chapter 2 .
HIV-1 Serology
The presence of HIV-1 antibody was detected using a 
competitive inhibition ELISA (Wellcozyme, Wellcome 
Diagnostics, Beckenham, Kent) and confirmed by Western 
blotting (Dupont).
4.2.3 RESULTS
The peak annual incidence of HIV-1 infection in this 
cohort occurred in 1984, (Figure 4.1.3).
Host associated risk factors for HIV-1 infection 
Table 4.2.1 shows the age, previous hepatitis B 
infection, and the severity of liver disease prior to the 
peak period of HIV-1 infection (1983). The median age 
of HIV-1 antibody positive patients was significantly 
lower than seronegative patients. Hepatitis B surface
Table 4.2.1 A comparison of the characteristics of HIV-
1 antibody positive and negative patients.
HIV s ta tu s  
-VE +VE p v a lu e
Number 114 19
Age 32
(25-45)
21
(18-35)
0 .001
Mean Annual Dose 6503 80,000 0.0008
of clotting factor (1000-27298) (50000-100000)
concentrate
Liver disease 3.5 3 0.06
severity (2-5) (2-3)
Hepatitis B surface 44 (39%) 12 (63%)
antibody
Hepatitis B surface 
antigen
The medians and interquartile ranges are shown. HIV-1 
antibody positive patients were significantly younger, 
and had used more clotting factor concentrate than 
seronegative patients. More HIV-1 positive patients had 
hepatitis B antibody than seronegative patients. (p=0.01, 
Fisher's Exact Test).
antigen and antibody was more frequent in HIV-1 antibody 
positive patients.
Treatm ent r e la t e d  r is k  fa c to rs  f o r  H IV -1 in f e c t io n  
Type o f  tre a tm e n t
The most striking difference was the low incidence of 
HIV-1 infection in factor IX deficient patients (6 
percent) compared to factor VIII deficient patients (20 
percent) (p = 0.05, Fisher's Exact Test). The relative 
risk for HIV-1 infection in factor VIII deficient
patients was 3.3 times greater than in factor IX
deficient haemophiliacs. Table 4.2.2 shows there were no 
other significant differences between factor VIII and IX 
deficient patients.
Between 1980 and 1985, eight factor VIII deficient
patients had been treated with cryoprecipitate alone; 
none had HIV-1 antibody. Ten factor VIII deficient
patients had received both cryoprecipitate and factor 
concentrate, none had serological evidence of HIV-1 
infection. No patient seroconverted while receiving 
activated prothrombin complex concentrates.
Amount o f c lo t t in g  fa c to r  c o n c e n tra te  used 
Patients with HIV-1 antibody had used significantly more 
clotting factor concentrate than those without HIV-1 
antibody, Table 4.2.3.
Source o f treatment
Table 4.2.2 A comparison of Factor VIII and Factor IX 
deficient haemophiliacs in 1984.
Type of haemophilia VIII IX pvalue
Number of patients 100 30
HIV antibody 18
Mean annual dose 
of clotting factor 
concentrate
8778.5
(1627-46782)
9500
(1000-38000) 0.7
Severity of liver 
disease
3
(2-5)
4
(2-5)
0.5
Age 32
(23-45.5)
27
(23-29)
0.09
The medians and interquartile ranges are shown. There 
were significantly more HIV-1 antibody positive patients 
with factor VIII deficiency than factor IX deficient 
patients, (p=0.05, Fisher's Exact Test). There were no 
other significant differences between the two groups.
Table 4.2.3 A comparison of HIV-1 antibody positive and
negative patients.
HIV S ta tu s
Mean annual (total) 
dose of clotting 
factor concentrate
+VE
78016.5 
(50,000-88,371)
-VE
6210
(900-26,000)
Total dose of local 
concentrate
95485 
(0-289,138)
15282.5 
(1730-59,184)
Total dose of 
commercial concentrate
76,473
(8387-41,3070)
0
(0-1765)
Severity of haemophilia
(Mild >J0iu/dl )
(Moderate >.5 <10iu/dl)
(Severe <5iu/dl )
0
1
18
28
30
56
The median and interquartile ranges are shown. HIV-1 
antibody positive patients had used more clotting factor 
concentrate (total), similar amounts of concentrate 
fractionated from local plasma donations but more 
concentrate prepared from USA plasma donations. There 
were significantly more HIV-1 antibody positive 
haemophiliacs with a severe deficiency.
Seropositive patients had used significantly more 
commercial concentrfl&e (p=0.001, Fisher's Exact Test).
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Table 4.2.4 shows the number of patients treated with 
local and/or commercial concentrate. Patients who 
acquired HIV-1 infection prior to 1985 had used more 
factor VIII concentrate prepared from USA plasma 
donations than HIV-1 antibody negative subjects, Table 
4.2.4. There were no statistical differences in the two 
groups for use of local products, Table 4.2.4.
HIV-1 infection with local blood products
Of those patients who had seroconverted prior to 1985 
only one had never received factor VIII concentrate 
fractionated in the USA. He had no other risk factors 
for HIV-1 infection. His infection occurred between 
1.7.82 and 12.12.83 (Patient 1). Two other patients had 
subsequently seroconverted while receiving clotting 
factor concentrates fractionated from local plasma 
donations; both were infected in 1985. The batches of 
clotting factor concentrate used between the first 
positive and 6 months prior to the last negative HIV-1 
test were noted for patient 1 and all other patients 
treated with the same batches identified.
The index patient had used a total of nine different 
batches. Table 4.2.5 shows the number of infusions 
received by patients of each batch. Only one batch had 
been used by both the index patient and another HIV-1 
antibody positive patient. This second patient had 
received this batch prior to his first antibody positive 
sample and the last negative serum specimen. He had not 
been treated with commercial clotting factor concentrate.
Table 4.2.4 The association between source of
concentrate and HIV-1 status.
HIV S ta tu s
+VE -VE
Local 1 49
Commercial only 0 0
Local and commercial 18 61
Not treated 0 4
Total 19 114
The number of patients who had received clotting factors 
according to the source of the donated plasma,commercial 
indicates clotting factor concentrates fractionated from 
plasma donations in the USA. Significantly more positive 
patients had been treated with both local and commercial 
concentrate. (p=0.001, Fisher's Exact Test)
Table 4.2.5 The number of infusions of each implicated 
batch used by treated patients.
BATCH NUMBER
Last First
HIV -ve +ve 378 593 595 604 606 627 666 682 692
Index + 7/82 12/83 3 8 10 23 13 20 31 40
46
MK + 8/81 11/82 12 20
AC + 5/82 1/84 20 5 28 30 29
IC + 82 31 20 28
NS + 80 81 3 3 1
HM + 81 83 12 24 90
AD - 22 7 26
AF - 3
DG - 1 4 3
DH - 64 31
DI - 4
MJ - 28 2
JMcA - 24 39
JMcK - 20 24
WMcK - 20 30 20 27
JMcS - 19 3
JM - 28
McE - 19 28
TM - 12 3 20
JQ -
SV - 20 33 40 20 18 31
PW - 2 5 1
A total of sixty six patients had been treated during 1982 and 1983 
at this centre. 21 patients had received one of the batches used by 
the index patient. It is not known whether batch 692, the most 
likely batch, had been distributed elsewhere in Scotland.
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It is however difficult to be sure if this batch can be 
implicated.
R egression  A n a ly s is
A multiple regression analysis showed that HIV-1 antibody 
status showed an independent direct correlation with the 
mean annual dose of clotting factor concentrate (r=0.64/ 
p=.0001)/ and amount of commercial concentrate used 
(r=0.64/ p=0.001). A poorer correlation was seen with
mean annual dose of local concentrate (p=0.24/ p=0.004). 
Age showed a weaker indirect correlation (p=-0.3/
p=0.002) .
To clarify the influence of age in acquiring HIV-1 
infection a stepwise variable selection analysis in 
which age was the dependent variable and mean annual dose
of total concentrate and total dose of local and
commercial concentrate independent variables, only use of 
commercial concentrate was retained in the equation on 
both forward and backward selection (r=-0.7).
L iv e r  D isease
In a stepwise variable selection analysis in which HIV-1 
antibody status was the dependent variable and the
independent variables were severity of liver disease and
mean annual dose of clotting factor concentrate used, 
liver disease was not a significant contributory factor 
but mean annual dose of clotting factor concentrate used 
was (r=-0.62, p=0.04).
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Significantly more HIV-1 antibody positive patients had 
hepatitis B surface antibody (Table 4.2.1), the presence 
of hepatitis B surface antibody was independent of HIV-1 
infection but was related to mean annual dose of clotting 
factor concentrate used (r=-0.62, p=0.002, stepwise
variable selection analysis). More HIV-1 antibody
haemophiliacs had persistent hepatitis B surface antigen, 
Table 4.2.1.
The results of the present study show that mean annual 
dose of clotting factor concentrate, type and source of 
factor concentrate were independent risk factors for HIV- 
1 infection.
The relative risk of acquiring HIV-1 infection from 
factor VIII clotting factor concentrates was four times 
higher than factor IX concentrates. Similar findings 
have been reported by others (360, 370) with one
exception (361). In France a 43% incidence of HIV-1 
antibody was found in patients treated with locally 
(french) fractionated factor IX concentrates whereas 
prevalence of HIV-1 antibody in factor VIII deficient 
treated with locally prepared concentrates was 34 
percent. This may be due to differences in fractionation 
methods. In most countries the first step in the
fractionation of pooled plasma to prepare clotting 
factor concentrates is cryoprecipitation. The
prothrombin group of plasma proteins fractionates into
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the supernatant. In vitro studies of plasma seeded with 
HIV-1 have shown that 90 percent partitions into the 
cryoprecipitate fraction (330). This preferential 
partitioning of HIV-1 may explain the lower incidence of 
HIV-1 infection in factor IX deficient haemophiliacs.
An alternative explanation may be that differences in 
host susceptibility exist between factor VIIIC and
factor IX deficient haemophiliacs. In a previous study it 
was shown that factor IX concentrates did not suppress 
mitogen induced lymphocyte proliferation in vitro 
(Chapter 3, section 3.1). It is therefore possible
that factor IX deficient patients are not as predisposed
to HIV-1 infection as factor VIIIC deficient patients.
The finding of a higher prevalence of HIV-1 infection in 
those patients who had used large quantities of factor 
VIII concentrates is in keeping with similar studies 
(221, 360). However, it remains undetermined whether the 
immune aberrations associated with clotting factor 
concentrate predisposed to HIV-1 infection, or if the 
more frequent use of clotting factor concentrate 
increased the risk of exposure to an infected batch.
A strong statistical association was also found between 
the use of concentrate prepared from plasma donations
obtained in the USA and HIV-1 infection. This finding
has been subsequently confirmed by others (361, 370,
377, 378).
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However it was also found that one patient with HIV-1 
infection had never been exposed to USA clotting factor 
concentrate, this would suggest that the HIV-1 infection 
was present in the UK donor population as early as 1982. 
Ludlam et al similarly found that locally fractionated 
clotting factor concentrates transmit HIV-1 infection 
(221). In both the present study and Ludlam's report 
exposure to a potentially infected batch was not 
invariably associated with seroconversion. It is not 
known if false negative results were obtained using 
serological tests. An alternative explanation may be (a) 
innate immune reactions and the initial cell mediated 
immune response to HIV-1 cleared the virus, or (b) that 
such individuals have a reduced ability to mount an 
antibody response either because of a intrinsic B cell 
defect or abnormal T cell control of B cell function. In 
this regard recent studies have shown that individuals 
exposed to HIV-1 but without serological evidence of 
infection have HIV-1 provirus integrated into their 
genome (379, 380).
In the present study patients with HIV-1 antibody were 
significantly younger, (Table 4.2.1), this was probably 
due to the more frequent use of commercial clotting 
factor concentrates in younger patients rather than a 
true age related predisposition to HIV-1 infection.
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Significantly more HIV-1 antibody positive patients had 
previous evidence of hepatitis B infection. This was due 
to a higher mean annual dose of clotting factor
concentrate used rather than a feature of HIV-1 
infection.
A higher frequency of hepatitis B surface antigen
carriage in HIV-1 antibody positive patients was clear, 
because of the small numbers of HIV-1 antibody negative
hepatitis B surface antigen carriers no firm conclusions 
can be made. There are, however, several possibilities: 
first, this may be another aspect of the more frequent 
use of commercial clotting factor concentrate; second, 
immune impairment due to HIV-1 may have contributed to 
failure to clear the hepatitis B virus and lastly, 
persistent immune stimulation due to hepatitis B may have 
primed the immune system to allow HIV-1 to establish 
infection.
Other suggested factors in susceptibility to HIV-1 
infection in haemophilia include a genetic 
predisposition. To date only the influence of HLA-DR 
phenotype has been examined and no statistically
significant association was found (371). This has been 
confirmed by others (381-382).
In conclusion, the amount, source and type of clotting 
factor concentrate were independent risk factors for HIV- 
1 infection. These risk factors can be reduced by donor
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screening for HIV-1 antibody, heat treatment of factor 
concentrates and by restricting the number of different 
batches that a patient is exposed to.
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CHAPTER 4.3
The a b i l i t y  to  is o la t e  H IV -1 . is  i t  governed by th e  
anti - v i r a l  immune response?
Summary
Study objective: To attempt HIV-1 isolates from antibody
positive patients.
Study population: 10 HIV-1 antibody positive patients.
Measurements: Pro-virus expression indicated by
syncitium formation in stimulated peripheral blood 
mononuclear cells co-cultured with C8166 cells, a HIV-1 
permissive cell line.
Results: Pro-virus expression was obtained in only one
patient in two of three sequential cultures. The failure 
to obtain a third isolate coincided with a dramatic 
increase in circulating CD8+ve T-lymphocytes.
Electronmicrographs from the first isolate showed 
replication deficiency viral particles.
Conclusions: The ability to isolate HIV-1 may be
determined by anti-viral immune responses. Some of the 
clinical features of HIV-1 infection may be due to 
replication deficient viral particles.
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4.3.1 INTRODUCTION
The ability to isolate human immunodeficiency virus (HIV- 
1) from antibody positive patients has several 
advantages. Serological tests can be confirmed, and if 
HIV-1 could be isolated from haemophiliacs with HIV-1 
antibody, it would argue against passive immunization 
with viral proteins as has been suggested (383) . 
Identifying the virus in cultures may give an insight 
into mechanisms of provirus expression in-vivo and yield 
prognostic information (219). In animal retroviral 
infections such as feline acquired immunodeficiency virus 
infection, replication deficient viruses are frequently 
isolated from fresh tissues but remain pathogenetic 
(384). By analogy such variants may exist during the 
course of HIV-1 infection. Furthermore, the sequence of 
envelope proteins could be determined in isolates and 
frequency of mutations over time studied. Such 
information would be of potential value in determining 
the host-virus relationship.
The aim of this study was to obtain serial HIV-1 isolates 
from seropositive patients.
4.3.2 METHODS 
P a tie n ts
Heparinised venous blood was obtained from 10 HIV-1 
antibody positive haemophiliacs. Included in the present 
study were two patients who had clinically significant
121
HIV-1 related disease: one patient had AIDS related
complex and one patient recurrent oral candidiasis.
Cell separation
Peripheral blood mononuclear cells (PBMC) were separated 
by density centrifugation on sodium metriazoate as 
previously described (Chapter 3.1.2). The cells were 
resuspended in RPMI-1640 with 15 percent heat inactivated 
fetal calf serum and supplemented with Lglutamine and 
antibiotics (Chapter 3.1).
5x1 03 -1x10^ PBMN cells/ml were cultured in the presence 
of 5ug/mls phytohaemagglutinin (PHA) (final
concentrations) and 3x105 C8166 cells (a hybrid cell line 
obtained by fusing human umbilical cord blood lymphocytes 
with a HTLV-1 transformed cell line obtained from 
patients with T cell leukaemia and lymphoma (385). All 
cultures were performed in 80cm3 tissue culture flasks. 
PHA stimulated patient PBMC in the absence of C8166 
cells, (Costar, Cambridge, Massachusetts) and C8166 cells 
in the presence or absence of PHA, served as controls.
Virus identification
The cultures were examined daily for 7 days for syncitia, 
indicating provirus expression. The presence of syncitia 
was confirmed by an independent observer. 
Electronmicrographs were obtained in cultures which 
showed large numbers of syncitia. The presence of HIV-1 
was confirmed by immunofluorescence testing.
1 22
4 . 3 . 4  R e s u lts
Syncitium formation was noted in 5 of the 10 cultures.
No syncitia were seen in the control cultures. In only 
one patient was the presence of HIV-1 confirmed in 
syncitia by immunofluorescence. The presence of virus 
particles in culture was confirmed by electronmicroscopy.
Virus isolation in this patient was attempted on 2 
further occasions after six and twelve weeks. At week 
six large syncitia were again seen, provirus expression 
was not seen at week 12.
Figure 4.3.1 shows the results of T cell subset counts at 
the times HIV-1 isolation was attempted in this patient.
It is interesting that at week 12 when no virus was 
obtained in culture there had been a dramatic increase in 
the number of circulating T-suppressor/cytotoxic cells, 
(CD8+ve T-cells), but the numbers of T-helper/inducer 
cells had not changed.
4 . 3 . 4  DISCUSSION
In the present study HIV-1 was isolated from one of ten 
patients. The failure to isolate virus in remaining 
patients however does not imply that these patients were 
not infected with the whole virus. This may have been 
due to other factors, for instance it is well established 
that HIV-1 isolation is more difficult in asymptomatic
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individuals compared to those with AIDS (224). This 
variation in HIV-1 replication in cultured cells appears 
to mirror the increase of viral p25 antigen in the plasma 
of individuals as they advance in disease (386). In this 
study one patient had detectable p25 antigen in serum, 
virus however was not isolated.
The most interesting observation was in the patient in 
whom isolates were obtained in two of three occasions. 
The failure to isolate virus on the third occasion may 
have been due to the dramatic increase in the number of 
T-suppressor/cytotoxic cells at week 12. In this regard 
it has been reported from other laboratories that the 
ability to isolate virus from asymptomatic individuals is 
increased when CD8+ve T-cells are selectively removed 
from the blood sample (224) . Combined, these findings 
suggest that cell mediated immune response to HIV-1 may 
be important in the control of HIV-1 infection in vivo.
Electronmicrographs of the HIV-1 isolate of this patient 
showed that some of the released viral particles were 
defective. Similar findings have been reported from an 
isolate obtained from the lymph node of a HIV-1 antibody 
positive patient with persistent generalized 
lymphadenopathy (387). The clinical significance of this 
finding is not clear. Similar findings have been 
reported in the recently described syndrome of feline 
acquired immunodeficiency syndrome (FAIDS) which is also 
due to retroviral infection (384) . It has been
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considered that in FAIDS such viral particles may be 
pathogenic. Future studies of fresh tissue in HIV-1 
positive patients are indicated to confirm this finding.
In conclusion the results of this study confirms previous 
reports that HIV-1 isolation in cell culture is not 
invariable, this however does not indicate that these 
individuals were not infected with the whole virus (224). 
The anecdotal observation that isolates are more 
difficult to obtain in the presence of increased CD8+ve 
T-cells merits further investigation.
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CHAPTER 4.4
Human T-cell lymphotropic virus-1 (HTLV-1) is not 
implicated in the T-cell subset aberration in 
haemophilia.
Summary
Study objective: To determine the prevalence of HTLV-1
infection in haemophilia.
Study population: 133 haemophiliacs who had received
both locally and commercially fractionated clotting 
factor concentrates.
Measurements: Serum HTLV-1 antibody measured by a
commercial ELISA.
Results: No patient had serological evidence of HTLV-1
infection.
Conclusions: HTLV-1 is not transmitted by clotting
factor concentrates.
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4.4.1 INTRODUCTION
The human immunodeficiency virus-1 (HIV-1) is a
retrovirus which specifically infects T-lymphocytes of 
CD4+ve phenotype. Another lymphotropic retrovirus that 
is known to be transmitted by blood is Human T-cell 
lymphotropic virus-1 (HTLV-1) (388). The virus is 
endemic in some areas of Japan, Africa and the Caribbean, 
the south eastern United States and South America (389- 
391). In the UK, HTLV-1 antibodies are found 
particularly in individuals of West Indian origin (392).
Both viruses are CD4+ve T-cells tropic (393). Unlike 
HIV-1, HTLV-I is a cell transforming virus-1 (393). 
Clinically, HTLV-I is implicated in the aetiology of 
certain T-cell cutaneous, lymphomas, tropical spastic 
paraparesis and other myelopathies (394-396).
Increasingly, dual infections with both HTLV-I and HIV-1 
have been recognized in intravenous drug abusers (397).
The influence of HTLV-I on the course of HIV-1 related 
immunodeficiency has not been clearly established.
Like HIV-1, HTLV-I can be transmitted by blood and blood 
products, sexual contact, from mother to fetus, and by 
sharing of contaminated needles by drug abusers (397,
398) .
Reduced numbers of CD4+ve T-cells have been reported in 
HIV-1 antibody negative individuals (399). It was 
important to exclude the possibility that HTLV-1 may be
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causing these changes. In the present study HTLV-1
antibody was sought in a well defined cohort of treated 
haemophiliacs.
4 . 4 . 2 .  METHODS 
P a tie n ts
All haemophiliacs recruited were enrolled in 1983; 
details of patient selection and evaluation are given in 
detail elsewhere (chapter 2) . Briefly, all factor VIII 
or IX deficient haemophiliacs who had received a blood 
product from the West of Scotland Adult Haemophilia 
Centre between 1980 and 1985 were included. Serum 
obtained during 1984 was used. Heat-treated factor 
concentrates have been used at this centre since 1 985, 
and like HIV-1, HTLV-1 is heat sensitive.
4 . 4 . 3  Methods and p a t ie n ts
The presence or absence of antibody to HTLV-1 was 
assessed using a commercial ELISA (Dupont).
4 . 4 . 4  R e s u lts
No patient was found to have HTLV-1 antibody.
4 . 4 . 5  D iscu s s io n
The results of this study indicate that HTLV-1 cannot be
implicated in the CD4 T-cell lymphopenia in HIV-1 
antibody negative haemophiliacs.
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The absence of HTLV-1 antibody in this group of 
haemophiliacs is in keeping with previous reports that 
HTLV-1 infection is absent in haemophiliacs (400, 401).
To my knowledge there is only one haemophliac with HTLV-1 
antibody in Scotland, this individual is of West Indian 
origin and it has been considered unlikely that he 
acquired infection via blood products (402).
Despite the negative findings it is difficult to be 
certain that HTLV-1 is not transmitted by clotting factor 
concentrates because first: HTLV-1 antibodies are
directed against envelope glycoproteins which may not 
have been detected in the assay used; second: the sample
size may have been inadequate if prevalence of the virus 
is low; third: the factor concentrate used was derived
mainly from local plasma donations from an area not 
known to be endemic for HTLV-1.
Transmission of HTLV-1 by blood products has recently 
been reported in a group of patients with leukaemia in 
the USA (403) . None had clinical findings to suggest an 
illness related to HTLV-1 infection or HIV-1 infection. 
The occurrence of these seroconversions confirms 
transmission of HTLV-1 by blood in areas of presumed low 
HTLV-1 prevalence. It is however not clear if testing 
blood donations for HTLV-1 antibody should be instituted 
in areas where HTLV-1 infection is not endemic.
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CHAPTER 5.1
SERUM HIV-1 ANTIGENAEMIA - CLINICAL AND SEROLOGICAL 
CORRELATIONS
SUMMARY
Study objective: To determine frequency of serum HIV-1
antigenaemia and its relationship to clinical and
serological parameters.
Study design: Open, cross-sectional with retrospective
review.
Study population: 22 haemophiliacs with serum HIV-1
antibody and 20 without.
Measurements: Serum HIV-1 antigen levels and western
blot profile.
Results: HIV-1 antigen was found in 4 of 22 (18%) HIV-1
antibody positive patients and in none of seronegative 
patients. Absence of antibody to core proteins was 
associated with serum HIV-1 antigenaemia. Patients with 
serum antigen had an increased frequency of clinical 
disease.
Conclusions: Serum HIV-1 antigenaemia may be a useful
additional marker of disease progression.
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5.1.1 INTRODUCTION
Human immunodeficiency virus-1 (HIV-1) specifically
infects and depletes lymphocytes that express the CD4 
molecule (T-helper; T-h, CD4+ve) (339-345). The natural 
history of infection is characterised by a progressive 
depletion of CD4+ve lymphocytes, impairing the host's 
ability to mount an effective immune response, 
predisposing to opportunistic infections and malignancies 
(344). Infection however, does not preclude an immune 
response to the virus particularly in the early stages of 
infection.
Exposure to HIV-1 is followed by a well-characterised 
humoral immune response (404). Serum IgG antibodies to 
all the structural and functional gene products can be 
identified by Western blotting. At present there is not 
entire agreement in the sequence of serological 
responses, current opinion using competitive immunoassays 
employing recombinant-DNA produced HIV envelope proteins 
as antigen indicate that envelope protein, gp41, appears 
earlier than antibody to the core protein, p24 (404).
When p24 antibody is present in antigen excess, serum 
antigenaemia is less frequently found (404). In general, 
in individuals without significant clinical 
immunodeficiency increasing titres of antibody using 
ELISA tests to all viral proteins are found (375). 
Symptomatic immunodeficiency is often associated with 
loss of p24 antibody as assessed by competitive ELISA and
131
Western blotting and may be associated with a 
reappearance of serum antigen (405).
The aim of this study was to determine the frequency of 
HIV-1 antigenaemia in serum, its relationship to core 
antibodies and symptoms.
5.1.2. PATIENTS AND METHODS 
Patients
Stored serum samples from haemophiliacs treated with 
clotting factor concentrates since 1980 at the West of 
Scotland Adult Haemophilia Centre were used. The 
criteria for selecting patients have been previously 
described (Chapter 2).
Serum was tested for HIV-1 antibody by ELISA (Wellcozyme) 
and confirmed by Western blotting (Chapter 4) . In 
addition serum levels of HIV-1 antigen were measured in 
all HIV-1 antibody positive patients. HIV-1 serum 
antigen levels were also measured in 20 HIV-1 antibody 
negative patients. These patients were specifically 
chosen because:
1 • Mean annual dose of clotting factor used was 
■>40,000iu per annum.
2. They had been exposed to batches of clotting factor 
concentrate fractionated by the Scottish National Blood
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Transfusion service which could have resulted in HIV-1 
infection (Chapter 4.1 and 4.2).
HIV ANTIGEN DETECTION
Serum samples were assayed for HIV-1 antigen by a solid 
phase immunoassay (Abbott laboratories). 200ul of serum
was incubated overnight at room temperature with a human 
anti HIV-1 coated bead. The beads were washed with 
distilled water and rabbit anti HIV-1 IgG was added and 
incubated for four hours at 45°C. The beads were washed 
as before and then incubated for two hours at 45°C with 
goat anti-rabbit IgG conjugated to horseradish 
peroxidase. After a final wash the beads were
transferred to tubes and 0 -phenylenediamine was added and 
allowed to react for 30 minutes at room temperature in
the dark. The reaction was stopped with 1ml 1N sulphuric 
acid and absorbance at 429nm was read. Results were 
read as positive when the optical density was >0.050 plus 
the mean of 5 replicates of normal human serum.
5.1.3 RESULTS 
HIV-1 Antibody
22 (16.5%) of the 133 treated haemophiliacs were HIV-1
antibody positive by ELISA and Western blotting. On
Western blotting all patients had HIV-1 envelope protein 
antibodies. Antibody to core proteins was absent in 4
patients.
HIV-1 Antigen
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None of the twenty HIV-1 antibody negative patients had 
serum HIV-1 antigen. Four (18%) of the 22 HIV-1 antibody 
positive patients had serum antigen. Table 5.1.1 shows 
the results of retrospective samples from these patients.
Sequential Western blots in these 4 patients showed that 
the presence of serum antigen is often associated with 
the absence of core antibodies, (Figs 5.1.1-4), Figure
5.1.4 shows that in this patient loss of p24 antibody 
preceded the appearance of serum antigen and that in his 
most recent sample antibody to p24 has reappeared. In 
patients without serum antigen all bands to HIV-1 were 
present on Western blotting.
C lin ic a l  Outcome
Full details of clinical outcome are given in Chapter 5. 
Briefly; one patient has recurrent oral candidiasis (Ag=- 
ve; p24Ab=+ve); one patient died of AIDS, ie. HIV 
encephalopathy and salmonella septicaemia, he had 
thrombocytopenia prior to the onset of this illness 
(Ag=+ve; p24Ab=-ve); two patients have AIDS related
complex (in one Ag=+ve; p24ab=+ve).
5.1.4 DISCUSSION
The findings in the present study that 4 (18%) of 22 HIV- 
1 antibody positive patients had persistent antigenaemia 
after a median of 24 months (range: 12-37) is in keeping
with previous findings in seropositive haemophiliacs.
/Table 5.1.1 Temporal pattern of serum antigen to
antibody.
YEAR 81 82 83 84
Patient No
85 86 87 88
1 Ab
Ag
2 Ab - N/A +
Ag - N/A N/A WEAK+ / - / - +/- -/-/+ + +
3 Ab
Ag
+ + + + + +
+ /+
4 Ab N/A + + + + + + +
Ag N/A -/- N/A - +/+ +/ + /+ +/ + /+ +
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Figure 5.1.1. Western blot from a patient found to have 
declining p24 antibody and no p15 antibody and declining 
p55 reactivity. Reactivity to gp120 persisted. Lane 1 = 
first positive serum sample.
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Figure 5.1.2. Western blot from a patient with 
persistent p24,, p55, p15 reactivity but declining p31 . 
Lane 1 = first positive specimen.
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Figure 5.1.3. Western blot from a patient with 
persistent p24, p55, p31 but absent p15. This patient's 
first positive serum sample occurred in 1984, patient no. 
1 5 in Figure 4.1.4.
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Figure 5.1.4. Patient no. 3 in Figure 4.1.4. Lane 1 = 
1st positive p24 present but p55 and p15 absent. Lanes 
2-6 loss of p24 and lane 6 resurgence of p24 antibody.
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Allain et al reported a 23 percent prevalence (22 of 96 
patients) after a median period of 34 months (of HIV-1 
antibody presence, and Simmonds et al reported a 12.5 
percent incidence (2 of 18 patients) after 2 years 
follow-up (405, 406). There was no significant
difference between the three studies (Fishers Exact 
Test).
Three patterns of antigenaemia are reported during the 
course of HIV-1 infection. First, is occurrence of 
antigenaemia immediately after infection and prior to 
presence of anti p24 antibody, levels of antigen fall 
when p24 antibody is present in antigen excess. In the 
second pattern antigenaemia persists after infection 
despite presence of anti p24 antibody. Third, is 
resurgence of antigen occurring at variable times after 
infection (405).
Patients with the second and third pattern of 
antigenaemia have clinically more severe immunodeficiency 
(405) . It has also been found that antigenaemia is a
better predictor of disease progression than the absolute 
CD4+ve T-lymphocyte count (405). The clinical utility of 
this test however requires to be confirmed.
The association of antigenaemia and absent anti p24 
antibody was noted in 3 of the 4 patients in this study. 
In the other patient antigenaemia was associated with 
reduced or absent levels of anti p15 antibody (Figs
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5 .1.2-5). In one patient absent anti p55 antibody was 
noted in the face of undetectable antigenaemia. Similar 
findings have been reported by others (405). The 
implications of these findings are not clear. There are 
several possibilities; first antigen may have been 
complexed to antibody. Antigen has however not been
detected in precipitated immune complexes (407). Second, 
antigenaemia reflects enhanced proviral expression and 
the depletion of antibodies is a consequence of this. In 
support of this is the finding that individuals with
antigenaemia often have increased titres of envelope 
antibodies and it is unlikely that reduced antibody 
production should manifest in a decline of one specific 
antibody (405) . Lastly, the converse may be true that
the decline in p24 antibody response allowed enhanced 
HIV-1 provirus expression to continue unchecked. The 
anecdotal finding in this study that one patient (Fig
5.1.3) had a reappearance of p24 antibody would suggest 
that this may occur.
In conclusion the frequency of HIV-1 antigenaemia in HIV- 
1 Ab positive patients in this study was found to be 18 
percent. It was also found that the patients with 
antigenaemia had absent anti-core antibodies. The 
presence of antigenaemia was more frequently associated 
with HIV-1 related disease manifestations, although the 
number of patients were not sufficient to allow any 
definite conclusions. The frequency of antigenaemia
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increased with the duration of HIV-1 antibody positivity 
but occurred at random in individual patients.
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CHAPTER 5.2
THE ANTIBODY RESPONSE TO HIV-1 INCLUDES A PROTECTIVE 
ANTIBODY DEPENDENT CELL MEDIATED CYTOTOXICITY (ADCC) 
RESPONSE TO THE ENVELOPE PROTEINS.
SUMMARY
Study Objective: To determine ADCC responses to HIV-1
envelope glycoprotein.
Study Design: Open, cross-sectional.
Study Population: 21 HIV-1 antibody positive and 4 2
seronegative serum samples from haemophiliacs.
Measurements:
(i) Percent ADCC lysis of an episomally transfected 
cell line with HIV-1 gp120.
(ii) T-cell subsets.
(iii) Serum IgG.
(iv) Clinical outcome.
Results: HIV-1 antibody positive patients mediated
greater ADCC lysis of transfected cells. There was a 
correlation with CD4+ve cell count (r=.51, p=0.04) and
age of infection (r=-.5, p-0.05).
Conclusions: The antibody response to HIV-1 includes an
ADCC response to gp120 which correlates with the patients 
CD4+ve T-cell count.
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5.2.1 INTRODUCTION
Long terra follow-up studies of HIV-1 antibody positive 
patients indicate that between 1% to >12% with an average 
of around 5-7% per annum progress to AIDS (1). 
Progression to AIDS is more rapid in infants and the 
elderly (1). Predictors of progression include a reduced 
number of CD4+ve T-cells, an increased number of CD8 +ve 
T-cells, a low level of HIV-1 antibody and a resurgence 
of viral antigen (375, 405) .
In established infection the protective role of HIV-1 
antibody as measured by enzyme linked immunoassay or 
Western blotting is not clear. The presence of HIV-1 
antibody may play a role in limiting the rate of decline 
of CD4+ve T-cells but is not effective in totally 
eliminating established infection (375). Neutralizing 
IgG antibody demonstrates a limited capacity to inhibit 
viral infection in vitro but its protective role in vivo 
is not known (408-411). In animal retroviral infections 
antibody dependent and cellular mechanisms are important 
in protecting against disease (412 - 414). Antibody
dependent cell mediated cytotoxicity (ADCC) has been 
proposed as a potential method of tumour surveillance 
and in control of initial cell to cell spread viral 
infections in vivo. The ADCC process is initiated by 
binding of antibody directed to a target cell antigen and 
mediated by non-immune leucocytes bearing surface Fc 
receptors for IgG binding to antibody sensitized target 
cells (415) .
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ADCC against the p24 protein of HIV-1 has been previously 
demonstrated in infected individuals (416, 417). Levels 
were found to be higher in asymptomatic HIV-1 antibody 
positive individuals than AIDS patients. The ADCC 
process against envelope proteins may be important in 
controlling the cell to cell spread of HIV-1.
The present study was designed to determine first whether 
sera from HIV-1 antibody infection mediate ADCC against 
cells transfected with the gp120 gene of HIV-1 and 
secondly whether this correlates with the degree of 
immunodeficiency determined by counting CD4+ve T-cell 
numbers.
5.2.2 PATIENTS AND METHODS
The most recent serum specimen obtained between January - 
June 1988 of 70 haemophiliac patients was used. These 
patients were part of a prospective cohort of 133 
haemophiliacs, who had been treated with clotting factor 
concentrates since 1980, and were being closely 
monitored for signs of immunodeficiency. Included in 
this study were 21 of the 22 patients known to be HIV-1 
antibody positive by ELISA (Wellcozyme) and Western 
blotting.
T-cell subsets
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T-cells subsets were counted using monoclonal antibodies 
as described in Chapter 8.2, in all HIV-1 antibody 
positive patients and in 27 of seronegative patients.
Serum IgG
Serum IgG levels were measured in all patients by laser 
nephelometry.
Cell lines
To examine ADCC against gp120 protein of HIV-1, COS cells 
(418) were transfected (419) episomally with the gp120 
plasmid, and used as target cells. COS cells were sub­
cultured at 1.5x10^ cells per 80cm2 flask at 37°C in a 5% 
CO2 humidified atmosphere, in Dulbecco's minimum 
essential medium supplemented with antibiotics and 
glutamine. After 24 hours cells were harvested and 
washed twice in phosphate buffered saline.
The cells were transfected with 20ug of DNA plasmid of 
HIV-1 envelope protein (provided by Dr R Jarrett) using 
5mls serum free medium and 500ul of 100x DEAE-dextran. 
The transfection mixture was incubated with cells for 4 
hours, medium was removed and replaced with 2.5mls of 
serum free medium containing 50mM HEPES buffer and 10% 
glycerol. After 2 mins the transfection mixture was 
replaced with Dulbecco's minimum essential medium/10% 
fetal calf serum.
Assay for ADCC
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Transfected and non-transfected COS cells were washed and 
radiolabelled in suspension at a concentration of 2x 10 6 
cells in Dulbeccos' minimum essential medium containing 
10% fetal calf serum and 100 i^ fll/ml of [5 1Cr] sodium 
chromate for 60 mins at 37°C. The cells were washed, 
resuspended in DMEM at a concentration of 1x10^ cells/ml 
and dispensed in 100ul aliquots into wells of flat 
bottomed 96 well microtitre plates.
In preliminary studies, a 1:10 serum dilution was optimal 
for mediating ADCC. Numerically coded sera by an 
independent observer (Dr E Follet) were heat inactivated 
at 55°C for 30 mins and 20i^l of a 1:10 dilution added to 
appropriate test wells containing target cells. Each 
sample was tested in triplicate. Sera and target cells 
were incubated for 30 minutes at 37°C.
Peripheral blood mononuclear cells obtained by density 
centrifugation from a healthy HIV-1 antibody negative 
donor were suspended in DMEM at a concentration of 3x106 
cells and added in 1OOul aliquots to wells containing 
target cells. After a 4hr incubation at 37°C in 5% CO2 
in air at 1 0 0% humidity, supernatants were harvested and 
counted in a gamma counter.
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Percent lysis was determined by the equation
A-B
Percent lysis —  x100
C-B
A = mean cpm in supernatant from wells containing 
antibody - coated target cells plus effector cells.
B = mean cpm in supernatant from wells containing non­
antibody - coated target cells.
C = mean total cpm of target cells added to each well in 
the presence of detergent, Nonidet P40 (BDH Chemicals 
Ltd, Poole, England).
Effect of sera to mediate ADCC against non-transfected 
COS cells was also determined.
5.2.3 RESULTS
Twenty one sera from HIV-1 antibody positive 
haemophiliacs and 49 sera from HIV-1 antibody negative 
were tested to determine ADCC against COS cells 
transfected episomally with the gp120 gene. Table 5.2.1 
shows the characteristics of patients studied.
Table 5.2.1 Characteristics of patients studied.
Number
studied
HIV Status
+ve
21
ve
49
pvalue
Age
(years)
23.5
(19-35)
29.5
(24.5-37.3)
0.04
Mean annual dose 
of clotting factor 
concentrate used 
(units/annum)
78016.5 21163 0.001
(50,000-88,371) (7,962-40,500)
Severity of liver 
disease
3
(2-3)
3
(2-3)
0.9
CD4+ve T-cell
count
(cells/mm3
525.5
(373-648)
560
(472-789)
0.13
CD8+ve T-cell 
count
(cells/mm3)
595.5
(456-890)
355 0.005
(236-340)
Medians and interquartile ranges are shown.
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None of the HIV-1 antibody positive patients had AIDS.
One patient had recurrent oral candidiasis and one 
patient AIDS related complex.
ADCC
Figure 5.2.1 shows that sera from HIV-1 antibody positive 
patients mediated significantly greater percent ADCC 
lysis of transfected cells than sera from seronegative 
patients (p=0.05). There was no difference between the 
two groups for percent ADCC lysis of non-transfected 
cells (p=0.08) .
For HIV-1 antibody positive patients percent ADCC lysis 
of transfected cells did not correlate with the duration 
of infection (r=.13, p=0 .6 ) but showed a moderate inverse 
but significant correlation with the age of infection 
(r=-.5/ p=0.05). Furthermore in this group there was a
correlation with the CD4+ve T-cell count (r=.51/ p=0.04) 
and no correlation with the CD8+ve T-lymphocyte count 
(r=.14/ p = . 36) . There was no correlation with the IgG 
level (r=.1 ,p=.4 3 ).
In seronegative patients there was no correlation with 
age (r=0.04/ p=0.82); CD4+ve T-cell count (r=-0.00,
P=0.9) serum IgG level (r=-0/1/ p=0.93) and ADCC against 
transfected COS cells. However, a moderate direct 
correlation was seen with CD8 +ve T cell count (r=0.41,
P=0 . 3) .
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5.2.4 DISCUSSION
Longterm follow-up studies of HIV-1 seropositive 
individuals indicate that up to a third remain symptom 
free for at least seven years (1). Defining variables 
that predict latency should provide valuable information 
for the development of anti-viral strategies. Potential 
determinants of the course of HIV-1 infection include: 
levels of the antiviral immune response, inherent 
sensitivity of the host cell to virus replication and 
relative virulence of the virus strain.
Several findings indicate that the antiviral immune 
response may be an important variable. First, in rare 
cases asymptomatic HIV-1 seropositive individuals have 
become seronegative. In some the presence of a latent 
HIV-1 infection in peripheral blood mononuclear cells 
could be detected by the polymerase chain reaction - in 
others no virus could be detected (223). Second, 
cytotoxic T-lymphocytes that react with cells expressing 
HIV- 1 proteins have been noted in infected individuals 
but the clinical importance of this antiviral response is 
not known (420, 421). Lastly, in vitro virus yield in
HIV-1 asymptomatic individuals is greater when the subset 
of CD8 +ve T-lymphocytes is removed from the blood sample 
(224) .
The results of the present study show that sera from HIV- 
1 antibody positive haemophiliacs mediate ADCC against
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the major envelope glycoprotein of HIV-1. Furthermore, 
correlation was seen between the ADCC response and the 
CD4+ve T-lymphocyte count. No correlation was seen 
between the ADCC response and the duration of infection.
Thus, in addition to permitting the measurement of a 
specific immune response against the major envelope 
protein, the results of this ADCC assay showed an inverse 
correlation between progression of immunodeficiency as 
measured by the CD4+ve T-lymphocyte count and the 
presence of serum antibodies which can mediate ADCC.
In HIV-1 seronegative patients ADCC was observed in 2 7 
sera above the lower quartile of HIV-1 antibody positive 
patients (Figure 5.2.1). There could be several reasons: 
it is considered unlikely that this was due to non­
specific reactivity against COS cells. It may be that 
these patients had been exposed to HIV-1 and that the 
innate and specific immune responses cleared the virus 
prior to establishing infection. It was noteworthy that 
in HIV-1 antibody negative patients there was some 
correlation with CD8 +ve T-cell count. It may therefore 
be that these individuals have a specific subset of 
CD8+ve T-cells that has either suppressed HIV-1 antibody 
production or alternatively virus infected cells have 
been cleared by a specific cell dependent immune 
response. Viral isolation studies in such patients or 
detection of the virus by the polymerase chain reaction 
may clarify these findings.
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In conclusion the findings of this study indicate that 
the ADCC response in HIV-1 antibody positive patients may 
be one determinant in controlling HIV-1 disease 
progression. It is however, not clear whether this is a 
consequence of the CD4+ve T-cell depletion or a 
precondition. It was also found that a substantial 
number of HIV-1 seronegative haemophiliacs had serum ADCC 
activity, this may be an indicator of successful 
elimination of HIV-1 infected cells.
CHAPTER 6.1
HAEMOPHILIC MORTALITY: THE IMPACT OP HIV-1 INFECTION.
SUMMARY
Study objective: To determine changes in mortality data
in UK haemophiliacs between 1977 and 1986.
Study design: Retrospective review.
Study population: UK Haemophiliacs (Factor VIIIC and
IX deficient) registered at the Oxford Haemophilia 
Centre.
Measurements: Annual death rate per 1000 haemophiliacs.
Age specific death rate from all causes per 1000
haemophiliacs. Annual death rate from specific causes 
per 1000 haemophiliacs.
Results: The annual death rate increased from 4.5 in
1977 to 10.6 in 1986. This was due to more patients over 
the age of 49 years dying. HIV-1 related deaths showed a 
six fold increase since 1983. Liver disease accounted 
for 12 percent of all deaths and showed a five fold 
increase since 1984.
Conclusions: Infection related deaths including HIV-1
related disease but not hepatitis had exceeded bleeding 
as the prime cause of death by 1986.
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6.1.1 INTRODUCTION
Over the past two decades the therapeutic approach to 
control haemophiliac bleeding has changed considerably. 
The widespread availability of clotting factor 
concentrates and the institution of home treatment 
programmes allowed haemophiliacs to achieve a near normal 
lifestyle and life expectancy was similar to the general 
population (3, 150-154). The early use of clotting
factor concentrates also appears to delay onset of severe 
joint disease (155). The chief disadvantages of therapy 
include risk of acquiring human immunodeficiency virus- 1 
(HIV-1) infection and hepatitis due to the non-A, non-B 
(NANB) viruses and hepatitis B.
Studies of stored sera in the UK show that HIV-1 antibody 
was first detected in 1980 and the peak annual incidence 
of antibody occurred in 1982/3 (364). The incubation
period of HIV - 1 infection and the onset of the
acquired immunodeficiency syndrome (AIDS) is not yet 
established. The estimated average incubation period has 
been disconcertingly close to the time span over which 
the data are available, suggesting that the average could 
lengthen as more information accumulates. A recent 
analysis of 512 cases in which dates of transfusion and 
diagnosis of AIDS were known suggests that the mean and 
median incubation periods are both between 7 and 8 years 
in patients older than 12 years (422). A similar 
estimate is reported for homosexual men in a cohort study 
in which the dates of seroconversion were known (1).
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The average is somewhat less in children (<12 years) and 
the elderly (>60 years) (422, 424). Estimates of the
fraction of those infected with HIV-1 who will go on to 
develop AIDS have also increased with time. Current 
evidence suggests that 30 - 75 percent of infected
individuals will have progressed to AIDS in six years 
(425). Once AIDS is diagnosed the mean life expectancy 
is one year (426, 427).
Based on data available the number of UK HIV-1 related 
deaths in haemophilia should show a progressive increase 
from 1983/4 with a peak in 1988/9 and a gradual decline, 
if no effective therapy is found.
In this study the causes of death in haemophilia have 
been reviewed in the UK during two time periods 1977 -
1981 and 1 982 - 1986. The primary aim was to determine 
the extent to which HIV-1 infection had affected 
mortality in haemophilia. A secondary aim was to 
determine if any deaths could be attributed to effects of 
recurrent alloantigen stimulation.
6.1.2 METHODS
Death certificates listing haemophilia A or B as a 
primary or secondary cause death were obtained for the 
United Kingdom for 1 977 - 1986. The information was
collated by Ms R Spooner who first, confirmed 
individuals for whom death certificates were available 
were haemophiliacs registered at the Oxford haemophilia
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Centre (OHC) and second that the death had been reported 
to the OHC. Additional reports of deaths were obtained 
from the Oxford Haemophilia Centre.
Deaths were classified according to a modified 
International Classification of Disease (ICD) coding for 
the primary cause of death:
1 Haemorrhage or presumed haemorrhagic such 
as cerebrovascular accidents, gastrointestinal
bleeding.
2 Infectious diseases including pneumonia and 
HIV-1 related deaths.
3 Hepatic including hepatitis and cirrhosis.
4 Malignancies.
5 Cardiovascular and pulmonary disease
excluding pneumonias.
6 Misadventure which included accidents and suicide.
7 Miscellaneous included known medical conditions but
not associated with haemophilia.
8 Not known.
For each year annual death rate for all causes per 1000
haemophiliacs was calculated using the formula :
Total number of deaths during a year 
.........................    x 1000
Number of persons with haemophilia in 
the population during that year
In addition annual age specific death rates from all
causes for each time period was calculated :
Number of all deaths in each age group
............................    x 1000
Number of persons in the population in 
that age group
Annual death rate for each cause of death was determined:
Number of deaths in each category
............. .... ..... .................x 1000
Number of persons in the population 
with haemophilia
6.1.3 RESULTS
Table 6.1.1 is a comparison of the number of deaths 
obtained for each year from death certificates and those 
reported to the OHC, because the initial request for 
death certificates provided little additional information 
only deaths reported to the OHC were used for further 
analysis. This gave the additional advantage that total 
number of patients with haemophilia for each year was 
known.
A total of 329 deaths were reported to the OHC during the 
10 years of these 127 occurred between 1977 - 1981 and
202 between 1982 - 1986. Table 6.1.2 shows the number
of deaths in haemophilia A and B patients, there were 
significantly more deaths in factor VIIIC deficient 
patients.
Annual Death Rate
Figure 6 .1.1 shows the annual death rate per 1000
haemophiliacs for each year studied. A sharp increase 
in the annual death rate was noted from 1983 to 1 986,
Table 6.1.1 Comparison of number of deaths obtained 
from death certificates and those reported to Oxford 
Haemophilia Centre.
Year Death Certificate OHC Data
________________________________________ ___________Available
1977 18 19 19
1978 23 28 23
1979 20 20 16
1980 23 35 23
1981 19 25 19
1982 23 27 23
1983 32 34 32
1984 30 31 30
1985 0 46 46
1986 0 64 64
Further data for analysis could only be obtained from
directors annual report. Access to any other data kept 
at OHC was not allowed.
OHC = no. of deaths recorded at Oxford Haemophilia Centre 
by Ms R Spooner on behalf of directors.
Table 6.1.2 Number of deaths in haemophilia A and B 
patients.
1977-81
1982-86
TOTAL
Table 6 . ‘ 
increase
(p=0 .0 0 1 ,
TYPE OF HAEMOPHILIA 
VIIIC IX TOTAL
98 29 127
187 15 202
285 44 329
1.2 shows that there had been a significant
in number of deaths in haemophilia A^patients 
Fishers Exact Test) during 1982-86 compared to
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FIGURE 6.1.1 ANNUAL DEATH RATE /1000
IN HAEMOPHILIACS STUDIED
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Haemophilia A
1976 1978 1980 1982 1984 1986 1988
YEAR
Figure 6.1.1. An increase in the annual death rate
occurred in 19 84 continuing to 1986, this was due to more 
deaths in haemophilia A patients.
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Table 6.1.2. The increased trend was due to more 
haemophilia A patients dying.
Age S p e c i f ic  M o r t a l i t y
The age specific mortality per 1000 haemophiliacs was
calculated for 1980 and 1 985 and are shown in Figure
6 .1.2.Age specific mortality showed a 34 percent 
increase for patients aged between 50-59 years; a 54 
percent increase for patients aged 60-69 years and 104 
percent increase for patients over 70 years of age.
Figure 6.1.3 shows the age distribution in 1 980 and 1985 
for factor VIIIC deficient patients. Table 6.1.3 
compares the number of patients above 50 years registered 
at OHC in 1980 and 1985, there were significantly more 
patients over the age of 50 years registered in 1985.
Causes o f  Death
The cause of death was known for 65 percent of all 
deaths. Of deaths for which cause was not known, 40
occurred between 1 977 - 1981 and 21 between 1 982 - 1986
(p= 0.02), Fishers Exact Test).
The total number of deaths in for each category for the 
ten years is shown in Table 6.1.4 Thirty two percent of 
nil deaths were due to bleeding. Bleeding accounted for 
40 percent of deaths in 1977 - 1981, of these 60 percent 
were due to intra cerebral bleeds. During 1982 - 1 986,
28 percent of all deaths were due to bleeding (p = 0.05,
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IN HAEMOPHILIA
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Figure 6.1.2. Age specific mortality showed a
significant increase in those aged over 50 years. No 
changes were seen in those aged less than 50 years 
comparing 1980 and 1985 figures.
NU
MB
ER
 
OF
 
PA
TI
EN
TS
Figure 6.1.3 AGE DISTRIBUTION 
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Figure 6.1.3. Data obtained from Annual Directors 
reports and reproduced with permission. In both 1980 and 
1985 age distribution was similar except there were 
patients over 50 years in 1985.
Table 6.1.3 Numbers of registered patients over 50
years with factor VIIIC deficiency.
AGE GROUP (years)
Year <.49 >.50
1980 2224 314
1985 3881 1131
These were significantly more patients over the age of 
fifty years registered in 1985 than 1980 (p=0.001/
Fishers Exact Test).
Table 6.1.4 Causes of death.
Category
Haemorrhagic
Infectious
Hepatic
Malignancy
Cardiorespiratory
Misadventure
Miscellaneous
Not known
TOTAL
Number of Deaths
104 ( 3 1 . 6 )
59 ( 1 7 . 9 )
13 ( 3 . 9 )
36 ( 10 . 9 )
29 ( 8 . 8 )
32 ( 9 . 7 )
12 ( 3 . 6 )
44 ( 13 . 4 )
329
The causes of death in each category are shown, the 
numbers in brackets are the percentage number of deaths.
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Fishers Exact Test) of these 78 percent were due to intra 
cerebral bleeding, (p=0.005/ Fishers Exact Test).
Infections including HIV-1 related deaths accounted for 
18 percent of all deaths. Figure 6.1.4 shows the annual 
mortality per 1000 haemophiliacs in this group. From 
1982 there was a progressive increase in infection 
related deaths. Annual mortality rate for HIV-1 related 
deaths is shown in Figure 6.1.4, the first HIV-1 related 
death was reported in 1 983 and by 1 986 there was a six 
fold increase in HIV-1 related deaths. In 1986 deaths due 
to HIV-1 exceeded deaths due to intra cerebral bleeding.
Liver disease accounted for 12 deaths all but one of 
these occurred between 1982 - 1986. The overall relative 
risk of dying from liver disease was 4 times less than 
due to bleeding. Cancer related deaths were the next
most common cause of mortality accounting for 11 percent 
of all deaths. There were 14 deaths due to cancer in the 
first five years (14 percent) and 22 between 1982 - 1986 
(P = 0.53, Fishers Exact Test).
6-2.3 DISCUSSION
The results of this study show dramatic changes both in 
annual mortality rate and in causes of death in patients 
with haemophilia. First, there was a significant increase 
in annual death rate between 1 977 and 1986, in 1977 the 
annual death rate per 1000 haemophilacs was 4.5 per 1000
Figure 6.1.4 ANNUAL DEATH RATE /1000 
DUE TO INFECTION INCLUDING 
HIV-1 INFECTION
1976 1978 1980 1982 1984 1986 1988
YEAR
Figure 6.1.4. Annual mortality per 1000 due to 
infections including HIV-1 but excluding hepatitis are 
shown.
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Figure 6.1.5. Annual death rate for haemorrhagic and 
infections are shown. Infection excludes HIV-1 and 
hepatitis. HIV-1 deaths are shown separately.
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haemophiliacs, in 1986 this had increased to 10.6 
(p=0.02, Fishers exact test). Second, causes of death 
had changed; at the end of this study infection including 
HIV-1 related deaths were the commonest cause of 
mortality and although liver disease accounted for only 4 
percent of all deaths mortality due to liver disease 
showed a six fold increase over ten years.. Third, a 
comparison of the age specific mortality in 1980 and 1985
showed that increased annual death rate was due to more
haemophiliacs over the age 49 years and particularly 
patients over the age of 69 years dying, in 1985.
Bleeding related deaths accounted for 32 percent of all 
deaths of these 70 percent were due to intra cerebral 
bleeds. An apparent increase in the annual mortality
rate due to intracerebral bleeding from 0.4 per 1000 in 
1977 to 2.4 per 1000 haemophiliacs in 1986 was seen.
This was due to an increase in the number of
intracerebral bleeds and may be due to the increased 
numbers of patients over the age of 50 years, Table
6 . 1 . 2 .
Infection related deaths showed a progressive increase 
from 1982 onwards. There were significantly more
infection related deaths during the 1982 - 1986 (23
percent) compared to 1977 - 1981 (5 percent) (p=0.001,
Fishers Exact Test). Sixty four of the deaths were
found to be HIV-1 related. The first HIV-1 related death 
was recorded in 1 983 and by 1 986 there had been a six
1 55
fold increase. In 1 986 34 percent of all deaths were due 
to an HIV-1 related illness compared to 25 percent of 
deaths due to bleeding the relative risk of dying from 
an HIV-1 related illness was 1.4 times greater than that 
from bleeding.
Of HIV-1 related deaths for which age was available (35 
percent) all had occurred in individuals above the age of 
29 years of these 58 percent were above the age of 49 
years. This is in keeping with reports that show the 
rate of CD4+ve T-lymphocyte depletion is greater in older 
infected individuals and is independent of duration of 
HIV-1 infection (Chapter 8.2).
The increase in infection related deaths during the 
second five years cannot be entirely explained. It is 
possible that they were not recognized as HIV-1 related 
or were not reported as such. However, Aronson has also 
noted an increase in pneumonia related deaths in 
haemophiliacs in the USA prior to the AIDS epidemic 
(428). Although it is difficult to be sure, it is 
possible that the impaired ability to mount a cell 
mediated immune response in the absence of HIV-1 
infection was a contributory factor in these deaths. The 
cancer related deaths could not be attributed to such a 
defect using the data available, although cancers 
associated with immunodeficiency have been reported in 
the absence of HIV - 1 infection (329,429).
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Liver disease accounted for only 12 deaths (4 percent), 
of these all but one occurred between 1982- 1986. Since 
1984 there had been a five fold increase in the number of 
deaths related to liver disease. From the data available 
(50 percent of liver disease related deaths) death was 
more common in individuals over the age of 49 years. 
This is in keeping with the data available from the non 
haemophiliac transfusion related cases of NANB hepatitis, 
that older individuals have a poorer outcome (176, 178).
In conclusion the results of this study show that HIV-1 
related disease is now the major cause of mortality in 
haemophilia. Furthermore the major initial impact of 
HIV-1 related disease has been in older individuals than 
children. A increased incidence of infection related 
deaths was noted but the interpretation of this is
difficult. Liver disease was found
of mortality.
157
CHAPTER 6.2
DOES TREATMENT WITH CLOTTING FACTOR CONCENTRATES 
PREDISPOSE TO CLINICAL IMMUNODEFICIENCY IN THE ABSENCE OF 
HIV-1 INFECTION?
SUMMARY
Study objective: To determine if the in vitro
immunosuppression associated with clotting factor 
concentrates in the absence of HIV-1 antibody is 
associated with clinical immunodeficiency.
Study design: Retrospective case note review.
Study population: 80 factor VIIIC and 31 factor IX
deficient haemophiliacs regularly treated with clotting 
factor concentrates.
Results: 5 percent of factor VIIIC deficient
haemophiliacs had disease that could be attributed to 
immunodeficiency. No factor IX deficient patient had 
clinical cell mediated immunodeficiency.
Conclusions: Treatment with factor VIII containing
clotting factor concentrates is associated with a higher 
than expected incidence of clinical immunodeficiency in 
the absence of HIV-1 antibody.
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6.2.1 INTRODUCTION
The treatment of haemophilia is associated with a high 
risk of acquiring blood borne viral infections. The risk 
of acquiring HIV-1 infection depends on the amount, type, 
source and the number of infusions with an infected batch 
of clotting factor concentrate (Chapter 4). Non A, non B 
hepatitis infection is an invariable complication of 
treatment. Up to 25 percent of infected patients may 
develop histological evidence of progressive liver 
disease manifest as cirrhosis or chronic active hepatitis 
(2) . More recently concern has been expressed on the 
effects on cell mediated immunity of recurrent 
extraneous protein load that frequently treated 
patients are exposed to. In the previous chapter 
(Chapter 6.1) it was found that infections including HIV- 
1 related deaths were the second most frequent cause of 
death in haemophiliacs.
In vitro factor VIII concentrates impair lymphocyte 
activation and proliferation and the ability to produce 
interleukin 2 is impaired ,Chapter 3. In vivo clotting 
factor concentrates suppress cell mediated immunity as 
assessed by skin testing (Chapter 7) . This was found to 
be independent of HIV-1 antibody status and severity of 
liver disease. A moderate direct correlation was noted 
with the degree of impairment of response to a new 
antigen, dinitrochlorobenzene and mean annual dose of
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clotting factor concentrate. The clinical significance 
of these findings was not clear.
Significant impairment of cell mediated immunity from any 
cause predisposes the individual to intracellular 
infections and tumours. The tumours most commonly 
associated with impaired cell mediated immunity include 
non-Hodgkins lymphomas and epithelial carcinomas. The 
use of blood products is known to be immunosuppressive in 
non-haemophiliacs (279-304). This is seen particularly 
in the context of transplantation, pre-transfusion of 
blood has a beneficial effect on renal allograft survival 
but a detrimental effect in humans and animals with bone 
marrow transplants (279, 280, 282) .
The aim of the present study was to determine whether 
haemophiliacs studied as part of this thesis had 
developed disease suggestive of significant clinical 
immunodeficiency in the absence of HIV-1 infection.
6-2.2 PATIENTS AND METHODS
The criteria for recruiting patients into this study have 
been previously described (Chapter 2). The case notes of 
aH  patients were reviewed and any episodes of 
unexplained infection during the period 1980 - 1988 were 
recorded. The causes of death were verified by case note 
review.
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HIV-1 antibody status of all patients had been 
previously established by an ELISA method (Wellcozyme) 
and confirmed by Western blotting.
6.2.3 RESULTS
Mortality: Ten patients had died during the study. Of
these four had died prior to 1 982. The causes of death 
are listed in Table 6.2.1. One patient had died of 
AIDS, details of his case history are given in Chapter
6.3.2. In only one patient could death be attributed to
probable immunodeficiency in the absence of HIV-1 
infection. Details of his case history are given below.
Case report
A 50 year old patient deficient in factor VIII 
(<0 .01u/ml) was admitted with haemarthrosis of the right 
knee. He was taking Ibuprofen 1200mg daily and
dihydrocodeine for chronic haemophiliac arthritis. He 
had received 75,000 units of factor VIII concentrate in 
the previous four years. His bleeding episode was 
treated with transfusion of factor VIII concentrate, 
analgesia and physiotherapy. He was negative for 
antibody to HIV-1 by both enzyme linked immunosorbent 
assay (ELISA) and Western blotting. Tests for antibodies 
to human T-cell lymphotropic virus type I also yielded 
negative results. Intradermal infection of both purified 
protein derivative and dinitrochlorobenzene yielded no
Table 6 . 2 . 1  Causes o f  death  in  p a t ie n ts  p r o s p e c t iv e ly  
s tu d ied .
Cause o f  d ea th  Number o f  p a t ie n ts
Haemorrhagic 2 (1)
Infection 2
(including HIV-1 related)
Hepatic 2
Malignancy 2
Cardiorespiratory 1
Misadventure 1
TOTAL 10
The numbers in bracket are inhibitor patients.
Both haemorrhagic deaths were intracerebral bleeds. One 
patients died of AIDS and one of gram negative 
septicaemia after rupture of a colonic diverticulum.
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reaction. The T lymphocyte ratio was 0.36 (T-helper 
cells 0.7x109/l and T suppressor cells 1.925x109/l).
Two weeks after admission he had a haematemesis and his 
blood pressure fell to 80/50mmHg. Three units of blood 
and 3000 units of factor VIII concentrate were 
transfused. Endoscopy showed superficial gastric ulcers; 
Ibuprofen was stopped, and he was treated with factor 
concentrate and Ranitidine.
Though there was no further gastric bleeding, his renal 
function deteriorated, having been normal on admission. 
Serum urea concentration on the day of the haematemesis 
was 32.3mmol/l and creatinine 180umol/l; a week later 
creatinine had risen to 370umol/l. He was initially 
presumed to have acute tubular necrosis, and fluid 
overload was corrected with diuretics. Renal
ultrasonography showed both kidneys to be enlarged. 
Management was complicated by chest infections, and on 
one occasion he suffered septicaemia and cardiopulmonary 
arrest, from which he was resuscitated. Fourteen days 
after his haematemesis serum creatinine concentration was 
900umol/l. Renal biopsy was not performed because of the 
risk of bleeding: an inhibitor to factor VIII was
detected six weeks after the onset of renal failure. 
Prednisolone 40mg was then started, with a transient 
improvement in renal function (creatinine concentration 
450umol/l). His condition deteriorated, and he was
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considered unsuitable for dialysis. He died of
bronchopneumonia and septicaemia due to Escherichia coli.
At necropsy both kidneys were enlarged (250g) with 
uniform pale cut surfaces. The corticomedullary junction 
was poorly defined, and there was no evidence of scarring 
or haemorrhage. Microscopy showed a diffuse, mainly 
cortical infiltrate of large lymphoid cells, which were 
pleomorphic with convoluted nuclei and numerous mitoses. 
Results of immunocytochemical staining with common 
leucocyte antigen were positive. Fresh tissue was not 
available to define the lymphocyte infiltrate in more 
detail. There was no evidence of tumour infiltrate in 
the rest of the organs examined. A postmortem diagnosis 
of extra-nodal non-Hodgkin's lymphoma was made.
Two patients had died secondary to intracerebral 
haemorrhage. One was known to have treated essential 
hypertension prior to death, the other was a heavy 
cigarette smoker and had a high titre of factor VIIIC 
inhibitor.
Two patients died secondary to severe liver disease. 
Both had previous serological evidence of hepatitis B 
infection but had cleared hepatitis B surface antigen and 
had biochemical evidence of NANB hepatitis. One patient 
had prior history of heavy alcohol abuse and this was 
presumed to be the major factor in precipitating liver 
failure. Liver ultrasound in the second patient showed
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evidence of neoplastic deposits suggestive of a primary 
liver tumour. Postmortem permission was refused in
both.
In fe c t io n s
Of the 111 HIV-1 antibody negative patients 2 had been 
treated for pulmonary tuberculosis, one in 1979 and the 
other in 1986. In one other patient a florid positive 
reaction to the purified protein derivative of M. 
tuberculosis was noted in studies of cell mediated 
immunity, but no active infection was identified.
One patient developed a panophthalmic infection of his 
left eye, no organism was isolated and his illness 
settled after intensive parenteral antibiotic therapy. 
He has had no other infective illness.
Another patient presented with a history of night sweats 
and general malaise. Blood cultures grew a Staph Aureus. 
There was no echocardiographic evidence of infective
endocarditis, his initial symptoms responded to
intravenous antibiotics. He subsequently again developed 
symptoms and increasing pain in his left knee joint 
which had been previously replaced. Joint aspiration grew 
Staph, aureus. He was diagnosed to have a infected knee 
arthroplasty which was surgically removed. Culture of 
the removed prosthesis was negative.
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Three months later he was readmitted with a pyrexia, 
splenomegaly and night sweats. Blood cultures grew a 
Serratia organism. He was treated with intravenous 
gentamicin and cefotaxime. Recovery was complicated by 
frequent recrudescences of pyrexia. Gallium scanning 
showed increased tracer accumulation in the right lung. 
He developed a profound neutropenia presumed to be due to 
antibiotic therapy, recovery was complicated by probable 
systemic candidiasis which resolved without treatment.
Although he has had a further two episodes of pyrexia no 
route of infection has been identified yet. There was 
circumstantial evidence to suggest illicit intravenous 
drug abuse which may have been a contributory factor.
The last patient presented with a history of night 
sweats and weight loss of greater than ten percent of his 
previous body weight. Investigations showed activated 
circulating lymphocytes but no serological evidence of a 
viral infection was obtained. His symptoms have
persisted although there has been no further weight loss.
6 -1.4 DISCUSSION
In the present prospective clinical study, it was found 
that five percent of factor VIIIC deficient
haemophiliacs in the absence of HIV-1 antibody had 
clinical disease possibly indicative of impaired cell 
Mediated immunity. The absence of any disease in factor 
iX deficient haemophiliacs may be because the cohort was
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not large enough, alternatively it may be due to the 
lack of effect of factor IX concentrates on lymphocyte 
activation and proliferation (Chapter 3.1).
Aronson has reported in a retrospective study of 
haemophilia related deaths that more patients than 
expected had died of pulmonary infections in the USA
prior to the AIDS epidemic (328, 428). Furthermore, the 
incidence of primary tuberculosis in haemophiliacs 
inadvertently exposed to case of open tuberculosis was 
similar to that noted in children receiving cytotoxic 
therapy for tumors (327). The occurrence of primary
tuberculosis in haemophiliacs correlated with the amount 
of clotting factor concentrate infused in the preceding 
year but was independent of the HIV-1 status of the
patients.
The presentation, site and the nature of the lymphoma 
noted in one of the patients in this study is rare and 
not previously noted in HIV-1 antibody negative 
haemophiliacs. In a review of all haemophilia related
deaths in the UK between 1 977 - 1986 one other non
Hodgkin's and a Hodgkin's lymphoma were listed as the
cause of death in 1984, the relationship to HIV-1 
infection remains undetermined (Chapter 6.1). 
Interestingly, in Italy one patient with non endemic 
Kaposi sarcoma had been reported in the absence of HIV-1 
antibody by both ELISA and Western blotting (429).
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In conclusion this prospective study showed that HIV-1 
antibody negative factor VIIIC deficient haemophiliacs 
had a higher than expected incidence of clinical disease 
possibly indicative of impaired cell mediated immunity. 
Further studies of the nature of this defect and its 
relationship to clotting factor concentrate use are 
indicated.
CHAPTER 6.3
HIV - 1 RELATED DISEASE IN HAEMOPHILIACS AT THE WEST OF
SCOTLAND HAEMOPHILIA CENTRE.
SUMMARY
Study Objective:To describe the spectrum of HIV - 1
re lated disease in haemophiliac studied.To evaluate and 
compare the Center for Disease Control (CDC) and Walter 
Reed (WR) HIV - 1 disease stagings.
Study design s Retrospective review
Study population : HIV - 1 antibody positive
naemopniliacs.
Results : Manifestations of HIV - 1 related disease
included:thrombocytopenia - 3 patients; lymphadenopathy - 
3 patients; bacterial infections - 2 patients; AIDS
related complex - 3 patients; opportunistic infection - 3 
patients.There was a moderate correlation in CDC and WR 
disease classifications in December 1986 and January 
1988.WR classification showed a correlation with age.WR 
classification was able to detect change.
Conclusions : HIV - 1 related disease is associated with 
a spectrum of disease including bacterial infections and 
thrombocytopenia, these may be due to B cell 
abnormalities.The WR classification was found to be 
sensitive in detecting change.
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6.3.1 INTRODUCTION
Infection with the human immunodeficiency virus-1 (HIV - 
1) is classically associated with an impaired ability of 
the host to mount a cell mediated immune response. 
Clinically this is manifest by the occurrence of
opportunistic infections and tumours (430, 431). The
infections most frequently associated with end stage HIV- 
1 induced immunosuppression are listed in Table 6.3.1. 
The majority of infections result from endogenous 
reactivation of a previously acquired infection, for
example Mycobacterium tuberculosis and herpes zoster
(432). Infections are rarely single and concurrent or 
consecutive infections with different organisms are
common (432). Fungal and parasitic infections depend on 
the prevalence of asymptomatic infection with these 
pathogens in the local population (432). More recently 
certain bacterial infections have been recognized as HIV- 
1 associated diseases (432); the association may be 
partly due to defects in B cell function described in 
persons with HIV-1 infection (Chapter 11).
Until recently the Centre for Disease Control (CDC) in 
addition to Kaposi's sarcoma included primary central 
nervous system non-Hodgkin and high grade lymphoma 
occurring at all sites but excluded intermediate-grade 
non-Hodgkin lymphoma at non-central nervous system sites 
and all cases of Hodgkin disease from diagnostic criteria 
(430, 431). Nonetheless, an increasing number of reports 
of diffuse aggressive B cell non-Hodgkin lymphoma of
Table 6.3.1. Infections associated with HIV-1 infection.
Clinical Manifestations 
Organisms Common Infrequent
Protozoa
Pneumoncysitis carinii
Toxoplasma
Cryptosporidium
Isopora belli
Fungi
Candida sp.
Cryptococcus neoformans
Histoplasma capsulatum 
Coccidioides immitis
Pneumonia
Encephalitis 
Retino-choroiditis 
Enteritis
Enteritis
Stomatitis
Esophagitis
Meningitis
Dissemination
Dissemination
Dissemination
Bacteria
Mycobacterium tuberculosis Pneumonia
Dissemination
Mycobacterium avium-intracellulare Dissemination
Mycobacterium kansasii
Streptococcus pneumoniae (esp. pediatric)
Salmonella sp. 
Treponema pallidum 
Viruses
Cytomegalovirus
Herpes Simplex 
Herpes Zoster 
Epstein-Barr
Jacob - 
Creutzfeld
Dissemination
Upper respiratory
Pneumonia
Sepsis
Diarrhoea
Sepsis
Retino-choroiditis
Pneumonia
Colitis
Mucotaneous (mouth, 
digit, rectum) 
Dermatomal skin
Hairy leukoplakia 
Neoplasia (?) 
Progressive multifocal 
leuko- encephalopathy
Otitis
Dissemination
Pneumonia
Dissemination
Cholangitis
Bronchopleural
Proctitis
Vaginitis
Dissemination
Pneumonitis
Meningitis
Pneumonia
Diarrhoea
Pneumonia
Neurosyphilis
Adrenal
Encephalitis
Myelitis
Pneumonia
Encephalitis
Encephalitis
Disseminated
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intermediate as well as high grade histopathological 
types and of atypical, aggressive Hodgkin's disease
occurring in AIDS risk group populations have appeared in 
the literature (433-445). The activation with respect to 
Hodgkin's disease is not clear particularly as Hodgkin's 
disease normally also occurs in the same age group as 
persons at risk of HIV-1 infection.
More recently pro-viral HIV-1 DNA has been identified in 
brain tissue, endothelial and epithelial cells suggesting 
that HIV-1 has the potential to cause disease in many
organ systems independent of the effects of immune system 
(208-211). Host responses to HIV-1 infection may also 
contribute to pathological and immunological consequences 
of infection. However, progressive immunodeficiency 
remains the most serious outcome of HIV-1 infection.
The aim of this study was first, to describe the pattern
of HIV-1 related illness seen in this population and
second to evaluate the clinical utility of two recently 
proposed HIV-1 related disease classifications to detect 
change.
6 .3. 2 PATIENTS AND METHODS
The case notes of all HIV-1 antibody positive patients 
were reviewed and details of any clinical illness 
recorded. All patients had been regularly reviewed since 
1981 and from 1 983 all patients were specifically asked
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about symptoms that indicated HIV-1 related disease at 
each clinic visit. The weight of patients was also 
recorded.
In December 1986 and January 1988 all patients were 
staged according to the Walter Reed Classification and 
the criteria proposed by the Centre for Disease Control 
classification for HIV-1 infection (446, 447).
HIV-1 antibody status
HIV-1 antibody status had been previously established by 
ELISA (Wellcozyme) and confirmed by Western Blotting 
(Chapter 4). All retrospective sera available were 
tested to determine duration of infection (Chapter 4.2).
HIV-1 serum antigen
Serum antigen was measured as described in Chapter 5.
T-cell subsets
T-helper/inducer (CD4 +ve) lymphocytes were enumerated as 
described in Chapter 8.1.2.
6-3. 3 RESULTS
HIV-1 related disease:
Acute i n f e c t io n
No patient had symptoms attributable to acute HIV-1 
infection. However in one patient generalised
lymphadenopathy coincided with the date when he was first
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noted to be HIV-1 antibody positive. Enlarged, painless, 
mobile lymph nodes were noted bilaterally in the 
submental, supraclavicular and axillary areas. There was 
no associated skin rash or splenomegaly.
On subsequent examination four weeks later 
lymphadenopathy had regressed. Investigations showed: 
positive IgG anti - HIV-1 antibody by ELISA; his serum 
reacted to the following HIV-1 proteins on Western 
blotting: gp160, 120 and 41 and p64, 55, 31, 24 and 15.
Thrombocytopenia
3 patients had developed significant thrombocytopenia; in 
one this preceded onset of subsequent bacterial 
infections. No bleeding related to thrombocytopenia 
occurred. In two patients trephine bone marrow aspirates 
showed plentiful megakaryocytes with budding suggesting 
peripheral destruction. Only one patient was noted to 
have persistent splenomegaly. Anti-platelet antibodies 
were not measured.
The platelet counts in these patients are shown in Figure
6.3.1 (a-c) .
Lymphadenopathy
No patient could be classified to have persistent 
generalised lymphadenopathy as defined by the CDC. 
However 3 patients had intermittent cervical and axillary
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lymphadenopathy. During the episodes of lymphadenopathy 
there were no associated systemic symptoms.
Bacterial infections
Two patients had recurrent bacterial infections: their
case histories are given below:
Case 1
Factor VIIIC level: <0.01 iu/ml.Inhibitor = absent 
First positive serum HIV-1 antibody - 5/81 
Last negative serum HIV-1 antibody - 3/82
In January 1 987 he was noted to have clinical 
splenomegaly, no hepatomegaly and weight loss of eight 
kilograms. Platelet count was noted to be low 18,000/mm^ 
(described in thrombocytopenia section) and serum HIV-1 
antigen positive. He was diagnosed to have 
thrombocytopenia secondary to HIV-1 infection. There was 
no associated bleeding attributable to the 
thrombocytopenia.
In March 1987 he was admitted with a pyrexia of unknown 
origin and treated with intravenous cefotaxime and 
subsequently oral erythromycin. While in hospital he 
was inadvertently frequently exposed to a patient who was 
a salmonella carrier. He subsequently developed enlarged 
right posterior cervical lymphadenopathy - open biopsy 
and histology showed reactive changes. Subsequent 
cultures of the unhealed surgical incision grew
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salmonella and he developed a salmonella septicaemia. 
Despite intensive supportive and specific therapy his 
clinical condition deteriorated manifest as HIV-1 related 
encephalopathy, a painful peripheral neuritis and 
cachexia.
He died of an acute respiratory arrest.
Case 2
Factor IX < 2iu/dl. No inhibitor.
Date of first positive serum HIV-1 antibody = 4/82.
No negative specimens available.
In January 1986 he presented with a 3 day history of a 
febrile illness. On examination signs consistent with a 
left basal consolidation were present. He had small 
shotty nodes in both axillae but only one in the left 
axilla was >1cm. X-rays confirmed a left basal pneumonia. 
Emergency sputum gram stain showed gram positive cocci, 
he was presumed to have pneumococcal pneumonia and 
treated with benzyl penicillin. Recovery was complicated 
with an infected herpes simplex lesion on the left lower 
lip.
Further enquiry revealed that he had a prei^tous right 
sided pneumonia complicated by an effusion in January 
1985 while visiting relatives in Manchester. Aspiration 
°f the effusion was negative for mycobacterium
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tuberculosis and cytology did not reveal any neoplastic 
cells.
In March 1986 he presented with a 2 week history of an 
abscess in his left flank. Wound swabs showed a 
coagulase positive Staph Aureus sensitive to Erythromycin 
and Flucloxacillin. The abscess was drained under 
general anaesthetic. Recovery was uneventful.
In January 1 988 he was again admitted with a pyrexial 
illness. Chest x-ray showed patchy right basal
consolidation and sputum culture grew Haemophilus 
Influenzae sensitive to Ampicillin. After 5 days he 
developed a generalised erythematous rash presumed to be 
due to Ampicillin. Further recovery was uneventful.
Three patients were classified to have AIDS related 
complex (ARC).
Patient 1
Factor VIIIC level < 0 .0 1 iu/ml.Inhibitor = absent 
First positive serum HIV-1 antibody - 5/82 
Last negative serum HIV-1 antibody - 1/84
In July 1987 the patient complained of persistent throat 
discomfort on wakening. On examination there was no 
palpable lymphadenopathy but he was noted to have 
bilateral enlargement of his tonsils. There was no 
evidence of oropharyngeal candidiasis.
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A bilateral tonsillectomy was performed, his post- 
operatisfe- course was uneventful. Histology showed: 
expanded T-cell zones but preserved tonsillar 
architecture and prominent lymphoid follicles. These 
findings were consistent with reactive tonsillar 
enlargement.
Culture of tonsils grew only oral commensals. Peripheral 
blood T-cell phenotyping showed a reduced CD4+ve cell
count, CD4+ve T-cells = 304 cells/mm3 . In January 1988 
he was noted to have lost greater than ten percent of his 
weight and he complained of night sweats, fatigue and
malaise. Serum was positive for HIV-1 antigen and the 
number of CD4+ve T-cells had declined to 227 cells/mm3 *
Patient 2
Factor VIIIC <0 .0 1 iu/ml.Inhibitor = 13 Bethesda
units/mls.
First positive serum HIV-1 antibody - 10/85 
Last negative serum HIV-1 antibody - 12/85
In December 1988 he complained of lethargy and one upper 
respiratory tract infection. Clinical examination for 
stigmata of HIV-1 related disease was negative.
Investigations showed:
HIV- 1 antigen serum = positive
Total WBC = 2030 cells/mm3
o
CD4+ve T-cell count = 122 cells/ml
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CD8 +ve T-cell count = 238 cells/mm'*
He was reluctant to commence azidothymidine.
Four months later he was noted to have: facial and scalp 
seborrhoeic dermatitis. Oral hairy leukoplakia on both 
tongue margins. Candida intertrigo of groin, scrotum and
anus.
T-cell phenotyping showed:
CD4+ve T-cell count = 52 cells/mirr 
CD8 +ve T-cell count = 150 cells/mm^
He was commenced on nebuil zed pentamidine 300mg twice a 
week and 2 0 0mg azidothymidine four hourly.
After four weeks of therapy he developed a normochromic 
anaemia (haemoglobin 8 .1g/dl) due to bleeding and was 
transfused 3 units of whole blood.
By August 1988 the seborrhoeic dermatitis had improved 
and Candida intertrigo resolved. Oral hairy leukoplakia 
had also significantly improved.
Patient 3
Factor V i n e  level <0.01 iu/mls. Inhibitor = absent 
First positive serum for HIV - 1 antibody : 8/84 
No negative serum samples were available.
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Relevant previous medical history included significant 
congenital mental retardation.
In January 1988 he complained of sweats, a cough 
productive of purulent sputum of 3 days duration. He was 
noted to have: bilateral enlarged tonsils, shotty
cervical and right axillary lymphadenopathy and signs of 
right basal pulmonary consolidation. Chest x-ray
confirmed the clinical findings. No bacterial or 
opportunistic organisms were grown from sputum cultures.
He was treated empirically with oral erythromycin and had 
an uneventful recovery. On further questioning he
admitted to lethargy, occasional night sweats and weight 
loss.
Further investigation showed:
Serum HIV-1 antigen = negative 
Total WBC = 3792 cells/mm^
CD4+ve T-cell count = 263 cells/mm^ 
CD8 +ve T-cell count = 136 cells/mm^
He was classified as having possible early AIDS related 
complex. in view of resolution of his symptoms
azidothymidine therapy has not yet been commenced.
HIV-1 related disease attributable to immunosuppression.
Opportunistic in fections
One patient had recurrent oral candidiasis. His case
history is given below:
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The patient is a Caucasian born in the West of Scotland. 
Circulating factor level is <1iu/dl. He was first noted 
to have HIV-1 antibody in October 1985, and his last 
antibody negative sample was in October 1984. His serum 
was negative for HIV-1 p24 antigen on both occasions. On 
questioning he denied any symptoms that may have been 
attributable to acute HIV-1 infection.
In May 1987 he complained of white patches on the
undersurface of his tongue. Swabs grew Candida albicans. 
There were no symptoms to suggest oropharyngeal 
candidiasis. On examination he had intermittent cervical 
lymphadenopathy and tinea pedis of recent onset which was 
resistant to local treatment. T-cell phenotyping in 1988 
showed a markedly reduced CD4+ve T-lymphocyte count 200 
cells/mm3 and 382 cells/mm3 CD8+ve T -lymphocytes.
His most recent serum sample remains reactive to all
viral protein on Western blotting and HIV-1 p24 antigen
is absent from serum.
Disease c la s s ific a tio n
Tables 6 .3.2 and 6 .3.3 show the patients classified 
according to the CDC and Walter Reed Classification. 
There was a moderate correlation between the two methods 
at both time points, (r=0.42, p=0.05 for December 1986;
r=0.51, p=0.01 for January 1988). For the CDC
classification there was no correlation with age (r=0 .0 2 ,
Table 6.3. ? Walter Reed Classification of patients.
YEAR
Patient No. 1986 1988
1 1 1
2 1 1
3 1 3B
4 3 3
5 3 1
6 1 3
7 1 3
8 3 3B
9 3 1
10 1 1
11 1 1
12 1 3
13 1 6
14 1 1
15 1 3
16 1 3
17 1 5
18 1 1
19 6 6
20 1 1
21 1 1
22 3 3
A significant difference was noted using this classification 
- it therefore appears to be sensitive.
Table 6.3.2. Centre for Disease Control Classification of 
patients studied.
YEAR
Patient No. 1986 1988
1 2 2
2 2 2
3 2 IV .
4 2 2
5 2 2
6 2 2
7 2 2
8 2 IV
9 2 2
10 2 2
11 2 2
12 2 2
13 2 IV '
14 2 2
15 2 2
16 2 2
17 2 IV '
18 1 2
19 IV C2 IV i
20 2 2
21 2 2
22 2 2
No significant change in progression of disease was noted 
using this classification.
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p=0.91, Dec 1 986; r=0.31/ p=0.14/ Jan 1988), duration of 
infection (r=0.25, p=0.25 Dec 1986; r=0.28, p=0.19) or
age of infection (r=-0.02, p=0.91, Dec 1986; r=0.31,
p=0.14 Jan 1988). The Walter Reed classification in 
January 1988 showed a moderate correlation with age 
(r=0.49, p=0.02) but no correlation with age was seen for 
the December 1986 staging (r=0.30, p=0.18). There was no 
correlation with the duration of infection at either time 
point (r=0.07/ p=0.7 Dec 1986; r=-0.09, p=0.6 Jan 1988). 
Age of infection however showed a moderate correlation 
with disease staging in Dec 1988 (r=0.45, p=0.04) but not 
with the initial staging (r=0.24, p=0.26).
There was no significant change in the CDC classification 
at the two time points (p=0.5) however the Walter Reed 
classification was able to detect change (p=0.03), Table
6.3.3.
6.3.4 DISCUSSION
The low prevalence of HIV-1 antibody and relatively short 
duration of infection in this cohort have not allowed any 
detailed information to be culled from the clinical 
spectrum of disease observed. However, some interesting 
observations were made. First, more disease directly 
attributable to HIV-1 rather than immunodeficiency was 
observed, this occurred in 27 percent of patients. Three 
patients developed thrombocytopenia and three ARC. The 
occurrence of thrombocytopenia appeared to be a random
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event and was only associated with serum p24 antigen in 
one of three patients. In these patients
thrombocytopenia was not related to CD4+ve T-cell 
depletion and in two it could be attributed to peripheral 
platelet consumption. The most interesting observation 
was that platelet count recovered without further 
treatment. In previous studies aggressive treatment that 
may potentially lead to progression of HIV-1 related 
disease had been recommended in haemophiliacs (448-455). 
The mechanism of thrombocytopenia are unknown but it is 
frequently associated with anti-platelet antibodies 
(456) . It may therefore be that the thrombocytopenia is 
due to the B cell abnormalities that occur in patients 
with HIV-1 infection (Chapter 11).
Second, of the three patients with ARC in only one was 
serum p24 antigen absent. It may therefore be that in 
the two patients with serum antigen that symptoms and 
laboratory findings are a manifestation of declining cell 
mediated immunodeficiency and it is a matter of time 
before they develop an opportunistic infection.
Third, three patients (14 percent) developed infections 
that could be attributed to HIV-1. The two patients with 
bacterial infections had recurrent episodes. In one 
patient occurrence of a bacterial infection led to a 
progressive, rapid depletion of his CD4+ve T-cell count. 
In both patients occurrence of bacterial infections was 
not due to a significant depletion of the number of
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CD4+ve T-cells. As with thrombocytopenia it may be that 
the susceptibility of certain patients to bacterial 
infections is due to a B cell defect independent of the 
decline in cell mediated immunity.
The evaluation of the two disease classifications showed 
that the Walter Reed staging was more sensitive in 
detecting change. This may be because this system is 
based on CD4+ve T-cell depletion. Cutaneous tests of 
cell mediated immunity were not included in this study 
because haemophiliacs may be anergic in the absence of 
HIV-1 infection (Chapter 7). Although the CDC disease 
classification allows for a stratification of patients 
according to the CD4+ve T-cell count no substaging has 
yet been proposed.
The major deficiency in both classifications was that no 
numerical weighing of certain disease manifestations was 
provided so that progression could be statistically 
compared. Both classifications were, however, simple to 
use.
In conclusion, 36 percent of patients in this cohort had 
developed significant HIV-1 related disease. The 
correlation between age and the Walter Reed staging 
suggested that HIV-1 disease progression is a function of 
age and not duration of HIV-1 infection.
182
CHAPTER 7.1
IMPAIRED CELL MEDIATED IMMUNITY IN HIV-1 ANTIBODY 
NEGATIVE HAEMOPHILIACS.
SUMMARY
Study objective: To assess in vivo cell mediated
immunity in haemophiliacs with and without HIV-1
antibody.
Study design: Open, cross-sectional study.
Study population: Severe treated haemophiliacs in whom
HIV-1 antibody status was known.
Measurements: The cutaneous inflammatory response to a
new antigen - dinitrochlorobenzene (DNCB); mean annual 
dose of clotting factor concentrate used and severity of 
liver disease.
Main results: The DNCB response was depressed in
haemophiliacs. This was independent of HIV-1 antibody 
status. Response correlated with mean annual dose of 
clotting factor concentrate used in seronegative 
patients. Severity of liver disease showed no correlation 
with DNCB score in seronegative patients.
Conclusions: Treated haemophiliacs in the absence of
HIV-1 antibody have impaired cell mediated immunity in
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7.1.1 INTRODUCTION
A severe haemophiliac requires regular treatment with 
clotting factor concentrates to control or prevent 
bleeding episodes. The clotting factor concentrates are 
fractionated from pooled plasma donations (Chapter 1). A 
single haemophiliac may be exposed to alloantigens from 
as many as 1 0 , 0 0 0 different donors per batch of clotting 
factor concentrate used. Exposure to such a large
allogenic antigen load can both stimulate as well as 
directly, impair immune responses (Chapter 3.1). The 
use of blood products also carries an increased risk of 
hepatitis B, the non-A non-B (NANB) hepatitis viruses, 
and HIV-1 infection.
In chapter 3.1 it was shown that intermediate purity 
factor VIII concentrate impaired the ability of 
peripheral blood mononuclear cells to proliferate in 
response to soluble antigen and phytohaemagglutinin. The 
capacity of phytohaemagglutinin stimulated peripheral 
blood mononuclear cells to produce interleukin-2 was also 
reduced in a dose dependent manner. Haemophiliac patients 
also had high circulating levels of Fc Y receptor 
antibody, an immunosuppressive protein (Chapter 3.2). 
The significance of these findings is unclear.
The aim of this study was to determine if haemophiliacs 
treated with clotting factor concentrates are 
immunosuppressed in vivo. The dinitrochlorobenzene skin 
test is considered to be the best single test of cell
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mediated immunity in vivo and measures the ability of an 
individual to respond to a new antigen (457, 458). The
dinitrochlorobenzene score was compared to the mean 
annual dose of clotting factor concentrate used and the 
HIV-1 antibody status.
7.1.2 METHODS 
Patients
Thirty five patients with moderate or severe haemophilia 
(factor VIII or IX level <5iu/dl) were studied. Included 
were 14 of the 22 patients known to be seropositive for 
antibody to HIV-1. Patients were examined for features 
of disease related to HIV-1. Case records were examined 
for clotting factor concentrate use over the previous 
seven years, and mean annual exposure to clotting factor 
calculated.
The presence of significant liver disease was scored as 
described in Chapter 2. Previous exposure to hepatitis B 
virus as assessed by antigen and antibody testing at 
routine clinic visits was noted (Chapter 2.2).
Dinitrochlorobenzene testing
A modified dinitrochlorobenzene test was performed in 
each case (281). Patients were sensitized to
dinitrochlorobenzene (2 0 0 0ug dissolved in 0 .1ml acetone) 
0n the dominant forearm. After 14 days the patient was 
rechallenged with five doses of dinitrochlorobenzene (30, 
15/ 7.5, 3.7 and 1ug) , the dinitrochlorobenzene being
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dried onto 1cm diameter felt pads (A1 test patches, Astra 
Chemicals, Watford, UK) and applied on the opposite 
forearm. The reaction was assessed after 48 hours as 
follows: 0 , no reaction or erythema only; 1, erythema
and induration confined to the patch; 2 , erythema and 
induration extending beyond the patch; 3, as for 2, plus 
blistering. The maximum possible score was 15.
Serological testing
Blood was withdrawn for IgG HIV-1 antibody (ELISA, 
Wellcozyme) and screened for other viruses including 
measles, cytomegalovirus, the Herpes group including 
Epstein-Barr virus; IgM antibody was sought. HIV-1 
antibody status was confirmed by Western blotting.
Controls
The normal range for the DNCB response had been 
previously established for male volunteers from the West 
of Scotland using the same methods and scoring system 
(281). Historical controls were used because previous 
experience indicated that an intact immune system 
produced severe adverse reactions even in the absence of 
previous inadvertent sensitization. The control group 
were comparable to haemophiliacs for age.
7•1•3 RESULTS
Two patients had appreciable cervical lymphadenopathy but 
no other features of disease related to HIV-1. One 
Patient had persistent mild thrombocytopenia, the lowest
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Figure 7.1.1. The response in HIV-1 +ve patients was 
lower than controls (p<0.05) but did not differ from HIV- 
1 -ve patients (p=0.07). There was a significant 
difference between HIV-1 -ve and controls (p<0.05).
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recorded count being 96x109/l. No other patients had 
clinical features of HIV-1 related disease.
S e ro lo g ic a l r e s u lts
Fourteen patients were seropositive for antibody to HIV- 
1 . No patient had circulating IgM antibody to other 
viruses. Previous exposure to hepatitis B virus and 
presence of transaminasaemia at clinic visits was similar 
in the patients HIV-1 positive and negative (data not 
shown).
Dinitrochlorobenzene testing
The median score in normal subjects was 9 (IQR 7-11). 
All the patients in the present study had a score below 9 
(Figure 7.1.1). The median score in patients was 3 (IQR 
0-5) : this was significantly different from normal
(p<0.001). In patients positive for HIV-1 the median 
score was 0 (IQR 0-3) : this was significantly
different from normal (p<0.001). Among the three 
patients with features of disease related to HIV-1 the 
score was 0 in the patient with thrombocytopenia and 0 
and 4 in the two patients with lymphadenopathy. In 
seronegative patients median score was 3 (IQR 0-5): 
this was significantly different from normal (p<0 .0 0 1 ) 
but not significantly different from the score in the 
seropositive patients.
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Consumption of clotting factor
The median annual consumption of clotting factor over six 
years in all patients was 48,564 units/annum (IQR 21,878- 
83,000). The median consumption in seropositive patients 
was 73,360 units/annum (IQR 48,564-100,000) and in 
seronegative patients 38,000 units/annum (IQR 21,349-
65.224). This difference was not significant (p=0.07). 
An inverse correlation was noted between increasing usage 
of clotting factor and decreasing score on 
dinitrochlorobenzene testing for all patients (Figure 
7.1.2) (r=-0.3, p<0.05). In seronegative patients with a 
score less than normal (<4) median consumption of 
clotting factor was 40,000 units/annum (IQR 24,120-
65.224): this was significantly more than in
seronegative patients with a response in the normal IQR 
(median 23,183 units/annum, IQR 21,107-59,052;
p<0.02). An inverse correlation was noted in all 
seronegative patients between consumption of clotting 
factor and score on dinitrochlorobenzene testing (r=-0.4, 
p<0.05), but the correlation in seropositive patients was 
not significant (r=0.08); there was no significant 
difference, however, between correlations in seropositive 
and seronegative groups.
Liver disease
In all patients grade of liver disease showed a poor 
correlation with dinitrochlorobenzene score (r=-0 .1 2 , 
P=0.42). in seropositive patients there was a significant 
inverse correlation (r=-0.59, p=0.05) but correlation was 
Poor in seronegative patients (r=-0.009, p=0.9).
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Figure 7.1.2. Correlation between mean annual dose of 
clotting factor concentrate and DNCB score in all 
patients was r=0.4 (p=0.05).
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7.1.4 DISCUSSION
The response to dinitrochlorobenzene evaluates both the 
afferent and efferent arras of the immune response: it is
therefore a measure of a patient's current cell mediated 
immune state (457, 458). The results showed that all
patients with moderate to severe haemophilia treated with 
factor concentrate had a response below the median normal 
value, and in 20 of 35 patients studied response was on 
or below the lower limit of the normal range (that is, 
<4) . In addition, response was impaired in patients 
seronegative for antibody to HIV-1.
In patients negative for HIV-1 antibody response to 
dinitrochlorobenzene was inversely related to consumption 
of clotting factor (Fig 7.1.2). In particular, patients 
who had a subnormal response had used significantly more 
factor concentrate than patients with a response in the 
normal range. This association of consumption of 
clotting factor with reduced cell mediated immunity may 
be due to transmission of viral infections, to a direct 
chemical effect of concentrate, or to an indirect effect 
mediated via the immune system.
Concomitant serological studies excluded the possibility 
of a coincidental viral infection. Infection with HIV-1 
in the absence of antibody was considered to be unlikely, 
and no patient in the seronegative group had features of 
disease related to HIV-1. In our patient population HIV- 
1 seroconversion occurred during 1980-5, and in a 
Previous study it was found that seroconversion was 
associated with use of imported American concentrate
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(Chapter 4.2). No further seroconversions have been 
recorded in the patients studied. In addition, isolates 
of virus from seronegative patients are exceptional (3 5 4 , 
355) . It therefore appears that the depression in cell 
mediated immunity is probably due to either a direct 
effect or an immunological consequence of infusion of 
factor concentrate.
A previous study of patients reported high circulating 
levels of FcY receptor antibody (Chapter 3.2). This 
antilymphocyte antibody develops after repeated blood 
transfusions, and its presence correlated directly with 
survival of renal allografts. The FcY receptor is an 
important immunoregulatory protein, and blocking of this 
receptor with antibody or immune complexes stimulates a 
non-specific T suppressor cell response which could 
additionally inhibit macrophage activation or T-helper 
function (459). Excessive activity of T suppressor cells 
may therefore account for the abnormalities seen in 
seronegative patients on dinitrochlorobenzene testing.
In the 14 seropositive patients the score on 
dinitrochlorobenzene testing was significantly below 
normal (p<0 .0 0 1 ), and 11 patients had a score below the 
normal range (Figure 7.1.1). The score did not differ 
significantly from that in seronegative patients. No 
significant correlation in seropositive patients between 
the score and consumption of clotting factor could be 
shown. Both these negative findings, however, may have 
been due to the small numbers in this group. inverse
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correlation with the grade of liver disease was seen in 
this group.
In summary therefore, the results of the present study 
suggest that cell mediated immunity is decreased in 
patients with severe haemophilia treated with clotting 
factor concentrates and that this is related to the 
amount of clotting factor concentrate used. Whether this 
abnormality is partly related to risk of infection with 
HIV-1 or to its sequelae, or both, is not yet known. 
Although no significant difference in the score on 
dinitrochlorobenzene testing was observed between 
seronegative and seropositive patients, infection with 
HIV-1 in the seropositive patients was fairly recent. 
Further studies of the response to dinitrochlorobenzene 
in patients who have had infection with HIV-1 for a 
longer period may well show lower responses, as 
immunosuppression induced by HIV-1 may take many years to 
become firmly established.
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CHAPTER 7.2
IMPAIRED CELL MEDIATED IMMUNITY IN HIV-1 ANTIBODY 
NEGATIVE HAEMOPHILIACS - IS IT DUE TO LIVER DISEASE?
SUMMARY
Study objective: To exclude the possibly that the
impaired in  vivo cell mediated immunity in haemophiliacs 
is due to liver disease.
Study design: Open, cross-sectional study.
Study population: Haemophiliacs without HIV-1 antibody
and different grades of liver disease but matched for the 
mean annual dose of clotting factor used were studied.
Measurements: The cutaneous inflammatory response to 7
recall antigens was measured in addition to the mean 
annual dose of clotting factor concentrate used and 
severity of liver disease.
Results: HIV-1 antibody negative haemophiliacs had an
impaired cutaneous response to recall antigens. The 
response showed a poor correlation with grade of liver 
disease.
Conclusions: Severity of liver disease in the absence of 
clinical cirrhosis does not influence in  vivo cell 
mediated immune responses in haemophiliacs.
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7.2.1 INTRODUCTION
Haemophiliacs have an impaired ability to mount an immune 
response to a new antigen as assessed by the
dinitrochlorobenzene (DNCB) skin test (Chapter 7.1). It 
was previously shown that this is independent of the HIV- 
1 antibody status of the patient and that there is a
moderate inverse correlation to the mean annual dose of 
clotting factor concentrate used, (Chapter 7.1). This 
may be due to the contaminating alloantigen load
eliciting an immune response, a direct chemical effect of 
concentrate or a consequence of the viral infections
transmitted via blood.
Viral infections can suppress immune reactions by a 
direct effect on the immune system as in HIV-1 infection, 
or by non-specifically suppressing immune reactions (). 
Alternatively immunosuppression may arise due to the 
diseases caused by the virus, for example chronic liver 
disease due to hepatitis B virus or non-A, non-B (NANB) 
infection. Immune abnormalities have been described in 
patients with liver cirrhosis of diverse aetiologies 
(376) .
In this study, the in vivo immune response was measured 
using standard recall antigens and the response compared 
to mean annual dose of clotting factor concentrate used 
and severity of liver disease in patients with and 
without HIV-1 antibody.
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7.2.2 METHODS
Patients
Skin responses to seven recall antigens were tested from 
selected groups of haemophiliacs: patients known to have
HIV-1 antibody but in the absence of HIV-1 related 
disease, HIV-1 antibody negative haemophiliacs with a 
persistently raised serum alanine aminotransferase above 
one and a half times the upper limit of the laboratory 
range, and those patients with persistently normal serum 
ALT over the preceding five years. The mean annual dose 
of clotting factor concentrate used over the previous 
five years was known for all patients and therefore 
patients with and without abnormal serum ALT levels were 
matched for the mean annual dose of clotting factor 
concentrate used.
Further details of the methods used to assess the 
severity of liver disease are given in Chapter 2.
Skin testing
The response to the following antigens was tested: 
tetanus, diphtheria, streptococcus, tuberculin, Candida, 
trichophyton, proteus and a glycerine control, on the 
volar aspect of the non-dominant forearm, using a 
standardized commercially available test, Multitest-CMI 
(Institut Merieux, Lyons, France) (461).
The responses were read after 48 hours by measuring the 
diameter of indurated area in millimeter for each 
antigen. The results were expressed as a compound score, 
which was calculated by dividing the mean sum of the 
average diameter of the response to each antigen by the
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number of antigens to which a reaction occurred. The 
mean total score in mm of all reactions and the total 
number of antigens to which patients responded to was 
also analyzed.
7.2.3 RESULTS 
Clinical
32 patients were studied, included were 7 of the 22 known 
patients with HIV-1 infection. No HIV-1 antibody 
positive patient had clinical manifestations of cellular 
immunodeficiency.
Liver disease
Two patients had severe liver disease with evidence of 
portal hypertension; both had previous episodes of 
bleeding from oesophageal varices and one had episodes 
of jaundice. He continued to have ankle oedema due to 
low serum albumin during this study. Both patients 
failed to respond to any antigen and were excluded from 
the study.
Three of nine patients with persistently abnormal liver 
function tests had clinically detectable splenomegaly. 
Of the remaining 22 patients, 9 had intermittently 
abnormal ALT levels (grade 3), 10 had a normal serum ALT
levels but previous evidence of NANB, 2 patients acquired 
NANB during the study and one patient had no previous 
evidence of NANB infection. All patients had serum 
hepatitis B antibody but none had circulating antigen.
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Median score of liver disease in HIV-1 positive patients 
was not significantly different from HIV-1 antibody 
negative patients (p=0.07)/ Table 7 .2 .1 .
RECALL SKIN RESPONSE 
HIV-1 antibody status
The median total score in all haemophiliacs was 12mm (IQR 
9 to 15) and the median number of antigens to which 
haemophiliacs responded was 3 (IQR 2 to 4 ) giving a 
median compound score of: 4.75 (IQR 4 to 6 ), Table 7.2.1. 
Patients positive for HIV-1 antibody had a median total 
score of 11mm (IQR 4 to 11); this was not significantly 
different from HIV-1 antibody negative haemophiliacs, 
median total score 13mm (IQR 9 to 15), p=0.15.
Effect of treatment on recall skin response
The median annual dose of clotting factor concentrate 
used by patients studied was: 39,000 units per annum
(IQR: 5,855 to 61,905). HIV-1 antibody positive patients 
had used a median of 83, 000 units annum (IQR 56, 852 to 
117,400) HIV-1 antibody negative patients, median 24,487 
units annum (IQR 2,586 to 43,910), p=0.001.
Figure 7.2.1 shows the relationship between the mean 
annual dose of clotting factor concentrate used and the 
compound skin response. In all patients there was a poor 
inverse correlation (r=-0.23, p=0.09). In HIV-1 antibody 
positive patients, r=-0.7 (p=0.08) and in seronegative
Patients r =-0.22 (p=0.28).
Table 7.2.1. Results of skin testing in HIV-1
positive and negative haemophiliacs.
HIV antibody status
+ve -ve
No. of patients 7 25
Age 21 30
(years) (19-35) (24-39)
Mean annual dose 83000 24487
of treatment (56852-117400) (2586-43910)
(units/annum)
Liver disease 2.5 4
(2-3) (3-5)
No. of antigens 2 3
+ve (1-3) (2-4)
Total score 11 13
(4-11) (9-15)
Compound 3.5 5
skin score (3-6) (4-6)
antibody
p value
0.07
0.001
0.07
0.26
0.15
0.09
Medians and interquartile ranges are shown. The only 
significant difference was that seropositive patients had 
used more clotting factor concentrate.
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Figure 7,2.1 THE COMPOUND SKIN SCORE IN 
RELATION TO THE ANNUAL DOSE OF 
TREATMENT USED
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Figure 7.2.1. There was no significant difference in 
compound skin score between the two groups, p=0.15).
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E ffe c t  o f  l i v e r  d ise a s e  on th e  r e c a l l  s k in  response
In all patients there was a poor direct correlation with 
the severity of liver disease and the compound skin score 
(r=0.23, p=0.25) this was independent of the HIV-1
status, Fig 7.2.2.
7 . 2 . 4  DISCUSSION
The aim of this study was to determine if the impaired 
cell mediated immunity seen in HIV-1 antibody negative 
haemophiliacs was due to chronic liver disease or an 
effect of treatment with clotting factor concentrates. 
The recall skin response was used rather than DNCB. This 
test has several advantages; it is simple to use and 
more acceptable to patients. Furthermore, responses are 
standardized and there is no risk of sensitization.
This study confirmed that in vivo cell mediated immunity 
was impaired in haemophiliacs treated with clotting 
factor concentrates and was independent of HIV-1 status 
(Chapter 7.1). Previous infection with NANB viruses did 
not affect recall skin response. Furthermore, results 
showed that liver disease due to NANB hepatitis does not 
account for the impaired cell mediated immunity seen in 
haemophiliacs treated with clotting factor concentrates. 
However, in the presence of clinically severe liver 
disease in 2 patients the skin responses were impaired.
In previous studies it was shown that clotting factor 
concentrates have both a direct chemical effect on 
lymphocyte proliferation in vitro and that treatment
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Figure 7.2.3. There was a poor correlation between
compound, skin score and mean annual dose of treatment 
(r=0.23/ p=0.09).
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also results in FcY receptor antibodies (Chapter 3.2). 
In this study and the dinitrochlorobenzene study (Chapter 
7.1) only a moderate inverse correlation was shown 
between mean annual dose of clotting factor concentrate 
used and in vivo cell mediated immunity. Impaired skin 
responses may be due to an immune response to
contaminating allogenic proteins contained in clotting 
factor concentrates, rather than due to the total dose. 
Alternatively, a component or components contained in 
clotting factor concentrates may modify function of T- 
helper/inducer cells. The results could also be explained 
by excessive T-suppressor cell activity. Treated
haemophiliacs frequently have increased amounts of 
circulating immune complexes (247-251). The binding of 
such complexes to Fc receptors on T-suppressor may
stimulate a suppressive signal, which could inhibit
macrophage or T-helper/inducer cell function (459).
In conclusion, the previous observation that 
haemophiliacs treated with clotting factor concentrates 
have impaired cell mediated immunity in vivo was 
confirmed. The impaired response was not due to NANB 
hepatitis. Further in vitro studies of cell mediated 
immunity in haemophiliacs are indicated to determine if 
this is a quantitative or qualitative defect.
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CHAPTER 7.3
IMPAIRED IN VIVO CELL MEDIATED IMMUNITY IN HIV-A ANTIBODY 
NEGATIVE HAEMOPHILIACS - PACT OR FICTION ?
SUMMARY
Study Objective: Is there a functional defect in cell
mediated immunity to a recall antigen in treated 
haemophiliacs.
Study design: Open, cross-sectional.
Study population: 13 patients with severe haemophilia of
whom three had HIV-1 antibody.
Measurements: Histometric analysis of lymphocyte subsets
in biopsies of cutaneous tuberculin reactions.
Results: The principle abnormality noted was absence of
increasing CD4:CD8 ratio of diffusely infiltrating 
lymphocytes with depth.
Conclusions: Haemophiliacs appear to have a functional
abnormality of lymphocytes in  vivo.
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7.3.1 INTRODUCTION
In the previous studies reported in this section it was 
shown that haemophiliacs treated with clotting factor 
concentrates had impaired cell mediated immunity in vivo 
as assessed by responses to dinitrochlorobenzene (DNCB) 
and recall antigens. In chapter 8.2 it is shown that 
HIV-1 antibody negative haemophiliacs do not have reduced 
total numbers of T-helper/inducer (CD4+ve) lymphocytes. 
It may therefore be that the impaired cell mediated 
immunity is due to a functional defect of CD4+ve T-cells 
or of a subpopulation of CD4+ve T-cells.
Gibbs et al have described a histometric method for 
assessment of immunocytochemical staining of lymphocyte 
and monocyte/macrophage subsets in tuberculin skin test 
reactions; this method allows discrimination of
differences that cannot be readily separated on direct 
microscopic examination (462 - 465). In the present
study this histometric method was used to determine if 
there was a functional defect in cell mediated immunity 
to a recall antigen in treated haemophiliacs.
7.3.2 MATERIALS AND METHODS
Patients
Thirteen patients with clinically severe haemophilia were 
studied: 3 had serum antibody to HIV-1 and the remaining 
10 patients have been persistently seronegative for HIV-1 
antibody. The mean annual dose of clotting factor
concentrate used was calculated.
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The subjects were tested by an intradermal injection of 
0 .1ml of "new tuberculin" an ultrasonicated skin test
antigen prepared from k/^ycobacterium tuberculosis. The 
injection site was examined 48hrs later and the response 
was recorded as (a) "negative" if no change was
observed, (b) "+" if there was localized erythema, "++"
if the epidermis was blistered over the indurated area. 
A heparinised venous blood sample was collected for 
enumeration of CD-4+ve and CD-8+ve T-lymphocytes as
described in Chapter 8.2.
Thereafter the skin test site was anesthetized by
injection of 1% plain lignocaine and a biopsy removed 
with a 4mm skin punch under full aseptic conditions: the
procedure was covered by injection of additional clotting 
factor concentrate and local pressure was maintained 
until a stable haematoma was formed. All biopsy sites 
healed normally and none was complicated by infection. 
Recurrent bleeding was encountered in two patients and 
this was controlled with clotting factor concentrate and 
local measures.
The biopsy core was snap frozen with dry ice and sealed 
in aluminium foil. Immediately before sectioning, the 
tissue was cryopreserved in glycerol: 6 -8um cryostat
sections were cut for immunocytochemical staining. The 
major T lymphocyte subsets were localized with Leu-3a 
(anti-CD4) and Leu-2a (anti-CD8 ) and monocyte/macrophages 
with Leu-M3 murine monoclonal antibodies (Becton 
Dickinson, Sunnyvale, CA, USA); monoclonal antibodies to 
receptors for interleukin-2 (CD25) and transferrin
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(Becton Dickinson) were used to identify "activated" 
lymphocytes. The slides were stained with the peroxidase 
avidin-biotin complex (ABC kit, Vectastain, Sera-Lab Ltd, 
Crawley Down, Sussex) using diaminobenzidene as 
substrate.
Histometric counts were performed on large (20x16in) 
monochrome photographic prints (x166); the outline of 
perivascular and periappendicular foci was delineated 
using a felt pen to facilitate measurement of the areas 
of the foci and of intervening dermis with a semi- 
automated planimeter. The number of cells in the two 
compartments (the foci and the intervening dermis) were 
counted and each expressed as a density (number/mm^): in
addition to measurements over the whole of the section, 
cell density in the diffuse infiltrate was measured 
separately in three successive 250mm layers into the 
dermis.
7.3.3 RESULTS
The intensity of changes seen on clinical examination of 
tuberculin tests (a long term recall response) correlated 
with that observed with DNCB (a short term recall 
response) in the previous study. Two of the three 
seropositive patients were negative in both tests, but 
the other patient gave a relatively strong reaction in 
both tests. The intensity of the tuberculin test seen on 
clinical examination showed no correlation with mean 
annual dose of clotting factor used or HIV-1 antibody 
status.
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The microanatomical distribution of cellular infiltrate 
in the dermis at the site of the tuberculin test in the 
haemophilia patients was similar to that previously 
reported in normal subjects (463-465).
The focal infiltrates range in extent from 2.14% to 
26.96% of the area of dermis - this is similar in 
intensity to that previously reported in other patient 
groups. The size of focal infiltrate was not related to 
clinical appearance and percentage focal infiltrate did 
not correlate with mean annual dose of clotting factor 
concentrate used or HIV-1 antibody status.
There was no difference in density of lymphocytes (CD4 + 
CD8 ) in the diffuse infiltrate and intervening dermis; 
values range from 20.2 to 137.6 cells/mm2, except for 
one outlier with 674.6 cells/mm2 : thus 12 of 13 patients 
had diffusely infiltrating lymphocyte densities similar 
to that reported in other patient groups. The
measurements were not related to clinical appearances of 
the reaction, use of clotting factor concentrates, or 
HIV-1 antibody status.
The CD4:CD8 ratio of peripheral blood lymphocytes was 
within the normal range, but was generally lower in HIV-1 
seropositive subjects. The CD4:CD8 ratio in the 
lymphocytes in the dermal focal inflammatory infiltrate 
was not significantly different from that of cells in 
peripheral blood.
However, the CD4:CD8 ratio in diffusely infiltrating 
lymphocytes overall and in three successive 250mm layers
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into the dermis was significantly greater than that in 
either blood or focal lymphocytes (p<0.05) in 
seronegative patients: the ratio of diffusely
infiltrating lymphocytes in seropositive patients was 
only slightly increased. The CD4:CD8 ratio of diffusely 
infiltrating lymphocytes did not show any significant 
change with increasing depth into the dermis, either in 
seropositive or seronegative subjects: in this respect
the haemophiliacs differed from normal volunteers or 
patients with pulmonary tuberculosis or across the
spectrum of leprosy (p<0.01) studied previously (464).
The CD4:CD8 ratio of all lymphocytes (cells bearing 
receptors for IL2 and transferrin) was positively
correlated with lymphocyte density throughout the section 
(in both diffuse and focal infiltrates) . It was 
noticeable that some of the clinically "negative" 
reactions "activated" cells were present in the 
infiltrates.
The density of monocyte/macrophages throughout the
section (both focal and diffuse infiltrate) was 42.2 to 
167.9 cells/mm^, this density was not correlated with the 
intensity of changes seen clinically nor with the mean 
annual dose of clotting factor concentrate used or HIV-1 
antibody status. The overall density of macrophages was 
clearly related to that of the lymphocytes.
7 -3.4 DISCUSSION
The microanatomical distribution of CD4, CD8 lymphocytes 
and monocyte/macrophages in tuberculin reactions in
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haemophiliacs was similar to that previously reported in 
normal healthy controls and in patients with
mycobacterial infections where there is active antigenic 
stimulation (eg. tuberculosis and leprosy, (464). The 
number of "activated" lymphocytes at the site of 
stimulation was related to the total density of 
lymphocytes in the infiltrate*
The mean annual dose of clotting factor concentrate used 
was not related to the major indicators of the immune 
response (focal infiltrate as a percentage of the dermis 
and the density of lymphocytes in the intervening 
dermis), but it was inversely related to CD4:CD8 ratio of 
lymphocytes throughout the section. This ratio is 
usually substantially higher than that in peripheral 
blood (466). Furthermore, in healthy subjects, the 
relative preponderance of CD4+ve cells in diffuse 
infiltrates is high (3 to 5 fold greater than peripheral 
blood) (466). In haemophiliacs studied there were fewer 
CD4+ve lymphocytes in diffuse infiltrates than in 
peripheral blood. Moreover tuberculin tests in 
haemophiliac patients did not show a gradient of 
increasing CD4:CD8 ratio of diffusely infiltrating 
lymphocytes with depth into dermis:in this respect 
haemophiliacs differed from healthy controls tested with 
the same antigen (466).
These findings suggest that there is a functional defect 
in T-cells from haemophiliac patients and this may be 
related to the increasing evidence of clinically 
significant immunosuppression reported in patients
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treated with clotting factor concentrates in the absence 
of HIV-1 infection (327-329).
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CHAPTER 8. 1
THE ABSOLUTE LYMPHOCYTE COUNT IN HAEMOPHILIA 
Summary
Study objective: To study prevalence, aetiology and
outcome of lymphopenia in treated haemophiliacs.
Study design: Open, prospective longitudinal.
Study population: Haemophiliacs treated with clotting
factor concentrate since 1980 in whom HIV-1 antibody 
status, mean annual dose of clotting factor concentrate 
used and severity of liver disease was known.
Measurements: Absolute lymphocyte count.
Results: The prevalence of lymphopenia was 29.4 percent,
after 4 years observation the incidence did not change. 
Early HIV-1 infection was not associated with a 
lymphopenia. Two patterns were identified episodic (14.7 
percent) and persistent (14.7 percent). Persistent 
lymphopenia correlated with mean annual dose of clotting 
factor concentrate. No association with liver disease 
was noted. 13 percent of persistently lymphopenic 
patients developed infections in the absence of HIV-1 
antibody.
Conclusion: Treatment with clotting factor concentrate
and not blood borne viral infection results in 
persistent clinically significant lymphopenia.
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8.1.1 INTRODUCTION
Severe adult haemophiliacs with reduced numbers of 
lymphocytes (lymphocyte count <1 ,200/mm3) have an eight 
times higher mortality than non-lymphopenic patients 
(467). Lymphopenia may arise due to several mechanisms: 
(a) the viruses transmitted by clotting factor 
concentrates; (non-A, non-B hepatitis, hepatitis B and 
human immunodeficiency virus-1), (b) clotting factor 
concentrates may have a direct chemical effect or (c) an 
immune mediated response against a leucocyte
crossreacting alloantigen contained in clotting factor 
concentrates may be responsible (332).
HIV-1 selectively infects and depletes lymphocytes that 
express the CD4 molecule. The virus may also infect a T- 
helper/inducer (CD4+ve, T-h) precursor or stem cell, 
further contributing to the lymphopenia (468). 
Lymphopenia during NANB infection could be a consequence 
of chronic liver disease but may also be a direct or an 
immune mediated effect of the NANB viruses on 
lymphocytes.
The effect of clotting factor concentrates on the 
lymphocyte count in the absence of these infections is 
not known. Moreover, repeated exposure to contaminating 
allogenic leucocyte antigens contained in clotting factor 
concentrates may sensitise the individual to produce 
anti -lymphocyte antibodies (332). In this regard it was
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shown in Chapter 3.2 that clotting factor concentrates 
induce non - cytotoxic anti lymphocyte antibodies. 
Alternatively, anti - leucocyte antibodies may be 
passively infused; in this context haemolysis due to 
passive infusion of red cell agglutinins in factor 
concentrates (230-232).
In the present study the frequency of lymphopenia and its 
outcome in treated haemophiliacs over four years was 
investigated. The lymphocyte count was compared between 
patients with and without HIV-1 antibody. In this 
context, the association between mean annual dose of 
clotting factor concentrate used and chronic liver 
disease on total lymphocyte count was examined.
8.1.2. METHODS 
Patients
The patients in this study were part of a well defined, 
prospective, cohort to determine aetiological factors and 
frequency of immunodeficiency in treated haemophiliacs, 
(Chapter 2).
Lymphocyte count
Venous blood in potassium ethylenediaminotetraacetate 
(EDTA) was obtained from all patients annually or more 
frequently if clinically indicated. The total number of 
white blood cells were counted on a automated counter 
(Coulter S Plus), a differential white cell count was 
carried out on blood films stained with Wright's stain 
and the percent number of lymphocytes obtained.
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HIV-1 Status
Prevalence and duration of HIV-1 infection in this 
population was known (Chapter 4) and clinical outcome 
accurately documented (Chapter 6).
Liver Disease
The serum alanine aminotransferase (ALT) (Techicon, 
autoanalyser) was measured on at least two occasions per 
annum on all patients. Patients were graded for severity 
of liver disease based on serum ALT levels and clinical 
features as described in Chapter 2.
8.1.3 RESULTS
Clinical outcome of HIV-1 infection and liver disease 
have been described in Chapters 6 and 2 respectively.
Lymphocyte count
The lymphocyte count at the start of the study was 
available on 102 (77 percent) patients and after four
years on 121 (91 percent) patients. Thirty patients (29
percent) were lymphopenic (Total lymphocyte count < 1500 
cells /mm3 ) at the start of the study and after four 
years 42 patients (35 percent) were lymphopenic, (p=0.233 
Fishers Exact Test).
Of the original 30 lymphopenic patients, 15 had a 
lymphopenia after four years. The count did not fall 
significantly in this group (p=0.59), Table 8.1.1. 
compares persistently lymphopenic patients to patients
TABLE 8.1.1 Differences between patients with and
without lymphopenia at the start of the study.
Persistently Initial Normal
lymphopenic Lymphopenia lymphocyte
count
No of patients 15 15 72
Lymphocyte count 1070 1170 2236
(initial)
cells/mm^
(900-1220) (830-1320) (1820-2595)
Lymphocyte count 1 160 1740 2112
(final)
cells/mm^
(930-1300) (1628-2660)(1400-2970)
Mean annual dose 18760 26000 7724
of clotting factor
concentrate used 
units/year
(1980-36353) (4260-83000) (1160- 
43910)
Age 35 29 31
(years) (29-45) (21-37) (23-44)
Grade of 3 3 3
liver disease (3-5) (3-5) (2-5)
HIV-1 antibody 0 3 16
The median and interquartile ranges for persistently 
lymphopenic, initial lymphopenia and non-lymphopenic
patients are shown. There was no significant difference 
in the age, mean annual dose of clotting factor
concentrate used or grade of liver disease.
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who recovered from the lymphopenia and non-lymphopenic 
patients.
Two persistently lymphopenic patients acquired 
infections, one patient had an unexplained panophthalmic 
infection of his left eye and the other pulmonary 
tuberculosis. One patient had a florid reaction to 
intradermal purified protein derivative of Mycobacterium 
tuberculosis (PPD) but had no clinical evidence of 
tuberculosis. All three patients remained HIV-1 antibody 
negative. Patient age showed no correlation with 
lymphocyte count, (r=-0.12, p=0.17).
HIV-1 Antibody status
In four HIV-1 antibody positive patients the initial 
lymphocyte count was not available, the final count was 
available on 21 positive patients. Figures 8.1.1 and 2 
shows lymphocyte counts in HIV-1 antibody positive and 
negative patients. Twenty eight percent of HIV-1 
antibody positive patients were lymphopenic at the start 
of the study, after four years 24 percent had a 
lymphopenia, (p=0.395, Fishers Exact Test). The
frequency of lymphopenia on the initial or final counts 
did not differ between HIV-1 antibody positive and 
antibody negative patients, Figure 8.1.1, (p=0.285,
Fishers Exact Test).
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Figure 8.1.1 THE INITIAL LYMPHOCYTE 
COUNT IN HIV -1 ANTIBODY POSITIVE 
AND NEGATIVE HAEMOPHILIACS
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Figure 8.1.1. 30 patients were lymphopenic, there was no
significant difference in counts between HIV-1 +ve and 
HIV-1 -ve patients.
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Figure 8.1.2 THE LYMPHOCYTE COUNT 
AT THE END OF THE STUDY
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Figure 8.1.2. 42 patients were lymphopenic at the end of
the study. There was no significant difference between 
HIV-1 +ve and -ve patients. Final values did not differ 
from initial values in either group.
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In HIV-1 antibody positive patients there was no
correlation between age and lymphocyte count, (r=-0.18
p=0.42), or duration of infection (r=0.20, p=0.34).
Four HIV-1 antibody positive patients were lymphopenic at 
the start of the study, none were symptomatic. In all
four, the lymphocyte count was in the normal range at the
end of the study. Five patients were lymphopenic at the
end of the study, none had symptoms of HIV-1 related
disease.
Liver Disease
There was no correlation between lymphocyte count and 
grade of liver disease, (r=0.08, p=0.366), Table 8.1.2. 
Moreover, no correlation was seen with the lymphocyte 
count and grade of liver disease in persistently
lymphopenic patients, (r=0.06, p=0.53).
Clotting fac to r concentrate use
There was no correlation between the initial lymphocyte 
count and the mean annual dose of clotting factor
concentrate used (r=0.05, p=0.52) in all patients. Mean
annual dose of clotting factor concentrate used accounted 
for 5 percent of the variance of lymphopenia at the end 
°f the study (r=0.23, p=0.05). In persistently
lymphopenic patients (n=15), mean annual dose of clotting 
factor concentrate used showed a highly, significant 
correlation with final lymphocyte count, (r=0.64, 
P=0.02) .
TABLE 8.1.2. Liver disease, HIV-1 status and the total 
lymphocyte count.
All HIV-1+ve HIV-1-ve
Grade 1 1380 (9) 
(810-1690)
1768 (1) 1290 (8) 
(740-1605)
Grade 2 1800 (25) 
(1508-2970)
1664 (5) 
(1508-2142)
1900 (20) 
(1495-2995)
Grade 3 1836 (29) 
(1200-2980)
1836 (9) 
(1628-2397)
2110 (20) 
(1165-3235)
Grade 4 1340 (11) 
(1200-2140)
1316 (1) 1420 (10) 
(1200-2140)
Grade 5 2340 (21) 
(1470-2890)
2600 (3) 
(2397-2640)
2185 (18) 
(1200-2900)
Grade 6 1855 (22) 
(1240-2900)
1820 (1) 1890 (21) 
(1240-2900)
TABLE 8.1.2 shows the medians and interquartile range of 
the most recent lymphocyte count according to grade of 
liver disease and HIV-1 status. The numbers in brackets 
are the number of patients in each group. There was no 
significant difference in the lymphocyte count between 
different grades of liver disease (Kruskal-Wallis 
Analysis of Variance).
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8.1.4 DISCUSSION
In this study, 30 of 102 haemophiliacs had an initial 
lymphopenia and 42 of 121 had a reduced lymphocyte count 
after four years. In half of the patients with an 
initial lymphopenia (15 patients) the lymphopenia
persisted. These findings are similar to those reported 
by Eyster et al (468).
None of the persistently lymphopenic patients had HIV-1 
antibody. Furthermore it was found that HIV-1 infection 
was not associated with a higher prevalence of 
lymphopenia. It may however be that as CD4+ve cell 
lymphocyte count declines further in HIV-1 antibody 
positive patients that this will be reflected in total 
lymphocyte count.
In contrast to the findings of Eyster et al, who reported 
an association between lymphopenia and liver disease this 
was not found in the present study (468).
The discrepancy between the results of this study and 
Eysters retrospective study could be due to differences 
in the patient population and methodology. Further, in 
Eyster's study no account was taken of the amount of 
clotting factor concentrate used or HIV-1 status. The 
association with liver disease was based on four deaths 
due to cirrhosis, of these one had abused alcohol and
214
another had a hepatic carcinoma and was known to be a 
chronic hepatitis B surface antigen carrier.
In this study only 3 of the 15 patients with persistent 
lymphopenia had chronically elevated serum ALT activity 
above 150% of the upper limit of laboratory normal. The 
most frequent grade of liver disase seen in persistently 
lymphopenic patients was an intermittent rise in serum 
ALT Grade 3. In a previous report such a pattern of ALT 
activity has been attributed to an allergic/chemical 
effect of clotting factor concentrate on the liver (182). 
It is therefore possible that the lymphocyte count may be 
reduced in a similar manner in the patients studied.
There was no correlation between the total lymphocyte 
count and mean annual dose of clotting factor concentrate 
used in all patients, in persistently lymphopenic 
patients the amount of treatment used accounted for 40 
percent of the reduced count. In such patients 
lymphophenia was considered unlikely to be a consequence 
of passive infusion of anti-leucocyte antibodies but 
would be in keeping with an endogenous, persistent 
lymphocytotoxic antibody. Further studies to determine 
if such antibodies are present are indicated.
The clinical significance of the persistent lymphopenia 
is not clear, however, infections occurred in 2 patients 
from this group. Others have reported a higher attack 
rate of tuberculosis in haemophiliacs and in a review of
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haemophilia deaths in the USA prior to the AIDS epidemic
a higher than expected incidence of deaths due to
pneumonias was noted (327, 328).
The prevalence of non-persistent lymphopenia was 14.7%, 
of these, 20 percent HIV-1 antibody positive. As in the 
persistently lymphopenic group there was no correlation 
with grade of liver disease. There was however, a weak
association with mean annual dose of clotting factor
concentrate used. It may be that lymphopenia is due to 
passive infusion of antilymphocyte antibodies or a direct 
chemical effect of clotting factor concentrates. 
Lymphopenia in this group of patients was not associated 
with complications.
The total lymphocyte count represents a heterogenous 
population, the phenotypes can be identified by 
monoclonal antibodies. Studies using such markers may be 
more useful in identifying lymphocyte subpopulation that 
are reduced. Such studies may also explain why HIV-1 
antibody positive patients despite biological effects of 
HIV-1 showed no fall in total lymphocyte count. Such 
investigations should prove to be more useful in 
providing prognostic information particularly in HIV-1 
antibody positive patients.
In conclusion, persistent lymphopenia occurs in up to 15 
percent of haemophiliacs treated with clotting factor 
concentrates. It does not appear to be due to HIV-1
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infection or liver disease, but an association with mean 
annual dose of clotting factor concentrate used was seen. 
The presence of a persistent lymphopenia was found to be 
associated with infections, in the absence of HIV-1 
antibody.
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CHAPTER 8.2
THE IMMUNOREGLATORY RATIO IN HAEMOPILIACS 
SUMMARY
Study objective: i To determine the prevalence of changes 
in the immunoregulator ratio in treated haemophiliacs, ii 
To identify aetiological factors.
Study design : Open cross-sectional
Study Population; 63 haemophiliacs grouped according to 
HIV-1 status; liver disease and mean annual dose of 
clotting factor concentrate used.
Measurents : CD4+ve and CD8+ve T cell counts in
peripheral blood.
Results: The prevalence of CD4+ve lymphopenia was 44% and 
CD8+ve lymphopenia was 12%. 28% had CD8+ve lymphocytosis. 
HIV-1 infection was associated with a significantly lower 
CD4+ve count. No other associatios were noted.
Conclusions: HIV-1 infection in haemophiliacs is
associated with a reduced CD4+ve lymphocyte count.
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8.2.1 INTRODUCTION
The risk of infection with the human immunodeficiency 
virus - 1 (HIV -1) in haemophiliacs is related to the
mean annual amount of clotting factor concentrate used, 
the number of exposures to an infected batch (the size of 
the innoculum) (Ludlam et al 1986).
HIV - 1 infection is frequently associated with a reduced 
number of T - helper \inducer ( CD 4 +ve,T-h) cells, and 
suppressor T lymphocytes (CD 8 +ve, T-s) cells have been 
reported to be increase, decreased, as well as normal. 
Changes in the immuno - regulatory ratio have also been 
frequently reported in HIV - 1 antibody negative
haemophiliacs have been reported to be increased (Spira 
et al 1986) and CD 4 +ve lymphocytes reduced (Carr et al 
1985). in one study those haemophiliac who seroconverted 
after exposure to a single infected batch of factor VIII 
concentrate tended to have fewer CD - 4 +ve lymphocytes 
compared to those who did not (Ludlam et al 1986).
The prevalence and cause of reduced CD - 4 +ve
lymphocyte numbers is not known in haemophiliacs.In a 
previous study we showed that a reduced CD 4 +ve count 
was associated with all impaired cell mediated immune 
response in - vivo , the response was independent of the 
HIV - 1 status and an inverse correlation with treatment
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use was also seen (Madhok et.al.,1986). However,
treatment with clotting factor concentrates also
predisposes to non - A,non - B viral infections and
chronic liver disease .
in this study the absolute numbers of CD 4 +ve and CD 
8 +ve lymphocytes in haemophiliac patients have been 
countd and compared independently to HIV-1 antibody 
status, liver diseases severity and mean annual dose of 
clotting factor concentrate used.
8.2.2 PATIENTS AND METHODS 
Patients
In 1986, T cell subsets were enumerated in 60 of 133
haemophiliacs who formed part of a prospective study of 
a HIV - 1 infection and immuno - competence in
haemophilia. Included were 20 of the 22 patients know to 
be seropositive for HIV - 1 antibody. All patients were 
examined for clinical features of HIV - 1 related
disease. Additional information obtained from case 
records included :
(i) Mean annual amount of treatment used by patients over 
the previous five years.
(ii) Severity of liver disease.
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Further details of the methods have been previously given 
(Chapter 2).
MATERIALS
Cell-separation;
Heparinised venous blood was obtained and mononuclear 
cells (PBMC) separated by density centrifugation on a 
sodium metriazoate as previously described in Chapter 
3.1.1
T-lymphocyte-subsets
T-lymphocyte subset populations were counted by indirect 
immunofluorescence on a fluorescene activated cell sorter 
(FACS) (Becton Dickinson, Sunnyvale, California, USA) 
using commercially available monoclonal antibodies (OKT3u 
for T cells, OKT4 for T-helper cells and OKT8 for T- 
suppressor cells (Ortho Diagnostics, Raritan, New Jersey) 
The cells to be stained were resuspended in Hanks/10% 
fetal calf serum (FCS) and the cell concentration 
adjusted to 5x106/ml. 1x106 cells a 0.2mls aliquot) were
stained with 20ul of each monoclonal antibody and 
incubated on ice for 45 minutes. After incubation, the 
cells were washed twice in Dulbecco's phosphase buffered 
saline/10% FCS by centrifugation at 400 x g for 10 
minutes at 4°C.
The cells were then counterstained using 200uls at 1:250 
dilution of fluroscein isothiocyante (FITC) - conjugated
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goat — anti-mouse immunoglobulin. After 30 minutes 
incubation on ice, the cells were washed as previously 
and fixed with 1mls of 1% paraformaldehyde fixative 
solution and stored at 4°C till counted. For each 
patient a negative control for non-specific staining by 
the secondary antibody was also obtained, 1x106 cells 
were stained with counter mouse IgG instead of the 
monoclonal antibody and then stained with the secondary 
antibody as described.
The percentage positive cells stained with each 
monoclonal antibody were counted on a fluorescene 
activated cell sorter (Becton Dickinson, Sunnyvale 
California) . The absolute count was obtained by 
multiplying the percent count with the total lymphocyte 
count.
8.2.3 RESULTS
T cell subsets were counted in 63 haemophiliacs of whom 
21 were HIV-1 antibody positive. Table 8.2.1 compares 
the haemophiliacs studied and those patients who formed 
part of the prospective cohort but were not studied. The 
haemophiliacs studied were comparable to the control 
group for age.
Total T cell (CD-3, T-3) numbers
Table 8.2.1. A comparison of haemophiliacs in whom
T cell subsets were counted and not counted.
No. of patients
Age
(years)
Factor deficiency 
(iu/dl)
Mean annual
dose of clotting factor 
concentrate used 
(units/annum)
Grade of liver 
disease
HIV-1 antibody 
positive
Patients
Studied Not studied p value 
63 70
27 37
(20-36) (26-52)
0 5
(0-5) (0-14)
27300 2663
(6605-75880) (605-18520)
3
2-5)
21
4
(2-5)
0 . 001
0 . 001
0 .0 0 1
0.28
Median and interquartile ranges are shown.
Studied haemophiliacs had a more severe deficiency, 
used more clotting factor concentrate over the previous 
seven years and were younger than patients not studied.
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Table 8.2.2 and Figure 8.2.1 show the total CD-3+ve cell 
count in haemophiliacs, it did not differ from controls,
p=0.6.
HIV-1 antibody status
No difference was seen when HIV-1 antibody positive 
haemophiliacs were compared to seronegative patients 
(p=0.93) or controls (p=0.7). Seronegative patients did 
not differ from the control group (p=0.5).
Despite the absence of any statistical difference in the 
median counts, five patients (8 percent) had a CD-3+ve 
count below the normal range. All were HIV-1 antibody 
negative and had abnormal liver function tests, Figure 
8 . 2 . 1 .
Effect of Liver disease
There was a poor correlation with grade of liver disease 
and total CD3+ve T cell count for the whole group
(r=0 . 31 p=0.015) . In HIV-1 antibody positive patients,
the correlation was poor and not statistically 
significant (r=0.23 p=0.32) and in HIV-1 antibody
negative patients the relationship was significant but
remained poor, (r=0.31, p=0.4).
Effect of Mean annual dose of clotting factor concentrate 
used
There was no correlation between CD3+ve T-cell count and 
roean annual dose of clotting factor concentrate used in
Table 8.2.2. T cell subsets in haemophiliacs and controls.
Haemophiliac HIV-1 status
T cells 
(cells/mm3 )
CD-3+ve 
CD-4+ve 
CD-8+ve
Control
987
(767-1500)
765
(634-879)
532
(312-654)
All
(SWi-T7*)-
593
(453-814)
472 
(331 -741 )
1285
(972-1486)
525.5
(373-648)
484
(457-550)
1071 
(816-1971)
622
(483-1003)
415
(302-662)
Median and interquartile ranges are shown.
CD-3+ve T cells - Haemophiliacs did not differ from controls
HIV-1 Ab+ve vs HIV-1 Ab-ve p=0.93
CD-4+ve T cells - Haemophiliacs had fewer cells p=0.008
HIV-1 Ab+ve vs HIV-1 Ab-ve p=0.02
CD-8+ve T cells - Haemophiliacs did not differ from controls
HIV-1 Ab+ve vs HIV-1 Ab-ve p=0.35
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Figure 8.2.1 THE TOTAL T-CELL 
(CD-3 +VE) COUNT
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Figure 8.2.1. CD-3+ve T cell count in either group did 
not differ from control values.
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either HIV-1 positive patients (r=0.06/ p=0.78) or HIV-1 
negative patients (r=0.10/ p=0.49).
The CD4+ve T-cell count
Haemophiliacs as a group had fewer numbers of CD4+ve T- 
cells than controls (p=0.008), Table 8.2.2.
HIV-1 antibody status
Table 8.2.2, and Figure 8.2.2 shows that HIV-1 antibody 
positive haemophiliacs had a significantly lower CD4+ve 
T- cell count compared to seronegative patients (p=0.02) 
and controls (p=0.007). There was no significant 
difference in the CD4+ve T-cell count between HIV-1 
negative haemophiliacs and controls (p=0.17).
The Effect of Liver Disease
Patients with severe liver disease (Grades 1 and 2) and 
previous evidence of NANB hepatitis had reduced numbers 
of CD4+ve T cell lymphocytes, compared to patients with 
no previous exposure to NANB (Grade 6) . In both HIV-1 
antibody positive and negative patients there was a poor 
correlation with the severity of liver disease r=0.32 
(p=0.18) and r=0.32 (p=0.03) respectively.
The effect of the mean annual dose of clotting factor 
concentrate used
The mean annual dose of clotting factor concentrate used 
showed a poor correlation with the CD4+ve T-cell count 
(r=- 0.26, p=0.04). In HIV-1 antibody positive patients
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FIGURE 8.2.2 THE T-HELPER CELL (CD-4 +VE) 
COUNT IN HIV-1 ANTIBODY POSITIVE 
AND NEGATIVE PATIENTS
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Figure 8.2.2. HIV-1 +ve patients had a significantly 
lower CD-4+ve T cell count compared to HIV-1 -ve patients 
(p=0.02) and controls (p=0.007). HIV-1 -ve patients did 
n o t differ from controls (p=0.17).
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mean annual dose of clotting factor concentrate used did 
not influence CD4+ve T-cell count (r=0.1, p=0.65) whereas 
in HIV-1 antibody negative patients a poor but 
significant inverse correlation remained (r=-0.2/ 
p=0.05) .
Correlation Analysis
To determine the extent to which mean annual dose of 
clotting factor concentrate used, liver disease severity 
and HIV-1 status influenced CD4+ve T cell count, a 
stepwise logistic regression analysis was performed. The 
above variables were independent variables and the CD4 + ve 
cell count was the dependent variable. The analysis was 
weighted for patients age. Both liver disease, r=0.680 
(p=0.0001 ) and HIV-1 status r=0.807 (p=0.03) remained
significantly associated. The mean annual dose of 
clotting factor concentrate used no longer remained a 
significantly associated influence on the CD4+ve T-cell 
count.
CD8+ve T-cell count
figure 8.2.3 and Table 8.2.1 show the CD8+ve T-cell 
count in haemophiliacs and controls. There were no 
Sl9&ificant differences observed in the median CD8+ve T- 
CeH  counts. However, 28 percent of haemophiliacs had a 
CD8+ve T-cell count above the upper limit of the 
oratory normal, Figure 8.2.3. Forty-five percent of 
antibody positive patients had a raised CD8+ve T-
cei i
count and 20 percent of HIV-1 negative patients,
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Figure 8.2.3 THE T SUPPRESSOR /CYTOTOXIC 
(CD8+VE) CELL COUNT IN HIV-1 ANTIBODY 
POSITIVE & NEGATIVE HAEMOPHILIACS
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Figure 8.2.3. There was no significant difference 
counts between HIV-1 +ve and controls. HIV-1
patients did not differ from controls.
in 
- ve
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{p=0.04, Fishers Exact Test) . Twelve percent of patients 
had a CD-8 + ve count below the normal range, none of 
these patients had HIV-1 antibody, and all but one had 
abnormal serum ALT levels.
The E ffe c t o f L iv e r  D isease
No correlation was noted between the CD8+ve count and the 
grade of liver disease in either HIV-1 antibody 
positive or negative patients.
The e f fe c t  o f  mean annual dose o f  c lo t t in g  f a c to r  
concentrate used
There was no correlation between the mean annual dose of 
clotting factor concentrate used and the absolute CD8+ve 
count in HIV-1 antibody positive patients (r=-0.08, 
P=0.7) or seronegative haemophiliacs (r=-0.07, p=0.6).
The CD4+ve T - c e l l  count in  p a t ie n ts  w ith  in c re a s e d  CD8+ve 
count
Nine HIV-1 antibody positive patients (45 percent) had a 
CD8+ve count above the normal range, only two of these 
Patients had a CD4 + ve T-cell count below the normal 
range. Figure 8.2.4 shows that those patients with a 
raised CD8+ve count had more CD4+ve T-cells than those 
Patients with CD8 + ve count in the normal range, (p=0.05, 
°ne tailed test) .
8,2*4 DISCUSSION
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FIGURE 8.2.4 THE CD 8 +VE COUNT IN 
HIV-1 ANTIBODY POSITIVE PATIENTS 
WITH REDUCED & NORMAL 
CD 4 +VE COUNT
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Figure 8.2.4. Patients with a normal CD-4+ve count had 
more CD-8+ve cells (p=0.05 one tailed test).
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In chapter 6 haemophiliacs were found to have impaired 
cell mediated immunity in vivo, as assessed by skin 
testing to a new and recall antigens. A poor immune 
response to an antigen may be due to impaired T-cell 
help/induction or excessive T-cell
suppression/cytotoxicity. In this study we have counted 
T cell subsets to determine if quantitative
abnormalities could account for the previous 
observations.
The prevalence of CD4 lymphopenia in haemophiliacs was
found to be 37 percent. In patients with HIV-1 antibody
both the frequency of CD4 T-cell lymphopenia was
increased and the total numbers were reduced compared to
seronegative patients, Figure 8.2.2. These findings are
similar to previous reports (469-485). It is well
established that HIV-1 selectively infects and depletes
cells that express the CD4 molecule. The mechanism of
cytopathic effect however is not clear, in vitro cell to
Cell fusion and resulting syncitum formation due to the
crosslinking of neighbouring CD4 molecules and the viral
envelope protein gp120 is important in cytopathicity
(4®6) • However, syncita have not been seen in vivo 
(218).
accumulation of integrated virus DNA is important in 
animal retroviral infections (487, 488) this has been
c°nsidered unlikely in HIV-1 infections (489). Zagury et 
postulated that expression of HIV-1 may trigger the
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CD4+ve cell to begin terminal differentiation, and 
premature cell death (490) .
Other mechanisms may include, enhanced immune clearance 
of CD4+ve T-cells due to free gp120 coating CD4+ve T- 
cells rendering them foreign (491). Alternatively HIV-1 
infected cells may alter HLA Class II phenotype and 
therefore enhance immune clearance (492) .
In HIV antibody negative haemophiliacs 38 percent had 
reduced CD4+ve cell counts. The reasons for this are not 
clear, there was a poor correlation between the CD4+ve 
cell count and the mean annual dose of clotting factor 
concentrate used and liver disease severity.
There are two possibilities, first the CD4+ve T cell set 
represents a functionally heterogenous population which 
can be subdivided phenotypically with the use of the Leu 
8 monoclonal antibody (307, 308). CD4 + ve, Leu8-ve T cells 
are potent helpers of B cell responses whereas CD4 + ve Leu 
8-ve T cells have a minor role in B cell responses and 
are the prime responders in antigen induced proliferative 
assays and in the mixed autologous reaction. They may 
also induce CD8+ve T cell suppressor function (307,
• A better association may have been seen if these 
Phenotypes had been selectively counted. Second, the 
ln®unosuppression that occurs with clotting factor 
c°ncentrates is presumed to be due to the contaminating 
a^ oantigens and not factor VIIIC (Chapter 3.1). In the
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present study the amount of clotting factor activity 
infused was measured to accurately quantify the amount 
of extraneous protein previously infused was not 
p o s s ib le .
A poorly responsive immune system can result in poor 
helper induction or excessive suppressor influences. In 
this study we found that 29 percent of haemophiliacs had 
increased numbers of CD8 +ve T-cells, and this occurred 
more frequently in HIV-1 antibody positive patients (45 
percent), Figure 8.2.3. The CD8+ve T-cell population can 
also be further subdivided into phenotypic subsets that 
are associated with suppressor versus cytotoxic function 
by using two-colour immunofluoresence (493, 494) . The
increased number in HIV-1 antibody positive patients is 
due to CD8+ve T cells that do not express Leu 15 antigen 
(495) associated with cytotoxic precursor and effector 
functions.
in this study it was found that those individuals with 
hiV-1 antibody and increased CD8 + ve T cells had more 
CD4+ve T-cells compared to patients with normal numbers 
°f CD8+ve T -cells, Figure 8.2.3. This suggests that the 
Ceil mediated cytotoxic immune response to HIV-1 may be 
°ne determinant in the depletion of CD4 + ve T-cells.
In hHIV-1 antibody negative haemophiliacs, 21 percent had 
an increased CD8+ve T-cell count. No correlation between 
f^obers °f CD8 + ve T-cells and mean annual dose of
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clotting factor concentrate used or the grade of liver 
disease was found. However, it is possible that
abnormal suppressive signals are responsible for the
impaired in vivo response to antigen. In Chapter 3.2 it 
was found that haemophiliacs have increased amounts of Fc 
Y receptor antibody and that such antibodies can impair 
lymphocyte activation and transformation in vitro. The 
presence of such antibodies are implicated in the
transfusion associated immunosuppressive effect observed 
in uraemic patients who have received a renal allograft 
(304). It is therefore possible that immunosuppression 
in haemophiliacs without HIV-1 antibody is due to
qualitative rather than quantitative changes in the
CD8+ve cell population.
In conclusion it was found that HIV-1 antibody positive 
and negative haemophiliacs have abnormalities in T-cell 
subsets. These are more frequent and quantitatively
greater in HIV-1 antibody positive patients. In HIV-1 
antibody negative patients no consistent abnormality was 
found. There was no association between cell counts and 
severity of liver disease or use of clotting factor
concentra te .
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CHAPTER 8.3
COFACTORS IN THE CD4+VE T-CELL DECLINE IN HIV-1 INFECTED 
HAEMOPHILIACS
SUMMARY
Study objective: (i) To measure the decline in CD4+ve
lymphocytes. (ii) To identify cofactors that may
influence this decline.
Study design: Open, prospective longitudinal.
Study population: Haemophiliacs with and without HIV-1
antibody.
Measurements: T-cell subsets.
Results: HIV-1 infected patients showed a significant
decline in CD4 cell count and a significant increase in 
CD8 count. No changes were observed in seronegative 
patients. In seropositive patients age inversely
correlated with CD4 count, and this was shown to be due 
to fewer CD8 cells.
Conclusions: Older HIV-1 Ab+ve patients had a more rapid
decline in CD4+ve T-cells. Liver disease or the mean
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annual dose of clotting factor concentrate infused 
not associated with the CD4+ve T-cell count.
was
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8.3.1 INTRODUCTION
The human immunodeficiency virus (HIV-1), infects, 
replicates in and depletes cells of the CD-4 phenotype 
(T-helper/inducer T-h; CD4+ve) (335-345) . The
progressive, numerical depletion of CD4+ve cells 
predisposes the host to opportunistic infections and 
malignancies: the acquired immunodeficiency syndrome
(AIDS). In HIV-1 infected patients the latency period 
for AIDS shows considerable variation between 
individuals, furthermore differences between risk groups 
in outcome of HIV-1 infection have been observed (1). 
This may be a function of the duration of infection or 
alternatively host/environmental factors may be 
determinants of outcome.
In vitro, lymphocyte activation with mitogens, soluble 
antigen, and other viruses is a prerequisite to pro-virus 
expression (335-338, 496, 497). It has been suggested
that repeated antigenic stimulation by infectious agents 
alloantigens may be important cofactors in the latency 
Period of infection (490) . Physiological stimuli
enhancing pro-virus expression in vitro include 
9ranulocyte macrophage colony stimulating factor and 
1nterleukin-3, Y interferon had the opposite effect 
(498-501 ). This is in keeping with clinical
°hservations, for instance: in male homosexuals the
lumbers of sexually transmitted diseases is one co- 
a^ctor in disease progression (375) . Similarly in
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intravenous drug users the rate of CD 4 +ve cell loss 
correlates with the continued abuse of illicit drugs
(502). Possible co- factors in haemophiliacs include 
influence of pre- existing liver disease due to NANB 
infection or recurrent allogenic stimulation from the 
repeated use of blood products. The relationship 
between these factors and the CD 4 +ve T-cell count has 
not been investigated.
In the present study the numbers of CD4+ve and CD8+ve T- 
lyraphocytes have been prospectively counted in a cohort 
of treated haemophiliacs with and without HIV-1 antibody 
over four years. The effects of age, chronic liver 
disease and mean annual dose of clotting factor 
concentrate used on the T-cell subset numbers were 
investigated.
8.3.2 METHODS
Patients
In 1983, a l l  f a c to r  VIII and IX d e f ic ie n t  h aem o p h iliacs  
who had been t r e a te d  w ith  a b lood p ro d u ct a t  th e  West o f  
Scotland A d u lt  H aem op h ilia  C en tre  were e n ro lle d  in to  a 
Prospective study to  e v a lu a te  th e  r e la t io n s h ip  between  
^paired c e l l  m ediated  im m unity to  AIDS in  h a e m o p h ilia . 
Tlle aims o f th e  study and th e  c h a r a c te r is t ic s  o f  th e  
cohort have been d e s c rib e d  (C hapter 2) .
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Subjects selected for sequential counting of T cell 
subsets were chosen on the basis of being HIV-1 antibody 
positive in 1 984 and 1 986, and selected seronegative 
treated patients matched for the severity of haemophilia 
were the control group. Serum from all treated patients 
was tested for HIV-1 antibody (ELISA, Wellcozyme) and 
the following additional information was obtained.
(i) Age of HIV-1 infection.
(ii) Duration of HIV-1 infection (Chapter 4).
(iii) Severity of liver disease (Chapter 2) .
(iv) Mean annual dose of clotting factor concentrate
used (Chapter 2) .
(v) Clinical status (Chapter 6) .
T-lymphocyte subset co u n tin g
Lymphocyte subpopulations were stained using monoclonal 
antibody markers for T-helper/inducer (T-h, CD4+ve) using 
0KT4 antibody and T suppressor/cytotoxic (T-s, CD8+ve) 
using 0KT8 antibody and counted on a fluorescence 
activated cell sorter, as previously described (Chapter 
8.2 .2 ) .
8,3*3. RESULTS
*^cell subsets were counted in 1984 and 1986 in 29 
haemophiliacs, of these 11 were HIV-1 antibody positive. 
purthermore in all HIV-1 antibody positive patients 
^*21) patients' T-cell subsets were counted in 1988. T-
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cell counts prior to seroconversion were not available in 
the three patients who were infected in 1985.
T helper/Inducer (CD4+ve ,T-h) cell count
Table 8.3.1 shows that both groups (HIV - 1 antibody
positive and negative) were comparable for the absolute 
CD4+ve T-cell count in 1 984, by 1986 median count in HIV- 
1 antibody positive patients had dropped significantly 
and a further decline had occurred by 1988, Figure 8.3.1. 
Whereas in seronegative patients there was no significant 
change, Table 8.3.2.
Symptomatic patients had the lowest CD4+ve T-cell counts 
(see Chapter 6) .
Factors affecting the CD4+ve T-cell count in HIV-1 
antibody positive haemophiliacs.
The grade of liver disease and the mean annual dose of
clotting factor concentrate (1984- 1988) used did not
correlate with the CD4+ve T-cell count, r=0.31 (p=0.18)
Tor liver disease grade and r=-0.11 (p=0.62) for the mean
annual dose of clotting factor concentrate used.
However, age (r=-0.5, p=0.02) and the age of infection
(r~-0.5/ p=0.01) did inversely influence the CD4+ve T
CeU  count, but duration of infection did not (r=-0.02, 
P*0.01) .
Table s.3.3 shows differences between those patients with 
a C*)4+ve T cell count below the normal range and those
Table 8 . 3 . 1 .  S e q u e n tia l T c e l l  subsets in  H IV -1
s e ro p o s it iv e  p a t ie n ts .
T c e l l  subsets (ce lls /m m ^) 
Year CD4+ve CD8+ve
1984 692 484
(597-905) (437-550)
1986 525.5 595.5
(373-648) (436-890)
1988 356 470.5
(253-651) (377-600)
Medians and interquartile ranges are shown.
CD4+ve count 1984 vs 1986 p=0.02
1984 vs 1988 p=0.04
1986 vs 1988 p=0.3
CD8+ve count 1984 vs 1 986 p=0.05
1984 vs 1988 p=0.5
1986 vs 1988 p=0.1
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FIGURE 8.3.1 SEQUENTIAL CD-4 CELL COUNT 
IN HIV-1 ANTIBODY POSITIVE PATIENTS
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Figure 8.3.1. There was a significant fall in CD-4+ve T- 
cell count between 1984 and 1986 (p=0.003) and a further 
decline had occurred between 1986 and 1988 (p=0.05 one
tailed test) .
Table 8.3.2. Sequential T cell subsets in HIV-1 
antibody negative patients.
Year
1984
1986
T cell subsets (cells/ram3 ) 
CD4+ve CD8+ve
622 717.5
(483-1003) (553-847)
415 569
(302-662) (378-699)
Medians and interquartile ranges are shown. 
There was no significant differences.
Table 8 . 3 . 3 .  A com parison o f p a t ie n ts  w ith  low  and norm al 
CD4+ve count ( 1 9 86 ) .
Age
(years)
Mean annual
dose of treatment
used (units/annum)
Liver disease 
grade
Duration of HIV-1 
infection
CD-4 c e l l  count 
Low Normal
29 19
(22-39) (17-20)
77335 78698
(56852-100000) (50000-83000)
3
(2-3)
48
(35-60)
(2.5-4)
54 
(50-61)
i value 
.004
0.84
0.78
0.2
Medians and interquartile ranges are shown. Patients with a 
low CD-4 count were older but had a similar duration of 
infection to patients with a normal count.
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with a normal CD-4+ve T cell count, patients with a count 
below the normal range were significantly older.
T-suppressor/cytotoxic ( T - s ,  CD8+ve) c e l l  count
Table 8.3.1 and Figure 8.3.2 show sequential measurements 
of the CD8+ve T-cell count in seropositive
haemophiliacs. In seropositive patients there was a
significant increase in the CD8+ve T-cell count, 
(p=0.05) . The CD8+ve T-cell count did not significantly 
change in the seronegative group, Table 8.3.2 (p=0.09).
HIV-1 antibody positive patients with the CD4+ve T-cell 
count in the normal range had significantly more CD8+ve 
T-cells, Table 8.3.4.
Correlation A n a ly s is
When CD8 + ve T-cell count, age, mean annual dose of
clotting factor concentrate used, and liver disease were 
taken as the independent variables in a stepwise logistic 
Egression analysis with CD4+ve T-cell count as the
dependent variable and correcting for the duration of 
^fection, only the CD8+ve T-cell count remained 
signif icantly associated with CD4+ve T-cell count, 
(r=0.44, p=0.03) on both backward and forward selection.
8>3-4 DISCUSSION
3eguential measurements of T-cell subsets in 
haemophiliacs showed a significant decline in CD4+ve T-
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FIGURE 8.3.2 SEQUENTIAL T SUPPRESSOR / 
CYTOTOXIC (CD 8 +VE) COUNT IN HIV -1 
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Figure 8.3.2. A significant increase in CD-8+ve T cell 
count occurred between 1986 and 1988 (p=0.04 one tailed
test) .
Table 8 . 3 . 4 .  The CD8+ve c e l l  count in  h aem o p h iliacs  
(HIV-1 Ab+ve) w ith  low and norm al CD4+ve c e l l  count 
in 1986 and 1988.
CD4 count (c e lls /m m 3 )
Normal Low
CD8+ve count 828 472
(cells/mm3 ) (640-950) (414-824)
732.5 
(515-1071)
411.5
(277-502)
Medians and interquartile ranges are shown.
Patients with a normal CD4 count had significantly more 
CD8+ve cells, p=0.04 in 1986.
This was seen in the 1988 counts, p=0.01.
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cell count in HIV-1 antibody positive patients and an 
increase in CD8 + ve count over four years. This was in 
contrast to HIV-1 negative patients in whom neither count 
significantly changed. In HIV-1 antibody positive
patients CD4 + ve T-cell count was significantly lower in 
older patients. Furthermore this prospective study 
confirms a previous observation Chapter 8.2.3 that a 
low normal CD4+ve T-cell count is associated with a lower 
CD8+ve T-cell count.
A progressive decline in CD4+ve T-cell count in HIV-1 
infected patients with and without haemophilia has been a 
consistent finding (344). However it remains unexplained 
why certain patients have a more rapid decline than 
others. Eyster et al noted that patients with a more 
rapid decline were older when infected with HIV-1, in 
this study both age of infection and patient age but not 
duration of infection influenced the CD4+ve T-cell count
(503) . a  stepwise logistic regression analysis showed 
that age was the main determining factor. Older patients 
did not have more severe liver disease and neither had 
they used more factor concentrate per annum. No 
correlation between age and CD4-ve T-cell count in HIV-1 
negative patients was noted.
How age influences CD4+ve cell count decline is not 
toown. There was however, a moderate inverse
^relation with age and CD8 + ve T-cell numbers in HIV-1 
antibody positive patients. A more detailed analysis
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showed that CD8+ve count and not age has a more 
important influence on the CD4+ve T cell count suggesting 
that older patients may mount a poorer T-cell cytotoxic, 
suppressive immune response against HIV-1.
This observation is in keeping with studies in which 
viral isolation has been attempted, removal of CD8+ve T- 
cells is associated with more success in viral isolation 
and provides a higher yield of virus (224). HIV-1 
replication in these in vitro studies was inhibited by a 
soluble suppressive factor secreted by CD8 + ve cells and 
not a cell mediated cytotoxic mechanism (224).
It has been previously shown that once the CD4+ve T-cell 
count falls below 200 cells/mm^ there is a 25 percent 
chance of developing AIDS in the subsequent year and this 
doubles for the second year (503). At present it is not 
clear whether all such "high risk" individuals should be 
treated with azidothymidine (Zidovudine, Wellcome) : 
controlled trials are in progress.
Extrapolating from in vitro observations in  (Chapter 
•^1)/ recurrent a lloantigen load from treatment w ith  
dotting fac to r concentrates could be another cofactor.
 ^poor correlation was found between mean annual dose of 
dotting factor concentrate used and the CD4+ve T-cell 
count. it may be that number of infusions or total 
Protein load received would be a better measure of
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alloantigen load rather than mean annual dose of 
clotting factor concentrate.
In HIV-1 antibody positive homosexuals, an increased 
number of sexually transmitted infections is a risk 
factor of subsequent AIDS (375) . In haemophiliacs 
concommitant infections include hepatitis B and NANB 
hepatitis. In both, chronic liver disease arises due to 
viral persistence because of immune defects and their 
activity can be presumed from the resulting liver disease 
(171). Using a clinical and laboratory based grading of 
liver disease severity it was found that in HIV-1 
positive patients, chronic liver disease made only a
minor contribution to depletion in CD4+ve T-cell numbers.
In conclusion, a progressive decline in CD4+ve T-cell 
numbers during the course of HIV-1 infection was seen. 
Increasing age appears to influence quantitative, 
suppressive/cytotoxic response to HIV-1 and is one 
contributing factor in depletion of CD4+ve T-cell 
numbers. Presence of chronic liver disease and mean 
annual dose of clotting factor concentrate used did not 
contribute to CD4 + ve T-cell lymphopenia in haemophilia.
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CHAPTER 9 . 1
lymphocyte a c t i v a t i o n  a n d  p r o l i f e r a t i o n  i n h a e m o p h i l i a  -
THE EFFECT OF HIV-1 INFECTION, LIVER DISEASE AND 
TREATMENT.
SUMMARY
Study objective: (i) To compare lymphocyte function in
vitro in HIV-1 antibody positive and negative 
haemophiliacs. (ii) To determine whether chronic NANB 
hepatitis or treatment with clotting factor concentrates 
impairs lymphocyte function in vitro.
Study design: Open, cross-sectional.
Study p o p u la tio n : 40 haemophiliacs grouped according to
serum HIV-1 antibody status, liver disease severity and 
roean annual dose of clotting factor concentrate.
Measurements: Lymphocyte activation and proliferation in
response to the non-specific T-cell mitogen 
Phytohaemagglutinin (PHA) and to purified protein 
Privative (PPD) of M. tuberculosis, a specific soluble 
stimulator of T-cells.
^®sults: HIV-1 antibody positive haemophiliacs had
Oppressed responses to PHA, proliferation correlated
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with CD8+ve T-cell count and age of infection. 
Seronegative patients showed normal responses to PHA. 
PPD responses were impaired independent of HIV-1 antibody 
status. Seropositive patients had a more impaired 
response than seronegative patients. In seropositive 
patients PPD response showed a moderate inverse 
correlation with CD4+ve T-cell count.
Conclusions: HIV-1 infection results in a selective
defect of CD4+ve T-cell function which is partly 
accounted for by CD4+ve T-cell depletion. In seronegative 
patients a selective defect of CD4+ve T-cell function 
also occurs but this was not due to quantitative changes. 
In seronegative patients this could not be accounted for 
by liver disease or mean annual dose of treatment used.
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9.1.1 INTRODUCTION
Human immunodeficiency virus-1 (HIV-1) infection results
in a progressive decline in the host's ability to mount 
an immune response (344). Clinically, immunodeficiency 
results in recurrent opportunistic infections and 
'opportunistic' tumours or AIDS. In AIDS both 
quantitative and qualitative changes occur: CD4+ve T-cell 
numbers are reduced and CD8 + ve T-cell counts may be 
increased, normal or reduced (207,375). Qualitative 
changes include an impaired proliferative response of 
peripheral blood mononuclear cells to non - specific 
stimulators of cell activation and proliferation 
mitogens and specific soluble antigens such as tetanus 
toxoid or purified protein derivative of M. Tuberculosis 
(PPD) (345, 504). It is not known if such functional
changes are due to a reduced ability to recognize 
antigen, inadequate effector mechanisms or both. Similar 
quantitative and qualitative changes occur in HIV-1 
antibody positive in the absence of AIDS (207, 344). In 
Chapter 8.2 it was found that 38 percent of HIV-1 
antibody negative haemophiliacs had quantitative changes 
Su9gestive of immunodeficiency. Such changes could not be 
eutirely accounted for by chronic non-A, non-B hepatitis 
0r mean annual dose of clotting factor concentrate used, 
furthermore, in vivo skin response to a new antigen 
^nitrochlorobenzene was impaired to an extent similar to 
^'1 antibody positive haemophiliacs (Chapter 7.1 and 
7‘2)* In seronegative patients a moderate significant
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correlation with mean annual dose of clotting factor 
concentrate was noted. Moreover, factor VIII concentrates 
suppressed activation and proliferation of cultured 
lymphocytes to both mitogens and antigen in vitro in a 
dose dependent manner (Chapter 3).In the absence of 
clinical immunodeficiency haemophiliac lymphocytes have 
an impaired proliferative response to alloantigens (505). 
It is however not clear if such findings are due to
(a) liver disease, (b) an effect of contaminating 
alloantigens contained in clotting factor concentrates, 
or (c) due to latent HIV-1 infection. Alternatively, 
cellular abnormalities could be due to a suppressive 
factor present in haemophiliac serum.
In this study, immunocompetence in haemophiliacs was 
evaluated by measuring proliferative responses of 
peripheral blood mononuclear cells to specific and non 
specific T-cell activators.Presence of HIV-1 infection, 
liver disease and treatment was assessed independently. 
In addition the effect of haemophiliac serum on 
lymphocyte proliferation was measured.
9*1-2 METHODS
^ t i e n t s
haemophiliacs included in this study were part of a 
Prospective cohort, in whom the mechanism and outcome 
impaired cell mediated was being evaluated.
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Forty haemophiliacs were studied and were grouped 
according to HIV-1 antibody status. Patients were further 
subdivided according to severity of liver disease. The 
method used to subdivide for liver disease has been
previously described (Chapter 2.2).Age-matched, healthy, 
male, volunteers with no risk factors for HIV-1 infection 
were used as controls.
Lymphocyte preparation:
Peripheral blood mononuclear cells (PBMC) were separated 
from heparinised venous blood by sodium metriozate 
density centrifugation, (Chapter 3.1.2). The PBMC band 
was removed and washed twice in Eagle's minimum essential
medium and PBMC resuspended at 1x10^ PBMC/mls in RPMI
1640 and 10 % pooled human serum supplemented with
glutamine, streptomycin and gentamicin (see Chapter 3.1.2 
for further details) .
Lymphocyte activation and proliferation
Proliferative responses were measured in 96 well, round 
bottomed microtitre plates (Nunc. Gibco, Paisley, UK) . 
Each well contained 100ul of PBMC in culture medium; and 
one of the following: phytohaemagglutinin (PHA) (Sigma,
Poole, UK) or antigen, purified protein derivative of M. 
^berculosis (PPD) (State Serum Institute, Copenhagen, 
Ttenmark); 5ug of PHA per milliliter and PPD 5ug/mls 
wore used. For PHA the cell concentration was adjusted to
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1x105cells/ml and for PPD cultures 1x1 0^ cells/ml in 
10Oul of culture medium were used.All cultures were 
performed in triplicate at 37°C in a humidified
atmosphere supplemented with 5 % C02
Proliferative responses to PHA were measured on day 3 and
PPD on day 5 by measuring incorporation of [3H] thymidine 
after a 4hr pulse (19 hours for PPD) with of [3H]
thymidine (Amersham, UK).The cells were harvested as
previously described (Chapter 3.1.2).
Effect of haemophiliac serum on normal lymphocyte 
proliferation
The PHA proliferative response was measured as described 
above except lymphocytes from a single normal donor were 
used and instead of using pooled normal serum in cell 
culture medium, serum from individual haemophiliacs was
substituted.
T-cell subsets
CD4+ve and CD8+ve T-cells were counted as previously 
described (Chapter 8.2.2).
Expression of results
Results were expressed as corrected counts per minute 
(CPM) . The mean of each triplicate of results obtained
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in the absence of mitogen (or antigen) ie. spontaneous 
incorporation of 3 [H]-Thymidine is subtracted from mean 
triplicate response in the presence of stimulus.
9.1.3 RESULTS
The 40 patients studied were comparable to the control 
group for age. Table 9.1.1 shows that those haemophiliacs 
not studied did not differ from study patients except in 
having a milder severity of haemophilia and a lower mean 
annual dose of clotting factor concentrate used.
HIV-1 Status
12 of the known 22 HIV-1 antibody positive patients were 
included in this study. There was no difference in mean 
annual dose of clotting factor concentrate used, age or 
clinical symptoms between those studied and not studied 
(Table 9.1.2), however studied patients had significantly 
reduced numbers of CD4 + ve T-lymphocytes, but this was not 
known prior to the study. None of the study patients had 
a previous opportunistic infection, two patients had 
Previous intermittent lymphadenopathy and one had 
thrombocytopenia (lowest recorded count = 50,000/mm3).
Table 9.1.2 compares HIV-1 antibody positive and 
ne9ative patients studied.
stimulated response
Table 9.1.1. A comparison of haemophiliacs in whom in 
vitro lymphocyte function was studied and not studied.
PATIENTS
Not s tu d ie d  S tu d ie d  p v a lu e
No. of patients 93 40
Age 32 30 .25
(years) (24-46) (21.5-39)
Factor Deficiency 5 0 .002
(i.v./dl) (0-10) (0-5)
Mean annual dose 5920 25892.5 .0004
of clotting factor (854-30000) (7409-61683)
concentrate used 
(units/annum)
Grade of liver 3 3 .24
disease (2-5) (2-5)
HIV-1 antibody 10 12
positive
Median and interquartile ranges are shown.Haemophiliacs 
n°t studied compared to haemophiliacs studied had a 
wilder severity of haemophilia and had used significantly 
less factor concentrate than those studied.
Table 9.1.2 A comparison of haemophiliacs studied
divided according to HIV-1 antibody status.
HIV-1 ANTIBODY STATUS
-ve +ve +ve
(not studied)
No. of patients 28 12 10
Age
(years)
31
(26.5-41.5)
21 .5 
(19-35)
26
(18-38)
Mean annual dose 
of clotting 
factor concentrate 
(units/annum)
18834 61683 79349
(4675-41112) (40435-101568) (6961 -
84756)
Liver disease 3
(2-5)
3
(2-3)
3
(3-4)
CD4+ve T-cell count 606 399
(cell/mm3) (482-833) (333-588)
CD8+ve T-cell count 343 668
(cells/mm3 ) (266-479) (471 -903)
679.5+
(483.3-
758.5)
594
(428-826
pHA stimulation 
(cpra)
43167
(34895-53565)
21358.5*
(18972-45312)
PPD stimulation 
(cpm)
7094 
(1821-43557)
3662** 
(892-6291)
j Medians and interquartile ranges are shown of patients 
i studied according to HIV-1 antibody status. Also included 
1 *s a comparison of HIV-1 antibody patients not studied.
It was found that the HIV-1 antibody patients studied had 
reduced numbers of CD4+ve T-cells compared to studied 
positive patients, patients were however selected without 
prior knowledge of CD4+ve T-cell count.
HIV-1 antibody negative patients studied differed 
significantly from positive patients in CD4 and CD8 cell 
numbers but were comparable for age and severity of liver 
disease. HIV-1 antibody patients had used significantly 
more treatment than seronegative patients.
+ p=0.04 
* p=0.002 
** p=0.03
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T a b l e  9.1.2 shows that corrected PHA stimulated values in 
HIV-1 antibody positive patients were significantly lower 
than in seronegative patients. Figure 9.1.1 shows that 58 
percent of HIV-1 antibody positive patients had a PHA 
response below the lower quartile of the normal range, 
this was similar to the numbers of HIV-1 antibody 
negative patients with a low normal response, 43 percent 
(p=0.29, Fishers Exact Test) .
Table 9.1.3 shows that HIV-1 antibody positive patients 
with a response above the lower quartile of the control 
group had significantly more CD8+ve T-lymphocytes 
(p=0.05) . Patients with a reduced response were also 
significantly older (p=0.05) but had used similar amounts 
of clotting factor concentrate per annum to normal 
responders. There was no correlation between PHA response 
and severity of liver disease (r=0.28, p=0.39) mean
annual dose of clotting factor concentrate used (r=0.35, 
P=0.28), duration of infection (r=0.35, p=0.23) but there 
was a strong inverse correlation with age of infection 
(£=-0.69, p=0.02). PHA induced proliferation showed no
correlation with CD4+ve T-cell count (r=0.25, p=0.43) but 
there was a good correlation with CD8+ve T-cell count 
(r=0.56, p=0.07) , in a simple regression analysis 
multiplicative model.
figure 9.1.1 shows that there was no difference in 
msdian proliferative response between HIV-1 antibody 
negative patients and controls, but 43 percent of
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FIGURE 9.1.1 PHA INDUCED LYMPHOCYTE 
ACTIVATION AND PROLIFERATION
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Figure 9.1.1. PHA induced proliferation in seropositive
haemophiliacs was significantly lower than controls 
(p=0.001). Seronegative patients did not differ from 
controls (p=0.2). 43 percent of seronegative
haemophiliacs had a response below the lower quartile of 
the control population.
Table 9.1.3 Differences between HIV antibody positive 
patients with a low normal response and a normal response 
to PHA.
PHA RESPONSE
CD4+ve
(cells/mm^)
Low
7
371 
(321-573)
Normal
5
537
(375-602)
p value
.37
CD8+ve 
(cells/mm^)
530
(345-785)
909
(897-950)
.05
Age
(years)
35
(22-39)
19 
(19-21)
.05
Liver disease 
severity
3
(2-3) (2.5-4)
.54
Mean annual dose 64336
of clotting factor (30870-103136)
concentrate
(units/annum)
58810
(500000-82164)
.7
ppD 3416.5 3 741.5 .9
(CPM) (1527-7843) (892-6291 )
Medians and interquartile ranges are shown. HIV-1 
antibody positive patients with a low normal response to 
pHA were older and had reduced numbers of CD8+ve T-cells 
compared to patients with normal responses.
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patients had a low normal response, ie. below the lower 
quartile of the normal range.
Table 9.1.4 compares these two groups, no significant 
differences were noted. No correlation was seen with 
severity of liver disease (r=-0.28, p=0.14), mean annual
dose of treatment used (r=0.08, p=0.66) or age (r=-0.15, 
p=0.42) and proliferation of PBMC with PHA. There was no 
correlation with PHA response and CD4 T-cell count 
(r=0.07, p=0.7) or CD8 T-cell count (r=-0.21, p=0.32) in 
a simple regression analysis (multiplicative model).
PPD stimulated response.
The PPD induced proliferative response was significantly 
impaired in haemophiliacs, (p=0.001) Figure 9.1.3. HIV-1 
antibody positive haemophiliacs had an impaired response 
compared to controls (p=0.007) and HIV-1 antibody 
negative patients (p=0.02), Table 9.1.2. As shown in 
Figure 9.1.2, seronegative patients had a significantly 
lower response compared to controls, (p=0.01).
In HIV-1 antibody positive patients there was a moderate 
inverse correlation with age but this did not achieve 
statistical significance (r=-0.45, p=0.17).
Interestingly, there was no correlation with age of 
lnfection (r=-0.09, p=0.74) or duration of infection
(rsQ .48, p=0.09). There was no correlation with mean
annual dose of clotting factor concentrate used (r=0.46, 
P50.16) and grade of liver disease (r=0.45, p=0.17). In
Table 9.1.4 A comparison of the characteristics of HIV- 
1 antibody negative haemophiliacs with a low normal and 
normal response to PHA.
PHA RESPONSE
Age
(years)
Low
12
31 .5 
(23-44.5)
Normal
16
30.5
Liver disease 
severity (3-5.5) (1 .3-4.5)
Mean annual dose 
of clotting factor 
concentrate used 
(units/annum)
15834
(1812-41112)
15670.5
(6782-47290)
CD4+ve c e l l s  
(c e l ls /m m 3 )
649.5
(472-777)
590. 5 
(491-877)
CD8+ve c e l l s  
(ce lls /it im 3 )
355
(300-725
328
(212-452)
PPD
(cpm)
4352
(1480-22137)
12394
(2964-62174)
p value 
. 76
.09
.56
.9
.5
The median and interquartile ranges are shown. There 
were no significant differences between the two groups.
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FIGURE 9.1.2 THE PROLIFERATIVE RESPONSE
TO PPD IN HAEMOPHILIACS
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Figure 9.1.2. PPD induced proliferation was
significantly lower in seropositive patients (p=0.007) 
and seronegative patients (p=0.01) compared to controls.
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seronegative patients no correlations were seen, liver 
disease (r=0.27, p=0.16) mean annual dose of treatment
(r=0.19, p=0.32) or age (r=0.12, p=0.12).
Impaired proliferative PPD responses could be due to 
quantitative or qualitative change in the functional 
subset of CD4+ve T-lymphocytes that recognize antigen 
(CD4+ve, Leu 8+ve). In HIV-1 antibody positive patients a 
moderate inverse correlation was noted between 
proliferative capacity to PPD and CD4+ve T-cell numbers, 
r=-0.43 (p=0.15), suggesting (a) a quantitative defect
(b) a functional impairment or (c) presence of 
suppressive cytotoxic factors impairing response. There 
was no correlation with CD8+ve T-cell count (r=0.12, 
p=0.16) .
In HIV-1 antibody negative patients there was no 
correlation with either CD4+ve T-cell count (r=-0.02, 
P=0.9) or CD8+ve T-cell numbers )r=-0.08, p=0.7) and PPD 
induced lymphocyte proliferation.
! The Effect of Haemophiliac Serum on lymphocyte activation
; haemophiliac serum had no effect on PHA or PPD stimulated
| PBMC (normals) proliferation.
j
9-1.4. DISCUSSION
is a non-specific activator of T lymphocyte 
Proliferation (506) . An impaired response to PHA could 
he due to: reduced numbers of T-cells, or a shift in
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proportion of T cell phenotypes. For instance, if there 
were more CD8+ve T-cells, proliferation would result in 
suppressive/cytotoxic ratios that may dampen overall 
response. Alternatively, pre-stimulation, ie. in vivo 
stimulation would exhaust cells and result in impaired 
activation and proliferation, or there may be a 
functional defect.
In this study, HIV-1 antibody positive haemophiliacs had 
an impaired proliferative response to PHA compared to 
controls and seronegative haemophiliacs, Figure 9.1.1.
Both HIV-1 antibody positive and seronegative
haemophiliacs had a similar severity of liver disease but 
seropositive. patients had used more clotting factor 
concentrate than seronegative patients.A reduced 
proliferative response to PHA was one of the first
laboratory abnormalities reported in patients with AIDS 
and is a characteristic of HIV-1 infection regardless of 
the individual's risk group (345).It is therefore
unlikely that impaired activation and proliferation is an 
effect of clotting factor concentrates.In support of this 
It was found that in HIV-1 positive patients there was no 
correlation between proliferative response and mean 
annual dose of factor concentrate used, Table 9.1.3.
*t has previously been suggested that impaired PHA 
response in HIV-1 infection is a consequence of CD4 + ve T- 
CeH  depletion (345). However, recent studies of CD4+ve 
T-cell enriched lymphocyte populations show that response
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to PHA in HIV-1 infection is similar to normals (504). 
In the present study patients with an impaired response 
had similar numbers of CD4+ve T-cells but CD8+ve T-cell 
was reduced compared to patients with a response in the 
normal range, Table 9.1.3. It was also found that CD8+ve 
T-cell count showed a significant correlation with PHA 
response in a multiplicative regression analysis.An 
inverse correlation with age and age of infection but not 
with duration of infection was also found.
Furthermore, using PPD it was found that quantitative 
CD4+ve T-cell differences between low and normal PHA 
responders were due to a functional impairment or a 
selective depletion of CD4+ve T-cells that selectively 
proliferate in response to soluble antigen. Similar
findings have been reported in AIDS patients belonging to 
other risk groups (504). The data from this study further 
shows this is an early manifestation of HIV-1 infection 
occurs in the absence of clinical immunodeficiency and 
is influenced inversely by patient age. The latter
finding may be a determinant of the immune response to 
HIV-1 infection (Chapter 5.2).
Such a defect may be due to (a) a failure in recognition 
°f antigen presented by macrophages, (b) an impaired
ability to produce interleukin 2 or (c) an excessive 
cytotoxic/suppressive response to HIV-1, so that cells 
6xPressing HIV-1 are destroyed. Identical twin studies, 
0ne of whom had AIDS and the other was HIV-1 negative
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showed that the interaction of macrophages and CD4+ve T- 
cells is normal in HIV-1 infection (507).Furthermore, 
HIV-1 infected cells express normal amounts of IL-2 
messenger RNA (508) . The functional defect to soluble 
antigen therefore cannot be entirely explained on CD4+ve 
T-cell depletion, macrophage interaction or IL-2 
production but could be due to (a) HIV-1 blocking the 
CD4 receptor, (b) a non-infectious manifestation of HIV-1 
due to replication defective viral particles or (c) due 
to the immune response to HIV-1.
In HIV-1 negative haemophiliacs there was no statistical 
difference in PHA response compared to normals but a low 
response to. PHA occurred as frequently as in HIV-1 
antibody positive patients, Figure 9.1.1.An impaired 
response to soluble antigen (PPD), suggested a functional 
defect or quantitative depletion in the subset of CD-4+ve 
T-cells that proliferate in response to antigen may be 
the prime abnormality.
In a previous study, (Chapter 3.1) clotting factor 
concentrates impaired the proliferative response of 
normal lymphocytes to PHA and PPD in vitro. Others have 
shown that clotting factor concentrates impair macrophage 
function in vitro (326). In vivo treatment with factor 
concentrate induce FcY receptor antibodies, this blocking 
sntibody impaired lymphocyte activation and proliferation 
has the ability to stimulate CD8+ve T-cells to generate a 
Oppressive response (459). Alternatively, it may be due
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to an impaired ability to produce the T-cell trophic 
factor interleukin 2 (see Chapter 10).
In conclusion, in this study it was found that 
haemophiliacs have an abnormally low response to PPD; 
this was independent of HIV-1 infection. In HIV-1 
antibody positive patients in addition to reduced numbers 
of CD4+ve T-cells, there may be a functional defect or a 
selective quantitative reduction in CD4+ve T-cells that 
preferentially proliferate in response to soluble 
antigen. The impaired PHA response in seropositive 
patients was not due to reduced CD4+ve, T-cells but due 
to proportionally more CD8+ve, T-cells.An inverse 
correlation with patient age and age of HIV-1 infection, 
but not with duration of infection was a contributory 
factor.
In HIV-1 antibody negative patients impaired PPD response 
showed no correlation with CD4+ve or CD8+ve T-cell 
counts suggesting a functional defect in the subset of T- 
cells that selectively respond to antigen in vitro. No 
association with mean annual dose of clotting factor 
concentrate used or liver disease was observed. 
Haemophilic serum did not contain suppressive/cytotoxic 
factors.
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CHAPTER 9.2
the e f f e c t s  o f  NON-INFECTIOUS HIV-1 l y s a t e  o n  l y m p h o c y t e  
function .
SUMMARY
Study objectives Can HIV-1 impair lymphocyte function in 
the absence of productive infection.
Study design: Open.
Study population: Normal volunteers with no risk factors 
for HIV-1 infection.
Measurements: Lymphocyte transformation in response to
PHA and PPD in the presence of an HIV-1 lysate. 11-2 
production was also measured.
Results: HIV - 1 lysate inhibited PPD induced
transformation and IL-2 production in a dose dependent 
manner. PHA induced transformation was impaired at high 
concentrations but stimulated at low concentrations.
Conclusions: HIV-1 proteins impair lymphocyte function
in the absence of productive infection.
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9,2.1 INTRODUCTION
In the previous studies it was found that human 
immunodeficiency virus - 1 (HIV-1) results in a
progressive decline of CD4+ve T-cell (Chapter 7.1 & 7.2) 
and in abnormalities of lymphocyte function independent 
of CD-4+ve T-cell depletion (Chapter 8.2).
The mechanism remains unexplained. The use of
fluoresinated antibodies against viral encoded proteins 
and in-situ hybridization techniques to detect cells 
expressing viral proteins, show that 1 in 105 cells in 
the peripheral blood of HIV-1 infected individuals are 
expressing virus at any time (217). A larger number of 
cells may however be latently infected. The depletion of 
infected cells is a direct cytopathic effect of HIV-1
(486, 489, 490) . However CD4 + ve T-cell depletion does
not parallel onset of clinical immunodeficiency,and other 
mechanisms must therefore be postulated (467).In feline 
AIDS it has been shown that non-inf ectious virus
particles may be implicated in the pathogenesis of
disease (384). In Chapter 4.3 it was found that such
replication deficient particles are present in HIV-1 
culture . In the present study therefore effects of a 
non-infectious HIV-1 lysate on lymphocyte function was 
investigated.
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9.2.2 METHODS
Cell separation and culture:
Peripheral blood mononuclear cells (PBMC) were isolated 
from 8 normal healthy volunteers as previously described 
and resuspended in cell culture medium Chapter 3.1.1). 
HIV-1 lysate was a kind gift from Dr R C Gallo. The 
protein content of HIV-1 lysate was 9mg/ml and was 
diluted in tissue culture medium to give a reference 
stock solution at 1mg/ml.
Triplicate PHA and PPD stimulation assays were used as 
previously (Chapter 9.1.2) and to each culture 100ul of 
HIV-1 lysate was added at final concentrations of 1:50; 
1:100; 1:250; 1:500; 1:1000 of reference stock solution 
and cultured for 3 days for PHA and 4 days for PPD. 
Cells were harvested and incorporated [^H] thymidine 
counted in a liquid scintillation counter, as previously 
described, Chapter 3. 1.2.The mean of each triplicate was 
expressed as a percentage of the maximal response in the 
absence of HIV-1 lysate.
The effect of HIV-1 lysate on interleukin 2 (IL-2)
Production was investigated, using methods similar to 
those described in Chapter 3.2.2.
Briefly, PBMC in tissue culture medium were adjusted to 
1*l06/ml8, stimulated with PHA 2ug/ml (final 
concentration) and 0.5mls of each concentration of HIV-1
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lysate. Supernatant was harvested after 48 hours and 
assayed for IL-2 activity in a bioassay (Chapter 3.1.2).
The IL-2 levels were expressed as a percentage of amount 
produced in the absence of HIV-1.
9.2.3 RESULTS
Figure 9.2.1 shows that at low concentrations probably 
similar to those found in serum, in the absence of 
biochemically detectable antigenaemia, HIV-1 stimulated 
lymphocytes, activated and proliferated in response to 
PHA.At higher concentrations HIV-1 inhibited the 
response.
HIV-1 inhibited PPD induced lymphocyte proliferation at 
all concentrations, Figure 9.2.2. HIV-1 inhibited IL-2 
production in a dose dependent manner, Figure 9.2.3.
9-2.3 DISCUSSION
The results of the present study show that non-infectious 
HIV-1 lysates inhibit PHA and PPD induced proliferation 
°f lymphocytes in vitro. These findings are similar to 
those reported by Pahwa et al (509) . Furthermore, in this 
study it was found that HIV-1 proteins inhibit 
interleukin-2 production in vitro in a dose dependent 
banner. One other observation in this study was that at 
similar concentrations (1:300) of HIV-1 increased PHA 
induced proliferation occurred whereas PPD driven
Figure 9.2.1. PBMC from normal volunteers were
stimulated with PHA in the presence of HIV-1 lysate. At 
low concentrations (11:250) HIV-1 enhanced proliferation 
but at >1:100 HIV-1 inhibited proliferation.
Pe
rc
en
t 
Ma
xim
um
 
In
hi
bi
tio
n
FIGURE 9.2.1 PHA RESPONSE OF PBMC
CULTURED IN THE PRESENCE
OF HIV-1 LYSATE
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FIGURE 9.2.2 PPD RESPONSE OF PBMC IN THE
PRESENCE OF HIV -1 LYSATE .
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F i g u r e  9.2.2. PBMC from normal volunteers
stimulated in the presence of HIV-2 lysate. A 
dependent inhibition was seen.
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FIGURE 9.2.3 IL-2 PRODUCTION FROM PBMC
IN THE PRESENCE OF HIV-1 LYSATE
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F i g u r e  9.2.3. PBMC from normal volunteers were
stimulated to produce IL-2 in the presence of HIV-1 
lysate a dose dependent inhibition of IL-2 production was 
seen.
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activation and proliferation was inhibited, Figure 9.2.1. 
This is in keeping with findings in Chapter 9.1 that HIV- 
1 antibody patients had a selective defect of T-cells 
that are prime responders to antigen in-vitro. 
Alternatively, HIV-1 may stimulate CD8+ve, T-cells at low 
concentrations.
The implications of these findings are that HIV-1 
proteins are immunosuppressive in the absence of 
productive HIV-1 infection. The binding of external 
viral envelope protein (gp120) to its receptor the CD4 
molecule may result in cell-cell fusion and giant cell or 
syncitia formation with subsequent cell lysis (496) . 
Alternatively, it may be that binding of HIV-1 to its 
receptor prohibits the T-cell to enter the cell cycle.
Mitogens such as phorbol mysirate have no effect on 
inositol lipid hydrolysis but activate protein kinase C 
directly (510). Antigen binding to T-cells induces 
inositol lipid hydrolysis, mobilizes intracellular 
calcium and causes the translocation and activation of 
Protein kinase C (510). It is therefore possible that 
binding of HIV-1 to the CD4 molecule inhibits protein 
kinase C.
*u conclusion in this study it was found that HIV-1 
Proteins inhibit T-cell proliferation in vitro, 
therefore part of the clinical immunosuppression seen 
during the course of HIV-1 infection may be mediated by
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replication deficient viral particles or free gp120 in 
serum.
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CHAPTER 9.3
CONCANAVALIN A INDUCED LYMPHOCYTE PROLIFERATION IN 
HAEMOPHILIACS.
SUMMARY
Study objective: To determine if there is a function
defect of haemophilic lymphocytes that selectively 
proliferate in response to Concanavalin A (Con A ) .
Study design: Open, cross-sectional.
Study population: 41 haemophiliacs with (n=13) and
without HIV-1 antibody.
Measurements: Con A induced lymphocyte transformation.
Results: All haemophiliacs had a normal Con A response.
Conclusions: The primary functional defect in HIV-1
antibody positive haemophiliacs is in the subset of T- 
cells that express CD4 antigen.
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9.3.1 INTRODUCTION
Haemophiliacs have an impaired immune response to a new 
antigen in-vivo, and this is independent of the patients 
HIV-1 status (Chapter 7.1).This may be due to an 
impaired ability to recognize and respond to an antigen, 
alternatively excessive T-suppressor/cytotoxic cell 
activity may be responsible. Although, in Chapter 8.2.3 
it was found that haemophiliacs do not have increased 
numbers of CD8+ve T-cells, others have reported an 
increased count (469). In a previous study it was also 
shown that haemophiliacs have increased amounts of FcY 
receptor antibody (Chapter 3.2). This antibody may have 
the capacity to stimulate release of suppressive 
substances, and it has been suggested that the 
beneficial effects of blood transfusion on renal 
allograft survival may be partly mediated by such a 
mechanism (304) .
In this study the proliferative capacity of peripheral 
blood mononuclear cells to concanavalin-A (Con-A) was 
measured, as a indicator of CD-8+ve T-cell activity. Con 
A is a specific mitogen for this subset of lymphocytes 
(506). The Con-A response was compared between HIV-1 
antibody positive and negative patients.
9-3.2 PATIENTS AND METHODS
Heparinised venous blood was obtained from 41 
haemophiliacs, who were taking part in a prospective
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study of immunodeficiency in haemophiliacs. The
selection criteria for inclusion are given in Chapter 2.
Cell s e p a ra tio n  and c u ltu r e ;
Peripheral blood mononuclear cells (PBMC) were obtained 
by density centrifugation of heparinised venous blood 
(see Chapter 3.1.2). Washed PBMC were resuspended in cell 
culture medium, RPMI 1640 supplemented with antibiotics 
and essential amino acids , (Chapter 3.1.2). 5x105 PBMC
were cultured in triplicate in the presence and absence 
of Con-A (final concentration 50ug/ml), at 37°C in a 
humidified atmosphere and air enriched with 5% CO2 • All 
cultures were performed in triplicate.
Four hours prior to harvesting, the cells were pulsed 
with 3 [H] thymidine. At 72 hours cells were harvested 
onto glass fibre discs and incorporated radioactivity was 
counted on a liquid scintillation counter (as previously 
described in Chapter 3.1.2).
Results were expressed as described in Chapter 9.1.3.
T-cell subsets;
T - c e l l  subsets were counted in PBMC as previously 
i described (Chapter 8.2.2).
!
| 9-3.3 RESULTS
I
| There was no significant difference in the median age of 
j P&tients and controls, 
status
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Thirteen of 41 haemophiliacs studied had HIV-1 antibody. 
Median duration of infection was 53 months (interquartile 
range (IQR) 4 3 to 60).Four of the HIV-1 antibody positive 
patients had detectable levels of free serum HIV-1 
antigen (Chapter 4.1.2).No patient had AIDS, two patients 
had a low platelet count, no other manifestations of HIV- 
1 infection were noted. Ages of HIV-1 antibody positive 
and negative patients were comparable, Table 9.3.1.
Con A induced lymphocyte proliferation:
Figure 9.3.1 and Table 9.3.1 shows that Con A responses 
corrected for background counts per minute (cpm) between 
patients and controls was similar (p=0.5). There was no 
difference in median cpm between HIV-1 positive and 
negative patients (p=0.5). HIV-1 antibody negative 
patients had a response similar to controls (p=0.7). 
Nineteen haemophiliacs (46 percent) had a Con A response 
below the lower quartile of the normal range (Figure 
9.3.1). Of these 6 were HIV-1 antibody positive (46 
percent of all HIV-1 antibody positive) and 13 were HIV- 
1 antibody negative (46 percent of all HIV-1 antibody 
negative, (p=0.6, Fishers Exact Test). Four of six HIV-1 
antibody positive patients with a response below the 
lower quartile of the normal range had serum HIV-1 serum 
antigen, three had symptoms of HIV-1 infection whereas 
aone of the high responders had antigen or significant 
finical symptoms, (p=0.02 Fishers Exact Test), Figure 
*•3.1.
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Figure 9.3.1. There was no significant difference in 
proliferative response between HIV-1 +ve and HIV-1 -ve 
haemophiliacs compared to controls.
»Table 9.3.1 The characteristics of patients in whom
the Con-A response was measured.
HIV Status
Number of patients 
Age
(years)
Haemophilia
severity
(i.u./dl)
Grade of liver 
disease
Mean annual dose 
of clotting factor 
concentrate used 
(units/annum)
CD4+ve 
(cells/mm^)
CD8+ve 
(cells/mm^)
Positive
13
22
(19-35)
0
(0 -0)
3
(2-3)
64556
(50000-10000)
423
(345-573)
551
(470-897)
Negative p value 
28 
31
(26.5-41.5) .14
0
(0-7)
3
(2-5)
15834 
(4675-41117)
.03
.28
.001
606 .01
(482-833)
343 .004
(266-479)
Medians and interquartile ranges are shown.HIV-1 antibody 
positive patients were comparable to seronegative 
patients for age and severity of liver disease.However, 
HIV-1 antibody positive patients had a more severe 
deficiency of haemophilia, had used more clotting factor 
concentrate and significantly fewer CD4+ve T-cells but 
wore CD8 + ve T-cell.
»Table 9.3.2 A comparison of HIV-1 antibody positive
patients with a low normal and normal Con-A response.
HIV-1 antibody positive pvalue
Con A Response low Normal
Number of patients 6 7
HIV serum antigen 
(no. of patients)
4 0
Age 35 21 .38
(years) (19-49) (19-26)
Mean annual dose 68072.5 64356 .94
of clotting factor 
concentrate used 
(units/annum)
(308870-103136) (30000-100000)
Grade of liver 3 3 .48
disease (3-3) (2-3)
CD4+ve 543.5 371 .35
(cells/mm^) (423-602) (321-537)
CD8+ve 668 330 .32
(cells/mm^) (472-883) (345-909)
Medians and in te rq u a rtile  ranges are shown, there were no 
significant d ifferences between the two groups.
Table 9.3.3 A comparison of HIV-1 antibody negative
patients with a low normal and normal Con-A response.
Con A response 
Number of patients 
Age
(years)
Mean annual dose 
of clotting factor 
concentrate used 
(units/annum)
Grade of liver 
disease
CD4+ve 
(cells/mm^)
CD8+ve 
(cells/mm^)
HIV-1 antibody negative p
low normal
12 16
41.5 30
(27-45) (26.5-32)
12861 22918
(4623.5-24137.5) (4675-53724)
(1.5-5)
554
(300-753)
540
(236-802)
3.5
(3-5)
608
(533-888)
328
(266-413)
value
.06
.29
. 44 
.25 
.39
Medians and interquartile ranges are shown. Patients with 
a low normal response were older than patients with a 
normal response.
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Con A responses in seropositive patients showed no 
correlation with age (r=-0.25, p=0.37), or duration of
infection (r=0.22, p=0.44).In seronegative patients there 
was a good inverse correlation with Con A response and 
age, (r=-0.61, p=0.001).
Liver disease
There was no correlation noted between Con A response and 
clinical grade of liver disease in HIV-1 antibody 
positive (r=-0.17, p=0.35).
Mean annual amount of factor concentrate
In neither HIV-1 antibody positive (r=-0.15, p=0.6) or
negative (r=0.06, p=0.7) patients did mean annual dose of 
clotting factor concentrate used have an effect on Con A 
response.
9.3.4 DISCUSSION
In the present study proliferative responses of 
lymphocytes from haemophiliacs to Con A was normal, and 
this was independent of the patients' HIV-1 status. This 
is in contrast to effects of PHA and PPD which are 
impaired confirming that the primary defect in HIV-1 
sntibody positive patients is in the subset of T cells 
that express the CD4 phenotype (344) .
Despite the absence of a difference in Con A response 
between HIV-1 positive patients and controls some
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interesting trends were seen. Patients with serum HIV-1 
antigen had a low normal response compared to those 
without serum antigen.This suggests that
suppressive/cytotoxic response may be another factor in 
determining disease progression.lt may be as duration of 
infection increases in this cohort that the Con A 
responses in patients with antigen will fall further.
As in HIV-1 antibody positive patients seronegative 
patients had normal Con A responses. In a previous study 
it was found that haemophiliacs had high levels of FcY 
receptor antibody (Chapter 3.2), 12 of these patients
were also included in this study. Two patients had normal 
PcYR levels, both had responses below the lower quartile 
of the normal range and only one of 10 patients with 
raised FcY receptor antibody levels had a low response. 
Additional studies to confirm this anecdotal observation 
are indicated.In seronegative patients the Con A response 
showed a significant inverse correlation with age.
In conclusion in this study there was no evidence to show 
that the Con-A response in haemophiliacs is impaired.
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CHAPTER 10
INTERLEUKIN-2 LEVELS IN THE ABSENCE AND PRESENCE OF HIV-1 
ANTIBODY IN HAEMOPHILIA.
SUMMARY
Study objective: To compare the capacity to produce
interleukin-2 (IL-2) in haemophiliacs with and without
HIV-1 antibody and determine whether impaired production 
was due to functional or quantitative abnormalities.
Study design: Open, cross-sectional.
Study population: Haemophiliacs were selected from a
well defined treated cohort on the basis of HIV-1 
antibody status, mean annual dose of clotting factor used 
and liver disease severity.
Measurements: Capacity to produce IL-2 from peripheral
blood mononuclear cells (PBMC), T-cell subsets and 
Proliferation of PBMC to purified protein derivative 
(PPD) of mycobacterium tuberculosis were measured.
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Results: The reduced capacity to produce IL-2 was
independent of HIV-1 antibody status. The mean annual 
dose of clotting factor concentrate used and liver 
disease severity did not correlate with IL-2 levels. In 
seropositive patients reduced levels correlated with PPD 
responses. No correlations were seen in seronegative 
patients.
Conclusions: The reduced capacity to produce IL-2 in
HIV-1 seronegative haemophiliac was due to functional 
defects. In HIV-1 positive patients it may be due to a 
functional or a quantitative defect in the CD4+ve cell 
subsets that are prime responders to soluble antigens.
10.1.1 INTRODUCTION
The human immunodeficiency virus-1 (HIV-1) primarily
infects and depletes T - helper/inducer lymphocytes (T- 
h, CD4+ve) (339, 340, 345) . The T cell receptor on
CD4+ve lymphocytes recognises processed antigen, 
presented by macrophages in the context of major
histocompatibility (MHC) class II molecules (511-513). In 
response to antigen and interleukin-1 secreted by 
macrophages, CD-4+ve cells produce the lymphokine 
interleukin 2 (IL-2) (514). IL-2 results in clonal
proliferation of CD4+ve T-cells expressing high affinity 
IL-2 receptors and induces both antibody dependent and 
independent effector immune responses (514). A reduced 
IL-2 production may therefore be one consequence of HIV-1 
infection.
In vitro HIV-1 infected cell lines show that IL-2 gene 
transcription is intact and normal levels of IL-2 are 
produced using purified CD4+ve lymphocyte preparations 
from AIDS patients (508, 504). Conversely, using
unfractionated peripheral blood mononuclear cells
capacity to produce IL-2 is reduced and the reduced 
proliferative capacity of phytohaemagglutinin stimulated 
Peripheral blood mononuclear cells from AIDS patients 
can be partially restored by addition of exogenous IL-2 
(515.-519). The reduced capacity to produce IL-2 appears 
to be independent of CD4+ve cell numbers suggesting an 
a^ ditional defect in the immune system in AIDS patients.
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It is not clear whether this is (a) a non-inf ectious 
effect of HIV-1 as shown in Chapter 9.2, (b) due to the
immune response to HIV-1 or (c) due to opportunistic 
infections and tumors that occur in AIDS. Borzy et al 
reported reduced IL-2 production in HIV-1 infected, 
asymptomatic, homosexuals suggesting that this is 
independent of secondary infections that occur during the 
course of in HIV-1 infection (519). No studies have yet 
been reported in haemophiliacs in whom the 
immunological environment is unique.
Haemophiliacs frequently have concomitant non-A, non-B 
(NANB) hepatitis and hepatitis B infection; both can 
potentially alter immune function both quantitatively 
and qualitatively. In addition haemophiliacs are
frequently challenged with a large contaminating 
alloantigen load which may be potentially deleterious. 
In Chapter 3.1 it was found that factor VIII concentrate 
is directly immunosuppressive, and reduced IL-2 
production.
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In the present study, capacity to produce IL-2 was 
measured in haemophiliacs with HIV-1 infection in the 
absence of present or previous opportunistic infections. 
Specifically unfractionated peripheral blood mononuclear 
cells were used to reproduce the in vitro intercellular 
relationships. Furthermore, values were correlated to 
immune status by measuring peripheral blood T-cell 
subsets. The proliferative response of peripheral blood 
mononuclear cells to soluble antigen was measured to 
determine if there is a functional defect in CD-4+ve 
cells to produce IL-2 in vivo.
10.1.2 METHODS
Patients
The study population consisted of 46 haemophiliacs 
regularly treated with clotting factor concentrates who 
were participating in a prospective study of HIV-1 
related disease and immune abnormalities. Selection 
criteria for entry into the prospective cohort are listed 
in Chapter 2. Included were 16 of the 22 patients known 
to be HIV-1 antibody positive. Serum HIV-1 antibody 
j negative patients were selected on the basis of NANB
| elated liver disease severity and mean annual dose of
!
j clotting factor concentrate used. Criteria for grading 
! NANB. liver disease have been previously stated (Chapter 
' 2).
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Cell preparation
Peripheral blood mononuclear cells (PBMC) separated from 
heparinised venous blood by density centrifugation over 
sodium metriazoate (Chapter 3.1) were resuspended in 
complete RPMI/2% heat inactivated fetal calf serum (FCS), 
and the cell concentration adjusted to 1x1 06 cells/mls.
IL-2 supernate production
IL-2 supernatant was produced by culturing PBMC in 24 
well flat bottomed tissue culture plates (Costar, 
Cambridge, Massachusettes, USA). Each well contained 1ral 
of cell suspension (1x10^ cells) and phytohaemagglutinin 
(PHA) at a final concentration of 2ug/mls (Wellcome 
grade) or no mitogen.
|
The cultures were incubated at 3 7°C in a humidified 
atmosphere supplemented with 5 % C02. After 48 hrs
supernatants were recovered by centrifugation and stored 
| at -20°C until assayed.
Supernatant IL-2 was measured as described in Chapter 3.1 
(306) .
T*cell Subsets
t
T-cell subsets were counted as previously (Chapter 
•^2.2) .
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Proliferative response to soluble antigen
The ability of PBMC to proliferate in response to 
purified protein derivative (PPD) of M. Tuberculosis was 
measured (Chapter 9.1.2).
10.1.3 RESULTS
The ability to produce IL-2 was measured in 46 
haemophiliacs. Median patient age was 30.5 years 
(interquartile range (IQR) 23-40 years), this was 
comparable to the control group. 45 patients had factor 
VIIIC deficiency and only one patient had factor IX 
deficiency. Of these 32 had factor levels <.5iu/dl, 11 had
levels of between 5-10iu/dl and 2 had factor levels 
>1 Oiu/dl.
Table 10.1.1 shows that HIV-1 antibody positive and 
negative patients were comparable for age, factor
deficiency, and grade of liver disease. However, HIV-1 
antibody patients had used significantly more clotting 
factor concentrate per annum (p=0.002). There was no 
j correlation between patients age and IL-2 production
| (r=0.12,  p=0 . 39) .
|
| HIV-1 s ta tu s
| Sixteen patients were HIV-1 antibody positive. Median 
Oration of infection was 53 months (IQR: 43 - 60) . Of
these three had serum HIV-1 antigen. None had AIDS, one
Table 10.1.1 A comparision of patients in whom IL-2 
levels were measured.
HIV-1 Status
No. of patients 
Age
(years)
Factor deficiency 
(iu/dl)
Mean annual dose 
Clotting factor cone 
(iu/annum)
Grade of liver 
disease
All
46
30.5
(23-40)
0
(0-5)
29084
(6605-
75880)
3
(2-5)
Antibody
+ve
16
27.5
(21-38.5
0
(0 -0)
73472.5 
(49282- 
101568)
(2-3)
Antibody 
- ve
30
31
(26-43)
0
(0-9)
10324.5
(4000-
40000)
3
(2-5)
Table 10.1.1 shows medians and in te rq u a rtile  ranges. 
HIV-1 antibody positive  patients did not d i f fe r  from 
antibody negative patients except in  mean annual dose of 
clotting fac to r concentrate used, p=0.002.
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patient had previous recurrent non-opportunistic 
bacterial infections but was infection free at the time 
of study, and one had intermittent thrombocytopenia which 
had not required treatment.
Neither HIV-1 antigen positive patients or symptomatic 
patients could be identified from the amount of IL-2 
produced (Figure 10.1.1). There was no correlation with 
the duration of infection, r=-0.2 (p=0.5).
IL-2 production:
Effect of HIV-1 infection.
Figure 10.1.1 shows HIV-1 antibody positive patients 
produced less IL-2 than controls, (p=0.002) and
seronegative patients (p=0.04). Seronegative patients
also produced less IL-2 than controls (p=0.05).Twenty 
eight (61 percent) haemophiliacs had IL-2 levels below 
the lower quartile of the normal range (18.6iu/dl), of 
these 11 were HIV-1 antibody positive (69 percent of HIV- 
1 antibody positive patients studied) and 17 were HIV-1 
antibody negative (57 percent of HIV-1 negative patients 
studied), (p=0.225 Fishers Exact Test).
Effect of liver disease:
The capacity to produce IL-2 was not related to grade of 
Uver disease for the whole group,(r=0.007 p=0.916),
however, in HIV-1 antibody positive patients there was a 
Moderate correlation, (r=0.53, p=0.04) and in HIV-1
FIGURE 10.1.1 INTERLEUKIN 2 PRODUCTION
IN TREATED HAEMOPHILIACS
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Figure 10.1.1. Seropositive haemophiliacs produced less 
IL-2 compared to controls (p<0.05) and HIV-1 -ve patients 
(p<0.05). HIV-1 -ve patients produced less IL-2 than 
controls (p<0.05).
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negative patients there was a poor inverse correlation 
(r=-0.24, p=0.2).
The e f f e c t  o f  mean annual dose o f  c lo t t in g  fa c to r  
con cen tra te  used:
Mean annual dose of clotting factor concentrate used did 
not affect the amount of IL-2 produced, in HIV-1 antibody 
positive patients, r=0.22 (p=0.38) and in HIV-1 antibody
negative patients, r=0.22 (p=0.23).
Mechanism o f reduced I L - 2  p ro d u c tio n :
A reduced in-vitro capacity to produce IL-2, could be due 
to (a) CD4 T-cell depletion, (b) a functional defect of 
CD4 +ve T-cells as measured by stimulating lymphocytes 
with PPD (see chapter 9.3) or (c) an effect of T -
suppressor /cytotoxic lymphocytes (CD8 +ve; T-s).
In HIV-1 antibody positive patients IL-2 production
showed a poor correlation with CD4+ve T-cell count, 
(r=0.3, p=0.2), a moderate correlation with CD8+ve T-cell 
count (r=0.5, p=0.05) and a high correlation with PPD
| response (r=0.6, p=0.04).
j
To determine relative contributions of each a stepwise 
variable regression equation was used,in which IL-2 level 
was the independent variable, and CD8+ve T-cell count and 
TPD values weighted for number of CD4+ve T-cells the 
dependent variables. PPD stimulation values remained
significantly associated with IL-2 values, (r=0.61,
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p=0.002). On both forward and backward analysis CD-8+ve 
count was not retained in the regression equation.
In HIV-1 antibody negative patients as a group there was 
no correlation between ability to produce IL-2 and 
CD4+ve, (r=0.09, p=0.6) CD8+ve cell (r=0.001, p=0.9)
counts or PPD stimulated values (r=.02, p = .1). This 
suggested a functional defect in the capacity to produce 
IL-2, but no correlation was seen with PPD response 
(r=0.3, p = 0 .2).
10.1.4 DISCUSSION
The most interesting observation in the present study 
was that haemophiliacs had a reduced capacity to produce 
IL-2; in vitro this was independent of HIV-1 antibody 
status. The finding that IL-2 production was reduced in 
HIV-1 infection has been reported by others (515-519), in 
this study it was found that this abnormality occurs 
early in the course of infection and in the absence of 
significant clinical immunodeficiency.
It was observed that those HIV-1 antibody positive 
individuals with the severest grade of liver disease also 
tad reduced levels of IL-2. This was not the case in HIV- 
1 antibody negative patients and suggests that either 
HIV-1 infection alters the course of NANB liver disease 
°r the converse may occur. It is presumed that HIV-1 
induced immunosuppression allows NANB hepatitis to 
Proceed unchecked. In such individuals treatment with
276
either recombinant IL-2 or recombinant gamma interferon 
may be desirable. These agents have been shown to: (a)
gamma interferon improves histological outcome of NANB 
liver disease (520, 521), (b) suppress HIV-1 replication
in vitro and (498-501) (c) gamma interferon is superior
to recombinant IL-2 in the management of AIDS patients 
(522) .
Furthermore this study shows that HIV-1 antibody positive 
subjects with reduced IL-2 production had impaired 
response to PPD. This implied that either the CD4 + ve 
lymphocyte subset that responds to antigen in vitro is
selectively depleted or functionally deficient. This 
observation is in keeping with the studies of Lane et al 
(504) .
The finding that IL-2 production was reduced in HIV-1
negative patients was surprising but in keeping with
previous observations of a reduced in vivo response to a 
new antigen, Chapter 7.1. The mechanism is not clear. 
The absence of a correlation with CD4+ve T-cells 
suggested a functional defect. The mechanism is probably 
different from HIV-1 positive patients as no correlation 
was seen with PPD stimulation. An alternative explanation 
would be that recurrent contaminating alloantigenic load 
from treatment with clotting factor concentrates
temporarily exhausts the capacity of lymphocytes to 
Produce IL-2. To test this hypothesis "resting" cells in 
Vitro prior to stimulation would be necessary.
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Interestingly in systemic lupus erythematosus resting 
cells prior to stimulation restored their capacity to 
produce IL-2 (533).
In conclusion, haemophiliacs with HIV-1 infection in the 
absence of clinical immunodeficiency have a reduced 
capacity to produce IL-2. Prospective studies in this 
cohort will allow the clinical utility of this test to be 
evaluated. The reduced IL-2 production appears to be due 
to a qualitative and quantitative defect.
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CHAPTER 11.1
SERUM IMMUNOGLOBULIN LEVELS IN HAEMOPHILIA.
SUMMARY
Study objectives: To compare serum immunoglobulin levels
in HIV-1 antibody positive and negative haemophiliacs.
Study design: Open, prospective, longitudinal study.
Study population: A well defined cohort of treated
haemophiliacs in whom severity of liver disease, mean 
annual dose of clotting factor concentrate used HIV-1 
status was known.
Measurements: Serum IgA, IgG and IgM measured by laser
nephelometry.
Results: In a stepwise variable selection analysis serum
IgG showed a good correlation (r=.77) with HIV-1 antibody 
status and a good correlation (r=-.57) with grade of 
liver disease and no correlation mean annual dose of 
clotting factor concentrate used.
Conclusions: Raised levels of serum IgG in haemophiliacs
are associated with the presence of HIV-1 antibody; in 
the absence of antibody a progressive rise indicates 
severe liver disease.
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11.1.1 INTRODUCTION
Severe haemophiliacs require regular treatment with 
clotting factor concentrates. The concentrates are 
derived from pooled plasma donations and contain a large 
contaminating alloantigen load. Sensitization to
specific alloantigens results in auto-antibodies and 
raised levels of plasma immunoglobulins are a frequent 
finding (233, 245, 246) . Hypergammaglobulinaemia could
occur due to infections transmitted by clotting factor 
concentrates. For instance hypergammaglobulinaemia is a 
frequent finding during the course of HIV-1 infection 
(344). Chronic liver disease due to non-A, non-B 
hepatitis (NANB) also results in raised gammaglobulin 
levels (376) .
Hypergammaglobulinaemia in haemophiliacs has been 
reported both in the absence and presence of HIV-1 
infection (186,192,399,524). Earlier studies attributed 
raised immunoglobulin levels to alloantigen stimulation, 
more recently Hay et al reported a correlation between 
serum IgG levels in patients who progressed to liver 
cirrhosis after chronic NANB hepatitis, the possibility 
that HIV-1 infection could have masked their results was 
considered but not excluded (192). Raised serum IgG 
levels have also been reported by others but the effect 
°f HIV-1 infection, liver disease and replacement therapy 
w®re not independently considered (525-528). The aim of 
this prospective study was twofold: (i) to establish the
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prevalence and pattern of hypergammaglobulinaemia; and 
(ii) to investigate whether raised levels correlate with 
clotting factor concentrate use, liver disease or HIV-1 
infection.
11. 1 . 2  PATIENTS AND METHODS 
P a tie n ts
Venous blood obtained in 1981/2 and 1986/7 and serum 
stored at -20°C from haemophiliacs attending the West of 
Scotland Adult Haemophilia Centre were used. Testing of 
serum samples of patients was restricted to those who 
fulfilled the criteria for entry into a prospective study 
of immunodeficiency in haemophiliacs (see Chapter 2.2).
The diagnosis, mean annual dose of clotting factor 
concentrate used and severity of liver disease was 
established (see Chapter 2). HIV-1 antibody status all 
patients was known and stored sera tested to obtain an 
estimate of the duration of HIV-1 infection (Chapter 
4.1). At the time of this study no patient had clinical 
immunodeficiency.
Immunoglobulin measurement
Serum levels of IgA, IgG and IgM isotypes were measured 
by laser nephelometry.
In samples with an elevated level above 10 percent of the 
formal laboratory range of any isotype, the clonality of 
the rise was established by protein electrophoresis.
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11.1.3 RESULTS
Clinical 
Liver disease
The grade of liver disease and manifestations of HIV-1 
infection are reported in detail in Chapter 2.1 and 6.2 
respectively.
HIV-1 Status
Figure 4.1.1 shows the cumulative annual incidence of 
HIV-1 antibody, only one patient had HIV-1 infection at 
the outset. No patient had an opportunistic infection 
during the study.
Serum Immunoglobulin
Immunoglobulin levels were measured in stored serum 
samples in 106 (80%) patients at the start of the study
and in 1986/7 in 130 (98%) patients.
At the start of the study one patient had all three 
isotypes elevated above 10 percent of the laboratory 
upper limit of normal, in two patients both IgG and IgA 
were raised and in another patient IgG and IgM were 
elevated. As shown in Figure 11.1.1, 24 patients (23
percent) had one isotype raised, 22 of these patients 
had a raised serum IgG and one of each had raised IgA or 
IgM.
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Figure 11.1.1. Only one patient was HIV-1 antibody 
positive at the start of the study. The most frequently 
elevated isotype was IgG.
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In 1986/87 seven patients had all three isotypes 
elevated, Figure 11.1.2, of these two were HIV-1 antibody 
positive. Nine had two isotypes elevated, of these six 
were HIV-1 antibody positive and 26 had one isotype 
elevated, 8 patients had HIV-1 antibody. In three of 26 
patients with a single raised isotype, IgM was elevated, 
two had HIV-1 antibody; the remainder (23 patients) had 
a raised IgG of whom six had HIV-1 antibody. The single 
HIV-1 negative patient with an isolated raised IgM had 
normal levels on retesting.
HIV-1 S ta tu s
Table 11.1.1 shows serum immunoglobulin levels in
patients with an without HIV-1 antibody. Of HIV-1 
antibody positive patients in 1986/87 only one had
antibody in 1981. There was no significant difference in 
initial immunoglobulin levels between those who 
subsequently developed HIV-1 antibody and those who did
not, Table 11.1.1.
At the end of the study seropositive patients had
significantly higher IgG (p=0.0001) and IgM levels 
(p=0.0001) but serum IgA was similar, Table 11.1.1. IgG 
and IgM levels increased significantly in seropositive 
patients, levels did not significantly change in 
seronegative patients, Table 11.1.1.
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Figure 11.1.2. Serum levels did not differ between 
seropositive and seronegative patients for IgM but were 
significantly higher for IgG (p=0.003) and IgM (p=0.03).
Table 11.1.1 Serum immunoglobulin levels.
HIV-1 STATUS p value
+ve -ve
IgG (pre) 14.8 13 0.06
(13.4-17.4) (10.8-15.2)
IgG (post) 19.1 13.2 0.001
(14-25.2) (11.2-15.4)
IgA (pre) 2.2 2 0.6
(1.8-2.8) (1.5-2.6)
IgA (post) 1.9 1.4 0.95
(1.7-2.4) (1-2.2)
IgM (pre) 1.3 1.3 0.36
(1.1-2.2) (1-7)
IgM (post) 2.8 1.4 0.001
(1.9-3.2) (1-2.2)
Serum IgG, IgA and IgM levels were similar in both groups 
at the start of the study. At the end of the study IgG 
and IgM were significantly higher in seropositive 
patients, there had been a significant increase in IgG 
(p=0.003) and IgM (p=0.03) but not IgA (p=0.9). There was 
no significant change in the seronegative group.
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In all patients there was a moderate inverse correlation 
between grade of liver disease and serum IgG (r=-0.38, 
p=0.001)/ Figure 11.1.3 and poor inverse correlations 
with serum IgA (r=-0.20/ p=0.02) and for IgM (r=-0.22,
p=0.01) .
Treatment Use
Mean annual dose of clotting factor concentrate used 
showed a moderate direct correlation with serum IgG level 
(r=0.40/ p=0.0001)/ no correlation with serum IgA level
(r=0.05/ p=0.05) and there was poor correlation with IgM 
(r=0.24/ p = 0 .005).
To determine the relative influence of HIV-1 status, 
severity of liver disease and mean annual dose of 
clotting factor concentrate used on serum immunoglobulin 
levels separate stepwise variable regression analysis
were used for each isotype. Dependent variables were 
serum IgG, IgA or IgM level, the independent variables 
included grade of liver disease and mean annual dose of 
clotting factor concentrate used, and HIV-1 antibody
status.
Serum IgG showed the best correlation for coefficient 
estimates with HIV-1 status (r=0.77) and a good
correlation with severity of liver disease (r=-0.58) and 
& poor correlation with mean annual dose of treatment 
used (r=0.22). For serum IgA, only severity of liver 
disease was retained in the analysis, (r=-0.23), and for
FIGURE 11.1.3 GRADE OF LIVER DISEASE 
AND SERUM IgG LEVEL IN SERONEGATIVE 
HAEMOPHILIACS
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Figure 11.1.3. A good correlation was seen between grade 
of liver disease and serum IgG, there was however 
considerable overlap between groups.
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IgM only HIV-1 status was retained (r=0.57). All 
correlation coefficient values were significant (p<0.05).
11.1.4 DISCUSSION
In most Centres, the incidence of HIV-1 infection 
especially in severe haemophiliacs is high. It has 
therefore been difficult to separate effects of HIV-1 
infection from NANB associated chronic liver disease and 
that due to alloantigens contained within blood products 
used for treatment. The low prevalence of HIV-1 
infection, availability of accurate medical records 
documenting total amount of clotting factor concentrate 
used and biochemical as well as clinical data to assess 
severity of liver disease allowed relative contributions 
of each variable to be assessed in this study. Moreover, 
in this cohort no HIV-1 antibody positive patient had 
clinical immunodeficiency, it was therefore possible to 
examine effects of HIV-1 on the immune system in the 
absence of an immune response to an opportunistic 
infection.
In the present study it was found that the most 
frequently elevated serum immunoglobulin isotype is IgG. 
A raised serum IgG level occurred more frequently in 
seropositive patients (59 percent) that HIV-1 
seronegative patients (23 percent) (p=0.001, Fishers 
Exact Test). Seropositive patients had significantly 
higher levels than seronegative haemophiliacs. The 
importance of the findings of this study lie in the
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analysis of the relevant contributions of alloantigen 
stimulation, HIV-1 infection and chronic liver disease. 
It was found that HIV-1 infection had a greater influence 
on serum IgG levels than liver disease and that the 
effect of treatment is in predisposing to infections, 
rather than directly contributing to
hypergammaglobulinaemia.
The finding of polyclonal increase in serum IgG and IgM 
in HIV-1 antibody positive haemophiliacs, indicates (a) 
in vivo activation of B cells, (b) impaired T-cell 
control of B cells or (c) subclinical infections evoking 
an antibody response. The frequent finding of
autoantibodies in patients with HIV-1 infection and 
absence of clinical symptoms in the face of compromised 
cell mediated immune system makes the latter possibility 
unlikely (344). In previous studies (Chapter 10) it was 
found that T-helper cell function is compromised in HIV-1 
infection, it is therefore unlikely that increased levels 
of immunoglobulin are due to excessive T-cell help. The 
possibility that there is direct B cell stimulation 
during HIV-1 infection is considered in Chapter 11.2.
It was also found that (Table 11.1.1) HIV-1 infection 
results in a progressive increase in serum IgG, whereas 
in the absence of HIV-1 infection despite levels being 
frequently elevated there is no significant statistical 
increase over five years. The findings in the present 
study further show that in the absence of HIV-1 infection
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up to 20 percent of the raised serum IgG level is 
accounted for by liver disease; Hay et al have shown that 
those individuals with histological evidence of chronic 
hepatitis who progress to develop liver disease have 
higher serum IgG levels (192). However, it is unlikely 
that serum IgG levels are likely to be of additional 
clinical help in predicting liver disease, first, as 
shown in Figure 11.1.3, there is considerable overlap in 
actual levels in patients with different grades of liver 
disease and second, levels do not significantly change 
over five years observation.
In conclusion, the results of this study show that IgG 
hypergammaglobulinaemia occurs in up to 31 percent of 
treated haemophiliacs. The significance of raised
levels in HIV-1 antibody positive patients is not clear, 
it is possible that despite this quantitative increase, 
there is a qualitative abnormality in secreted 
immunoglobulins. In HIV-1 antibody negative patients 
raised levels are not due to recurrent alloantigen 
stimulation of B cells due to use of clotting factor 
concentrates - a moderate correlation was seen with 
severity of liver disease.
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CHAPTER 11.2
B CELL FUNCTION IN HAEMOPHILIA.
SUMMARY
Study objectives: To compare B cell activation in HIV-1
antibody positive and negative haemophiliacs.
Study design: Open, cross-sectional study.
Study population: 58 haemophiliacs selected on the basis
of HIV-1 antibody status, liver disease severity and mean 
annual dose of clotting factor concentrate used.
Measurements: Spontaneous and stimulated production of
IgG and IgM in vitro.
Results: HIV-1 infection was associated with a
decreased resting B cell pool and increased partially and 
fully activated cells. In seronegative patients there 
was a shift to a greater proportion of partially 
activated B cells in patients with severe liver disease. 
The remainder had normal B cell proportions.
Conclusions: B cell abnormalities in HIV-1 infection
occur early in the course of infection. Liver disease 
and not clotting factor concentrate treatment causes B 
cell abnormalities in the absence of HIV-1 infection.
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11.2.1 INTRODUCTION
Cell mediated immunity in vivo is frequently impaired in 
treated haemophiliacs both in the absence and presence of 
human immunodeficiency virus-1 (HIV-1) infection (Chapter
7). In Chapter 11.1 it was found that serum
immunoglobulin levels are frequently elevated in
haemophiliacs. In patients with HIV-1 infection serum 
levels of IgG and IgM are higher than seronegative 
patients, moreover in these patients there is a
progressive increase in these isotypes over five years. 
In seronegative patients raised levels of IgG occur less 
frequently, do not substantially increase and are 
indicative of chronic liver disease. These findings 
imply polyclonal activation of B cells.
In normal individuals, the circulating B cell pool
contains B cells at different stages of activation. 
Fully differentiated B cells spontaneously secrete 
immunoglobulin, partially activated B cells, when
provided with adequate T-cell help, can differentiate 
into antibody secreting cells and resting B cells can be 
induced by a number of T independent B cell stimuli to 
undergo proliferation and to produce immunoglobulin 
(531) .
Previous studies in haemophiliacs showed that the number 
of fully differentiated and partially activated B cells 
are increased (525, 526). These findings were noted in
both HIV-1 antibody positive and negative patients. No
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account, however, was taken of the resting B cell pool. 
In seronegative patients these observations were 
attributed to the used of clotting factor concentrates 
and no account was taken of chronic liver disease (525, 
526) . Although it is possible that clotting factor 
concentrates may have influenced T cell control of B cell 
activation no association with mean annual dose of 
clotting factor concentrate used and serum IgG was found 
in Chapter 11.1.
In this study B cell function in both HIV-1 antibody 
positive and negative patients was investigated. The 
effects of liver disease and allogenic antigen 
stimulation due to clotting factor concentrate use were 
considered independently. Furthermore, the possibility 
that there is an intrinsic B cell defect in haemophiliac 
patients was studied.
11.2.2 PATIENTS AND METHODS
58 factor VIIIC and IX deficient haemophiliacs attending 
the West of Scotland Adult Haemophilia Centre who had 
been treated with a blood product since 1980 were 
studied. All patients were examined for clinical 
features of HIV-1 related disease (Chapter 6.1) and 
chronic liver disease (Chapter 2) . The case notes were 
reviewed and the following additional information 
recorded:
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1. Mean annual dose of clotting factor concentrate 
used.
2. Grade of liver disease based on the
classification given in Chapter 2.
3. HIV-1 antibody status and duration of infection (see 
Chapter 4).
Heterosexual males with no known risk factors for HIV-1 
infection matched for age were used as controls.
Cell Preparation and Culture Conditions:
Peripheral blood mononuclear cells (PBMC) were obtained 
by density centrifugation of heparinised venous blood and 
washed, as previously described (Chapter 3.1.2). PBMC 
were cultured in RPMI 1640 medium supplemented with L 
glutamine, gentamicin, penicillin (Chapter 3.1.2) and 10 
percent heat inactivated fetal calf serum. Duplication 
cultures of 1x10^ PBMC in a final volume of 1ml culture 
medium were incubated in 24 well flat bottomed plates 
(Costar, Cambridge, Massachusetts, USA) for 7 days with: 
pokeweed mitogens (PWM), final concentration 1:500 
(Gibco, Paisley, UK); formalin inactivated Staph. Aureus 
Cowan strain A (SACA), final concentration 107 
bacteria/ml, or 1 ml of culture medium. Cultures were 
incubated at 37°C in air enriched with 5 % C02 •
Supernatants were harvested after 7 days and stored at - 
70°C till assayed for IgG and IgM using a solid phase 
snzyme linked immunosorbent assay (522) . For PWM
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stimulated cultures the sum of IgG and IgM was compared. 
For SACA stimulated cultures, only supernatant IgM was 
measured as protein A from SACA binds covalently with IgG 
and therefore gives falsely low values (532).
T c e l l  subsets
T-cell subsets were enumerated as previously (Chapter 
8.2.2) on the same venous blood sample.
1 1 . 2 . 3  RESULTS
Of the 56 patients studied 45 were factor VIIIC 
deficient and 11 had factor IX deficiency. 45 patients 
had factor levels 5iu/dl, 7 patients had factor levels of 
between 5-10iu/dl and 4 had factor levels >10iu/dl. The 
median age of the whole group was 27.5 years 
(Interquartile range (IQR) 21 to 38). Table 11.2.1 
compares patients studied and those not included in the 
study.
HIV-1 A n tib o d y  S ta tu s :
14 patients (25 percent) were HIV-1 antibody positive. 
Median duration of HIV-1 infection was 53 months (IQR 43 
to 60). At the time of this study no patient had AIDS or 
other clinical manifestations of HIV-1 infection. Table 
11.2.2 compares HIV-1 antibody positive and negative 
patients.
Liver D isease :
Table 11.2.2 A comparison of HIV-1 antibody positive
and negative patients studied.
Number of 
patients
Age
(years)
Mean annual dose 
of treatment 
(units/annum)
Liver disease 
severity
CD4+ve
cells/mm^
CD8+ve
cells/mm^
HIV-1 STATUS
+ve -ve p value
14 42
21 30 0.009
(18-27) (23.40)
10324.5 74154 0.001
(1141-4390) (5000-83000)
3 3 0.1
(3-5) (2-5)
423 650 0.04
(345-633) (451-951)
548 355 0.02
(442-883) (266-588)
The median and interquartile ranges are shown.
Seropositive patients were younger, had fewer CD4+ve 
cells and more CD8+ve cells than seronegative patients.
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35 patients (63 percent) had abnormal liver function 
tests during the study. Of these, six had grade I liver 
disease: 11 patients had grade II and 14 grade III
liver disease. Four patients had acquired NANB infection 
in the five years prior to this study (Grade IV). Of the 
remaining patients with normal serum ALT, 13 patients had 
previous NANB infection but during the study serum ALT 
was always below the upper limit of laboratory normal 
(Grade V). Eight had grade VI liver disease.
Of patients with HIV-1 infection, one had grade I liver 
disease, five grade II and 10 grade III.One HIV-1 
antibody positive patient acquired NANB, in the previous 
five years. Three patients had grade V liver disease.
Two patients were hepatitis B surface antigen carriers, 
both were HIV-1 antibody positive. There was no 
difference in the grade of liver disease between HIV-1 
antibody positive patients and HIV-1 antibody negative 
patients (p=0.16), Table 11.2.2.
Replacement Therapy with Clotting Factor Concentrates: 
Table 11.2.2 shows that HIV-1 antibody positive patients 
had used significantly more clotting factor concentrate 
per annum compared to seronegative patients (p<0.001).
There was a poor correlation between mean annual dose of 
clotting factor concentrate used and grade of liver 
disease (r=-0.09, p=0.5).
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IN-VITRO B CELL FUNCTION 
Spontaneous im m unoglobulin  p ro d u c tio n :
Table 11.2.3 and Figure 11.2.1 shows that HIV-1 antibody 
positive haemophiliacs secreted more immunoglobulin 
compared to controls (p<0.05) and HIV-1 antibody negative 
patients (p<0.05). In HIV-1 antibody positive
spontaneous total immunoglobulin production showed a good 
inverse correlation with CD4+ve T-cell count, (r=-0.52, 
p=0.04), there was no correlation with CD8+ve T-cell 
count, (r=-0.2, p=0.14). HIV-1 antibody negative
patients did not secrete more immunoglobulin than 
controls, Figure 11.2.3. In seronegative patients there 
was no correlation with CD4+ve T-cell count (r=0.05, 
r=0.4) or CD8+ve T-cell count (r=0.06, r=0.5).
S tim u la te d  im m unoglobulin p ro d u c tio n :
Pokeweed M itogen S tim u la t io n :
Table 11.2.3 and Figure 11.2.2 shows that PBMC from HIV-1 
antibody positive haemophiliacs could not be further 
stimulated to produce more immunoglobulin (p=0.57), 
whereas the control group produced significantly more 
immunoglobulin on stimulation (p=0.001). PBMC from HIV-1 
negative patients could be further stimulated to produce 
more immunoglobulin (p=0.001).Some HIV-1 antibody 
negative patients, however, failed to secrete more 
immunoglobulin, all had grade I liver disease, Table 
11.2.4. HIV-1 antibody negative patients with all other
Table 11.2.3 Basal and PWM stumulated immunoglobulin
levels.
IMMUNOGLOBULIN PRODUCTED (n g /m l)
B asal PWM p v a lu e
Control 140 495 0.001
(124-166.5) (424-635)
HIV-1 +ve 272 362.5 0.57
(100-472) (193-485)
HIV-1 -ve 132 430 0.001
(93-120) (267-313)
Median and interquartile ranges are shown. Basal levels 
were significantly higher in HIV-1 antibody positive 
patients. PWM stimulated values did not differ between the 
three groups. However, HIV-1 antibody positive patients 
could not be further stimulated to produce immunoglobulin 
with PWM.
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Figure 11.2.1. PBMC from seropositive haemophiliacs had 
higher basal immunoglobulin production than controls. 
Seronegative patients did not differ from controls, see 
table 11.2.3.
Table 11.2.4 In vitro B cell function in HIV-1 negative 
patients according to severity of liver disease.
Grade of
liver disease Basal PWM p value
1 172 480.5 0.22
(96-226) (420-522)
103 249.5 0.01
(61-138.5) (161-313.5)
143.5 521.5 0.01
(95-257) (398-622)
188 395 0.2
(136-267) (308-440)
163 477 0.005
(101-281) (451-525)
73 318 0.04
(39-185) (238-470)
Median and interquartile ranges are shown. No significant 
differences were seen between the groups in basal or 
stimulated values (Kruskal Wallis analysis of variance). 
However, patients with severe liver disease failed to 
secrete more immunoglobulin on PWM stimulation.
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11.2.2. PBMC from seropositive haemophiliacs could not 
be further stimulated to produce immunoglobulin with PWM. 
There was however a significant increase in both controls 
and seronegative patients, see table 11.2.3.
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categories of liver disease could be stimulated to 
produce more immunoglobulin, Table 11.2.4.
SACA stimulation:
Table 11.2.5 shows basal and SACA stimulated values. 
SACA stimulation did not result in a significant increase 
in IgM values in HIV-1 antibody positive patients. In 
HIV-1 negative patients values increased significantly, 
(p=0.05) .This was also true for the control group, 
(p=0.04) .
11.2.4 DISCUSSION
The results of the present study show marked B cell 
abnormalities in haemophiliacs. In patients with HIV-1 
infection these include: in vivo B cell activation, an
impaired response to the T dependent B cell activator, 
PWM and a failure to respond to SACA, a T independent B 
cell activator. Similar results were found in some HIV-1 
antibody negative patients but response to SACA was 
normal.
The findings in this cohort of asymptomatic HIV-1 
antibody positive patients are consistent with marked 
polyclonal B cell activation in vivo. These findings are 
similar to those reported in patients with AIDS in whom 
numbers of resting B cells are decreased and circulating 
pool of partially and fully activated B cells increased 
(534) . Furthermore, it was found that there was an 
inverse correlation between amount of immunoglobulin
Table 11.2.5 Basal and SACA stimulated values.
IMMUNOGLOBULIN PRODUCTION (ng/ml)
Basal (IGm) SACA p value
Control 30 180 0.04
(25-38) (123-210)
HIV-1+ve 71 140 0.5
(40-108) (107-200)
HIV-1-ve 38 73 0.05
(19-64) (47-109)
Median and Interquartile ranges are shown.
Basal IgM production was higher in HIV-1 positive patients. 
Sa CA stimulation values did nor differ, however, on 
comparing paired basal and SACA stimulated values HIV-1 
antibody positive patients failed to produce more IgM.
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secreted spontaneously and degree of cellular 
immunodeficiency as assessed by measuring numbers of 
circulating CD4+ve T-cells. Taken together these findings 
would imply viral transformation or stimulation of B 
cells.
In this regard, in vitro studies with various HIV-1 
isolates have shown that HIV-1 can result in polyclonal B 
cell activation to an extent that is comparable to that 
seen with standard B cell activators (535,536). 
Alternatively, reactivation of a prior, latent B cell 
transforming virus may explain these findings. Both 
Epstein-Barr virus and the newly described B cell tropic 
virus, human herpes virus 6, may have produced such 
changes (537 - 540) . Infection with both viruses is
common and both have been implicated in the pathogenesis 
of lymphomas which can occur during the course of HIV-1 
infection (435-445). The results of this study also show 
that the in vivo B cell activation during HIV-1 infection 
occurs in the absence of clinical immunodeficiency and is 
not restricted to paediatric age groups.
The impaired response to PWM in HIV-1 antibody positive 
patients in the present study is in keeping with previous 
reports and with the marked T-helper cell depletion that 
occurs during HIV-1 infection (534). However in 
seropositive patients there was also an impaired response 
to SACA implying an additional primary B cell defect. 
Similar findings have been reported in patients with AIDS
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(534). In this study an impaired SACA response was 
observed in four of nine patients studied. Prospective 
studies may indicate whether such an abnormality is 
invariable or occurs in selected patients who may be 
predisposed to develop a lympho-proliferative neoplasm.
The findings in HIV-1 antibody negative patients are 
particularly noteworthy. B cell abnormalities were noted 
only in patients with severe liver disease. These 
included in vivo B cell activation and an impaired 
response to PWM. This could be due to (a) a defect in T- 
cells providing excessive help, (b) impaired T-cell 
suppression or (c) a primary abnormality of B cells. As 
shown in Table 11.2.5, haemophiliacs without HIV-1 
antibody secreted more immunoglobulin in response to 
SACA, it is therefore considered unlikely that there is a 
primary B cell defect. In Chapter 8.2 it was shown that 
HIV-1 antibody negative haemophiliacs do not have reduced 
numbers of T-helper cells, but interleukin- 2 production 
was reduced (Chapter 10). Taken together, these results 
would indicate that the increased immunoglobulin levels 
in vivo (Chapter 11.1) and increased spontaneous 
immunoglobulin production ex in vivo could be due to 
decreased T-cell suppression in patients with severe 
liver disease.
In a previous study it was shown that numbers of 
circulating T-suppressor cells in HIV-1 negative 
haemophiliacs were in the normal range and therefore
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decreased suppression may be due to a functional defect 
in this subpopulation (469). Alternatively it may be due 
to reduced numbers or function of the T-helper cell 
subpopulation that induce T-suppressor cells (307 - 309).
In conclusion, the findings of this study show that 
polyclonal B cell stimulation in vivo is independent of 
HIV-1 status in haemophiliacs. In seropositive patients 
the present data implies that most circulating B cells 
are fully or partially activated. This occurs in the 
absence of clinical immunodeficiency but is inversely 
related to CD4+ve T-cell depletion. The major clinical 
implication of this finding is that serological tests to 
indicate secondary infections may be difficult to 
interpret. Furthermore, B cell clones secreting 
autoantibodies may emerge.
In the majority of HIV-1 antibody negative patients the 
circulating pool appears to consist of normal proportions 
of resting, activated and fully differentiated B cells. 
However, in patients with sever liver disease there is a 
shift to a greater proportion of partially activated B 
cells compared to resting B cells. This could be due to 
stimulation from gut associated antigens exposed by the 
abnormal portal circulation, alternatively there may be 
decreased T-cell suppression of B cells.
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Summary of MD thesis Dr Rajan Madhok 
Background:
Clinical and laboratory evidence of immunodeficiency has 
been frequently reported in haemophiliacs treated with 
clotting factor concentrates. Potential causes include:
1 The viruses transmitted by clotting factor concentrates
2 A direct chemical effect of clotting factor concentrates 
on the immune system
3 Alternatively immunodeficiency may arise due to the 
frequent extraneous alloantigens infused.
Impairment of cell mediated immunity can be due to:
1 Impaired T helper/inducer cell activity this may be due 
to quantitative or qualitative changes.
2 Excessive T suppressor/cytotoxic cell activity either 
quantitative or qualitative.
3 Impaired function of monocytes/macrophages 
The aims of this thesis are:
1 To establish presence of in vivo immunodeficiency in 
haemophiliacs.
2 To determine influences of each of the potential 
causative factors.
3 To study the immune response and effects of HIV-l on the 
immune system in haemophiliacs.
The aims were achieved by:
1 Assessing the in vitro effects of clotting factor 
concentrates on peripheral blood mononuclear cells from 
immuno-competent individuals.
2 Establishing the extent of exposure to HIV-l and 
determining the risk factors for HIV-l infection.
3 Measuring the longitudinal antibody response to HIV-l.
4 In chapter 6 the impact of HIV-l infection in haemophilia 
was determined and evidence for clinical immunodeficiency 
was sought in seronegative haemophiliacs.
5 In vivo cell mediated immunity was measured in 
seropositive and negative haemophiliacs (Chapter 8 )
6 Quantitative changes in the immunoregulatory ratio were 
measured (chapter 8 ).
7 Measurements of qualitative changes of lymphocyte
function were made and the effects of HIV-l proteins on 
the immune system in vitro were established.
8 The capacity to produce the lymphokine interleukin 2 was 
measured and reported in chapter 10.
9 B cell function is partly controlled by T cells and 
therefore assessed.
